{{Merge from|1=注意力不足過動症的非藥物治療|time=2019-01-25T04:58:32+00:00}}
{{NoteTA
| G1=Medicine  
| G2=Lifesciences
| T= zh-cn:注意（力）缺陷多动障碍的治疗; zh-tw:注意力不足過動症的治療; zh-hk:專注力失調或過度活躍症的治療;
| 
}}
{{medical}}
{{copyedit|for=將【 】之類的標點符號改為其他較常在條目中使用的標點符號|date=2019年1月}}
{{inappropriate tone|time=2019-01-01T11:56:14+00:00}}
<onlyinclude><!-- 于[[注意力不足過動症|注意力不足過動症]]包含本条目首段 -->
'''注意力不足過動症的治療'''是指在[[注意力不足過動症|注意力不足過動症]]（ADHD）治療上，以[[循证医学|醫學實證為基礎]]，已確認有一定程度治療效果的治療方式。注意力不足過動症的治療包括[[心理治療|心理治療]]、[[行為治療|行為治療]]及藥物，也有可能是用心理治療配合藥物進行治療。治療對病症會有長期的改善，但是無法完全根除病症的影響<ref name="pmid22947230">{{cite journal |vauthors=Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE | title = A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment | journal = BMC Med | volume = 10 | page = 99 | date = 2012-09-04 | pmid = 22947230 | pmc = 3520745 | doi = 10.1186/1741-7015-10-99 }}</ref>。[[美國兒科學會|美國兒科學會]]針對病患的年齡不同，有建議不同的治療方式。若是四歲至五歲的兒童，學會會建議有實證基礎，且由家長或／和老師監督的行為治療，只有在有中度到重度，持續性的功能紊亂時，才加上哌甲酯的藥物治療。若是六歲至十一歲的兒童，會建議使用藥物以及行為治療；而「中樞神經刺激劑」的藥效會比「非中樞神經刺激劑」的藥效要明顯一些，雖然「中樞神經刺激劑」和「非中樞神經刺激劑」都能讓孩子核心症狀減少的程度在統計學上達到明顯意義<ref name="Wolraich 2011"/>。若是十二歲至十八歲的患者，強烈建議使用藥物治療，但用藥仍需取得患者的同意；藥物治療之餘也建議能搭配行為治療<ref name="Wolraich 2011">{{cite journal |last1=Wolraich |first1=M. |last2=Brown |first2=L. |last3=Wolraich |first3=RT. |last4=Brown |first4=G. |last5=Brown |first5=M. |last6=Dupaul |first6=HM. |last7=Earls |first7=TG. |last8=Feldman |first8=B. |last9=Ganiats |first9=B. | displayauthors=8 |others=Steering Committee on Quality Improvement Management |last11=Meyer |first11=B |last12=Perrin |first12=B |last13=Pierce |first13=J |last14=Reiff |first14=K |last15=Stein |first15=M |last16=Visser |first16=MT |last17=Visser |first17=S |title=ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents |journal=Pediatrics |volume=128 |issue=5 |pages=1007–22 |date=November 2011 |doi=10.1542/peds.2011-2654 |pmid=22003063 |last10=Kaplanek |first10=B |pmc=4500647|quote=5b: For elementary school-aged children (6–11 years of age), ...<br/>Action statement 5c: For adolescents (12–18 years of age), ...<br/>Similar to the recommendations from the previous guideline, stimulant medications are highly effective for most children in reducing core symptoms of ADHD.44 One selective norepinephrine-reuptake inhibitor (atomoxetine45,46) and 2 selective α2-adrenergic agonists (extended-release guanfacine47,48 and extended-release clonidine49) have also demonstrated efficacy in reducing core symptoms. Because norepinephrine-reuptake inhibitors and α2-adrenergic agonists ...  Compared with stimulant medications that have an effect size [effect size = (treatment mean — control mean)/control SD] of approximately 1.0,50 the effects of the nonstimulants are slightly weaker; atomoxetine has an effect size of approximately 0.7, and extended-release guanfacine and extended-release clonidine also have effect sizes of approximately 0.7.}}</ref><ref name="UpToDate additional behavior therapy"/>。有其他研究指出若能合併藥物治療及行為治療、認知行為治療等[[心理治療|心理治療]]，將可帶來更樂觀的[[預後|預後]]<ref name="UpToDate additional behavior therapy">{{cite web | title=Attention-deficit-hyperactivity-disorder-in-children-and-adolescents-overview-of-treatment-and-prognosis | website=UpToDate | url=https://www.uptodate.com/contents/attention-deficit-hyperactivity-disorder-in-children-and-adolescents-overview-of-treatment-and-prognosis?search=pharmacotherapy%20for%20adolescent%20adhd&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H24 | access-date=2018-03-17 |quote=For school-aged children (≥6 years) and adolescents with ADHD, ...}}</ref>。適度且規律的運動，特別是[[有氧運動|有氧運動]]有助於改善許多{{tsl|en|central nervous system disorders|中樞神經系統疾患}}的症狀，已經證實為注意力不足過動症的有效{{tsl|en|add-on treatment|附加療法}}{{efn|即表示可附加在現有具備科學實證且能在[[統計學|統計學]]上達到顯著意義之有效改善症狀的醫學療法。}}<ref name="找回專注力"/><ref name="books2000"/><ref name="分心也有好成績">{{cite book|url=http://books.google.com/books?id=NEyiGQAACAAJ|author1=Edward M. Hallowell, M.D.|author2=John J. Ratey, M.D.|others=丁凡譯|title=《分心也有好成績》，| location =台北|year=2006 |publisher=遠流出版社 |isbn=9573259311 |date= |accessdate=2016-12-09}}</ref><ref name="ADHD exercise 2016 SystRev">
{{cite journal | vauthors = Den Heijer AE, Groen Y, Tucha L, Fuermaier AB, Koerts J, Lange KW, Thome J, Tucha O | title = Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review | type=systematic review (secondary source)| journal = J. Neural. Transm. (Vienna) | volume = | issue = | pages = | date =  2016-07 | pmid = 27400928 | doi = 10.1007/s00702-016-1593-7 | url = http://link.springer.com/article/10.1007%2Fs00702-016-1593-7 }}</ref><ref name="ADHD Exercise 2014">{{cite journal | vauthors = Kamp CF, Sperlich B, Holmberg HC | title = Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters | journal = Acta Paediatr. | volume = 103 | issue = 7 | pages = 709–14 | date = 2014-07 | pmid = 24612421 | doi = 10.1111/apa.12628}}</ref><ref name="wiley1">{{cite journal|url=http://onlinelibrary.wiley.com/doi/10.1111/apa.12628/abstract|title=Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters|first1=Carolin Friederike|last1=Kamp|first2=Billy|last2=Sperlich|first3=Hans-Christer|last3=Holmberg|date=2014-07-01|publisher=|journal=Acta Paediatr|volume=103|issue=7|pages=709–714|via=Wiley Online Library|doi=10.1111/apa.12628|deadurl=no|archiveurl=https://web.archive.org/web/20170216212225/http://onlinelibrary.wiley.com/doi/10.1111/apa.12628/abstract|archivedate=2017-02-16}}</ref><ref name="autogenerated4">{{cite journal|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257065/
|title=Protection from genetic diathesis in ADHD: Possible complementary roles of exercise|first1=Anna-Sophie|last1=Rommel|first2=Jeffrey M.|last2=Halperin
|first3=Jonathan|last3=Mill|first4=Philip|last4=Asherson|first5=Jonna|last5=Kuntsi|date=2017-02-16|publisher=|journal=Journal of American Academy of Child and Adolescent Psychiatry|volume=52|issue=9|pages=900–910|via=PubMed Central|doi=10.1016/j.jaac.2013.05.018|pmid=23972692|pmc=4257065}}</ref>。

注意力不足過動症患者甚至其家屬可能對自身或患者的問題存有否認心理，包括：高估自己的能力及低估自己的困難、並因此做出不合理的決定（為反對而反對地否認診斷，即便確實有需要仍拒絕接受學習及醫療上的協助、排斥旁人包括醫師、老師、父母與家人的幫忙等）。鼓勵患者甚至其家屬勇於面對注意力不足過動症將使注意力不足過動症的長期預後變得更為樂觀。<ref name="auto"/><ref name="Singh 2003 pp. 308–316">{{cite journal | last=Singh | first=Ilina | title=Boys Will Be Boys: Fathersʼ Perspectives on ADHD Symptoms, Diagnosis, and Drug Treatment | journal=Harvard Review of Psychiatry | publisher=Ovid Technologies (Wolters Kluwer Health) | volume=11 | issue=6 | year=2003 | issn=1067-3229 | doi=10.1080/10673220390264221 | pages=308–316}}</ref><ref name="Barkley 2013 p. over parents and children in denial of ADHD diagnosis">{{cite book | last=Barkley | first=Russell | title=Taking charge of ADHD : the complete, authoritative guide for parents | publisher=The Guilford Press | publication-place=New York | year=2013 | isbn=978-1-4625-0789-4 | oclc=825196454 | page=152-153}}</ref><ref name="Chan Fogler Hammerness p=1997">{{cite journal | last=Chan | first=Eugenia | last2=Fogler | first2=Jason M. | last3=Hammerness | first3=Paul G. | title=Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents | journal=JAMA | publisher=American Medical Association (AMA) | volume=315 | issue=18 | date=2016-05-10 | issn=0098-7484 | doi=10.1001/jama.2016.5453 | page=1997}}</ref>對於那些難以著眼於長遠報酬（報償、酬賞）的注意力不足過動症患者（傾向著眼於眼前立即回饋、追逐{{tsl|en|novelty seeking||新奇感}}的注意力不足過動症患者），大量且持續的正向激勵可以增進患者的任務表現，注意力不足過動症的用藥亦有相同的功效。<ref name="VTA+LC projection systems">{{cite journal | vauthors = Chandler DJ, Waterhouse BD, Gao WJ | title = New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons | journal = Front. Neural Circuits | volume = 8 | issue = | pages = 53 | date = 2014-05 | pmid = 24904299 | pmc = 4033238 | doi = 10.3389/fncir.2014.00053 | quote = }}</ref><ref name="Malenka ADHD neurosci">{{cite book |vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2009 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071481274 | pages = 266, 315, 318–323 | edition = 2nd | chapter = Chapters 10 and 13 | quote = Early results with structural MRI show thinning of the cerebral cortex in ADHD subjects compared with age-matched controls in prefrontal cortex and posterior parietal cortex, areas involved in working memory and attention.}}</ref><ref name="Sethi Voon Critchley Cercignani pp. 1545–1557">{{cite journal | last=Sethi | first=Arjun | last2=Voon | first2=Valerie | last3=Critchley | first3=Hugo D | last4=Cercignani | first4=Mara | last5=Harrison | first5=Neil A | title=A neurocomputational account of reward and novelty processing and effects of psychostimulants in attention deficit hyperactivity disorder | journal=Brain : a journal of neurology | publisher=Oxford University Press (OUP) | volume=141 | issue=5 | date=2018-03-13 | issn=0006-8950 | pmid=29547978 | pmc=5917772 | doi=10.1093/brain/awy048 | pages=1545–1557}}</ref><ref name="Taiwanese Society of Child and Adolescent Psychiatry seasonal digest">{{cite journal| url=http://www.tscap.org.tw/TW/ImgTscapOrg/20181129120321.pdf| title=以神經計算模型探討注意力不足過動症之酬賞與追求新奇歷程，以及中樞神經興奮劑治療反應 | author=台大醫院精神醫學部住院醫師李律恩 摘譯 | journal=兒童青少年精神醫學通訊 | volume=17 | issue=3 | date=2018-12-03 | page=07 | archive-url=https://web.archive.org/web/20181225061404/http://www.tscap.org.tw/TW/ImgTscapOrg/20181129120321.pdf | archive-date=2018-12-25 | access-date=2018-12-25}}</ref> 許多文獻及指引都表示，ADHD的治療（包含藥物治療）並非是要將患者們標準化（一致化）或是控制患者，而是一本教育的初衷，協助每一位患者發掘、發揚自己的優點、並避免缺點。<ref name="幫助ADHD孩子快樂成長"/><ref name="books2000"/><ref name="分心也有好成績"/>

<!--對於治療方式的不同論點-->
臺灣兒童青少年精神醫學會發文指出，對於ADHD患者而言，應注意所接受的療法是否受到政府的密切監督以確保符合嚴謹的研究設計及是否奠基於嚴謹實證醫學科學證據、充分研究證據支持療效且符合台灣現行的[[法律|法律規範]]；對於政府衛生醫療相關單位而言：應給予足夠資源，強化對[[弱勢群體|弱勢]]家庭的支持，包括提升[[家庭教育|親職]]功能以及家族治療等，以便提供患者更完整有效的醫療模式<ref name="tscap4">
{{cite web
 |url         = http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=122
 |title       = 20160728公聽會-建議新聞稿
 |date        = 2016-07-28
 |publisher   = 臺灣兒童青少年精神醫學會
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20171215000403/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=122
 |archivedate = 2017-12-15
}}</ref><ref name="tscap_20170503_2">{{cite web| url =http://www.tscap.org.tw/TW/ImgTscapOrg/20170503112049.pdf| title =注意力不足過動症與妥瑞氏症的非藥物治療| last =| first =| date =2017| volume =16| issue =1| series =精神醫學通訊 Child & Adolescent Psychiatry Newsletter Vol.16 No 1. Spring 2017| website =台灣兒童青少年精神醫學會 官方網站| publisher =[[台灣兒童青少年精神醫學會|台灣兒童青少年精神醫學會]]| access-date =2017-06-07| quote =| deadurl =no| archiveurl =https://web.archive.org/web/20171213143647/http://www.tscap.org.tw/TW/ImgTscapOrg/20170503112049.pdf <!--須看著畫面loading全程才能成功顯示-->  <!-- Backup:  https://archive.is/jcjVI  -->| archivedate =2017-12-13}}</ref>。
-----

{{Bar chart
| title       = 1999年美國衛生署（NIH）所做的研究：MTA（多重治療模式研究）為期14個月的臨床研究結果<ref name="multi-model treatment of ADHD study">{{cite web| url=https://www.nimh.nih.gov/funding/clinical-research/practical/mta/multimodal-treatment-of-attention-deficit-hyperactivity-disorder-mta-study.shtml| type=tertiary source| title=Multimodal treatment of Attention Deficit Hyperactivity Disorder (MTA) Study.| website=National Institute of Mental Health of the United State of America.| date=2009-11| archive-url=https://web.archive.org/web/20170422132640/https://www.nimh.nih.gov/funding/clinical-research/practical/mta/multimodal-treatment-of-attention-deficit-hyperactivity-disorder-mta-study.shtml| archive-date=2017-04-22| access-date=April 22nd, 2017.| deadurl=no| accessdate=2017-04-22| archiveurl=https://web.archive.org/web/20170422132640/https://www.nimh.nih.gov/funding/clinical-research/practical/mta/multimodal-treatment-of-attention-deficit-hyperactivity-disorder-mta-study.shtml| archivedate=2017-04-22}}</ref><ref name="Multipmodal treatment of ADHD">{{cite web | last=Authors | first=No | title=A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Tr...  - PubMed | website=NCBI | date=1999-12-11 | url=https://www.ncbi.nlm.nih.gov/pubmed/10591283 | accessdate=2017-04-22 | deadurl=no | archiveurl=https://web.archive.org/web/20170504203428/https://www.ncbi.nlm.nih.gov/pubmed/10591283 | archivedate=2017-05-04 }}</ref>
| label_type  = 治療模式
| data_type   = 整體進步（單位：%百分比）
| bar_width   = 35
| width_units = em
| data_max    = 100
| label1   = ADHD藥物+ADHD行為暨認知行為治療 (MTA模式)
| data1    = 68
| label2   = ADHD藥物治療 (MTA模式)
| data2    = 56
| label3   = ADHD行為治療 (MTA模式)
| data3    = 34
| label4   = ADHD藥物治療 
| data4    = 25
| float    = center
}}

*【ADHD藥物治療 (MTA模式)】、【ADHD行為治療 (MTA模式)】與【ADHD藥物治療】，這三組治療模式對患者在許多領域應對能力的缺陷，例如：社交技巧、親子關係、情緒管理、課業表現等的改善程度幾乎一致。【ADHD藥物治療 (MTA模式)】+【ADHD行為治療 (MTA模式)】的改善效果則高於其他實驗組或其他實驗組的[[排列組合|排列組合]]<ref name="NIMH » Home game">{{cite web | title=NIMH » The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (MTA):Questions and Answers | website=NIMH » Home | url=https://www.nimh.nih.gov/funding/clinical-research/practical/mta/the-multimodal-treatment-of-attention-deficit-hyperactivity-disorder-study-mta-questions-and-answers.shtml | access-date=2019-01-01 | quote=Question: Why were the MTA medication treatments more effective than community treatments that also usually included medication? Answer: There were substantial differences in quality and intensity between the study-provided medication treatments and those provided in the community care group. During the first month of treatment, the MTA doctors worked hard to find the best dose of medication for each child receiving the MTA medication treatment. After this period, the children saw their MTA doctor monthly.}}</ref>。
*【ADHD藥物治療 (MTA模式)】+【ADHD行為治療 (MTA模式)】所需的藥物劑量少於【ADHD藥物治療】或【ADHD藥物治療 (MTA模式)】。<ref name="NIMH » Home game"/>
*藥物顯著壓抑用藥者的身高和體重的發展。<ref name="NIMH » Home game"/>
*88%的ADHD完成了這項為期十四個月的臨床實驗、有4%的ADHD受制於藥物的副作用而離開<ref name="NIMH » Home game"/>。
*統計呈現出的平均進步分數無法反映每位受試者的真實情況。事實上，即便是【ADHD藥物治療 (MTA模式)】、【ADHD行為治療 (MTA模式)】中的受試者，每個受試者之間的進步幅度都不同。另外，有一些受試者無論是在四個組別的任意一組，其ADHD的症狀都獲得顯著改善。<ref name="NIMH » Home game"/>
*上述四種治療型式都不是最佳的治療方案，依據患者的情況下判斷才是最好的選擇。<ref name="NIMH » Home game"/>
*實驗僅表明了各治療模式持續14個月的效果。<ref name="NIMH » Home game"/> 受試者在14個月後的自由意志不再受制於實驗的規定。因此這些人雖然在往後數十年仍定期接受MTA評估（非治療），但考量到他們之中有一些人即便在其他地方持續以藥物治療，但其藥物治療的方式不一定符合MTA的實驗規範，是故已經無法從定期長期追蹤評估的結果精準判斷上述四種模式的長期治療效果<ref name="NIMH » Home game"/>。不過該定期長期追蹤評估的結果可用來判斷注意力不足過動症本身的病程和帶給患者的人生境遇。<ref name="NIMH » Home game"/>
*【ADHD行為治療 (MTA模式)】包含27堂團體父母管理訓練課程、8堂個別父母管理訓練課程、為期八周的暑期ADHD治療課程、為期十二周的課堂ADHD行為治療課程與半互動的學習模式和十位ADHD專門教師的諮商課程。<ref name="Molina Hinshaw Swanson Arnold 2009 pp. 484–500 II">{{cite journal | last=Molina | first=Brooke S.G. | last2=Hinshaw | first2=Stephen P. | last3=Swanson | first3=James M. | last4=Arnold | first4=L. Eugene | last5=Vitiello | first5=Benedetto | last6=Jensen | first6=Peter S. | last7=Epstein | first7=Jeffery N. | last8=Hoza | first8=Betsy | last9=Hechtman | first9=Lily | last10=Abikoff | first10=Howard B. | last11=Elliott | first11=Glen R. | last12=Greenhill | first12=Laurence L. | last13=Newcorn | first13=Jeffrey H. | last14=Wells | first14=Karen C. | last15=Wigal | first15=Timothy | last16=Gibbons | first16=Robert D. | last17=Hur | first17=Kwan | last18=Houck | first18=Patricia R. | title=The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study | journal=Journal of the American Academy of Child & Adolescent Psychiatry | publisher=Elsevier BV | volume=48 | issue=5 | year=2009 | issn=0890-8567 | doi=10.1097/chi.0b013e31819c23d0 | pages=484–500 |pmc=3063150 | quote= (b) multicomponent behavior therapy (Beh), which included 27-session group parent training supplemented with eight individual parent sessions, an 8-week summer treatment program, 12 weeks of classroom administered behavior therapy with a half-time aide and 10 teacher consultation sessions.}}</ref>
*【ADHD藥物治療】：普通的精神科門診型式<ref name="Molina Hinshaw Swanson Arnold 2009 pp. 484–500">{{cite journal | last=Molina | first=Brooke S.G. | last2=Hinshaw | first2=Stephen P. | last3=Swanson | first3=James M. | last4=Arnold | first4=L. Eugene | last5=Vitiello | first5=Benedetto | last6=Jensen | first6=Peter S. | last7=Epstein | first7=Jeffery N. | last8=Hoza | first8=Betsy | last9=Hechtman | first9=Lily | last10=Abikoff | first10=Howard B. | last11=Elliott | first11=Glen R. | last12=Greenhill | first12=Laurence L. | last13=Newcorn | first13=Jeffrey H. | last14=Wells | first14=Karen C. | last15=Wigal | first15=Timothy | last16=Gibbons | first16=Robert D. | last17=Hur | first17=Kwan | last18=Houck | first18=Patricia R. | title=The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study | journal=Journal of the American Academy of Child & Adolescent Psychiatry | publisher=Elsevier BV | volume=48 | issue=5 | year=2009 | issn=0890-8567 | doi=10.1097/chi.0b013e31819c23d0 | pages=484–500 | pmc=3063150}}</ref><ref name="NIMH » Home game"/>。

-----

</onlyinclude>

==多管齊下<!--多元介入-->==

ADHD的多元介入治療包含藥物治療、親職[[心理輔導|諮商]]訓練、[[特殊教育|學校資源教育]]及社交技巧訓練等各種模式，這些治療模式的效果都有嚴謹而完整的科學研究加以證實<ref name="tscap4"/>。藥物包括中樞神經刺激劑、[[阿托莫西汀|阿托莫西汀]]、{{tsl|en|alpha-2 adrenergic receptor|α2腎上腺素受體}}刺激劑，有時也會使用抗憂鬱藥物<ref name="Wilens-2010"/><ref name="cognition enhancers II">{{cite journal |vauthors=Bidwell LC, McClernon FJ, Kollins SH | title = Cognitive enhancers for the treatment of ADHD | journal = Pharmacol. Biochem. Behav. | volume = 99 | issue = 2 | pages = 262–274 |date=August 2011 | pmid = 21596055 | pmc = 3353150 | doi = 10.1016/j.pbb.2011.05.002  }}</ref>。治療用的中樞神經刺激劑可以提昇ADHD兒童的持續力以及任務表現<ref name="Malenka ADHD neurosci" /><ref name="Motivation">{{cite journal | vauthors = Modesto-Lowe V, Chaplin M, Soovajian V, Meyer A | title = Are motivation deficits underestimated in patients with ADHD? A review of the literature | journal = Postgrad Med | volume = 125 | issue = 4 | pages = 47–52 | year = 2013 | pmid = 23933893 | doi = 10.3810/pgm.2013.07.2677|quote=Behavioral studies show altered processing of reinforcement and incentives in children with ADHD. These children respond more impulsively to rewards and choose small, immediate rewards over larger, delayed incentives. Interestingly, a high intensity of reinforcement is effective in improving task performance in children with ADHD. Pharmacotherapy may also improve task persistence in these children. ... Previous studies suggest that a clinical approach using interventions to improve motivational processes in patients with ADHD may improve outcomes as children with ADHD transition into adolescence and adulthood. }}</ref>。

國立臺灣大學醫學院醫師高淑芬強調及早發現並接受治療，絕對是最佳策略。<ref name="衛生福利部 注意力不足過動症">{{cite book
 | author = 蔣丙煌
 | author2 =陳快樂
 | author3 = 國立臺灣大學醫學院附設醫院精神醫學部
 | author4 =張雍敏、鄭淑心、賴淑玲、傅悅娟、張景瑞、侯育銘、郭約瑟、張君威、鄧惠文、陳嘉新、紀雪雲、黃雅文、連玉如、連盈如、吳其炘
 | author5 =高淑芬&陳劭芊
 | title = 注意力不足過動症
 | publisher = 中華民國衛生福利部
 | series = 衛生福利部精神疾病衛教叢書
 | volume = 02
 | edition = First
 | location = Taipei
 | language = zh-tw
 | date = 2015-06
 | doi = 
 | isbn = 9789860454154
 | url =https://www.mohw.gov.tw/dl-1728-547a9d89-00e5-4e9e-b998-26cff0ee69e7.html
 | archiveurl =https://web.archive.org/web/20170219181830/http://www.mohw.gov.tw/MOHW_Upload/doc/%E5%BF%83%E7%90%86%E8%A1%9B%E7%94%9F%E5%B0%88%E8%BC%AF/03%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E9%81%8E%E5%8B%95%E7%97%87.pdf
 | archivedate =2017-02-19
 | page = 19-20}}</ref><ref name="找回專注力"/>
本身也是注意力不足過動症患者的{{tsl|en|Edward Hallowell|愛德華·哈洛威爾}}醫師則建議治療的策略應把握發揚優點、避免缺點的原則。<ref name="books2000"/>
藥物治療合併[[行為治療|行為治療]]（[[認知行為治療|認知行為治療]]<ref name="UpToDate psychotherapy targeting executive function ">{{cite web | title=Pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | website=UpToDate | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder?search=adult%20adhd&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H437177578 | access-date=2018-03-17 | quote=The addition of a targeted cognitive-behavioral therapy to a partially effective first-line medication would be a reasonable alternative to medication. | deadurl=no | archiveurl=https://web.archive.org/web/20180317164936/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder?search=adult%20adhd&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H437177578 | archivedate=2018-03-17 }}</ref>）已證實為當前最有效的注意力不足過動症治療方式。<ref name="ChanFogler2016">{{cite journal|last1=Chan|first1=Eugenia|last2=Fogler|first2=Jason M.|last3=Hammerness|first3=Paul G.|title=Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents|journal=JAMA|volume=315|issue=18|year=2016|pages=1997|issn=0098-7484|doi=10.1001/jama.2016.5453 }}</ref><ref name="auto">{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=125 |title=青少年ADHD的治療-一系統性回顧 |doi=10.1001/jama.2016.5453 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161129210346/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=125 |archivedate=2016-11-29 }}</ref><ref name="tscap1">{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=121 |title=20160728公聽會-台灣兒童青少年精神醫學會新聞稿 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20170305001645/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=121 |archivedate=2017-03-05 }}</ref><ref name="Yen"/><ref name="tscap2">{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=117 |title=臺灣兒童青少年精神醫學會新聞稿20160603 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161130124759/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=117 |archivedate=2016-11-30 }}</ref><ref name="tscap2"/><ref>{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=104 |title=新聞稿20160412-回應質疑注意力不足過動症之診斷、藥物治療等議題 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161130034950/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=104 |archivedate=2016-11-30 }}</ref><ref name="Insight from a psychiatrist's perspecctive">{{cite web| author=翁士恒| title=ADHD 臨床現場的分裂與對話：以ICF為參照的反思| website=還孩子做自己行動聯盟| date=2017-03-13| url=http://www.letchildrenbe.org/archives/1838#more-1838| language=zh| access-date=2017-06-24| quote=ADHD不只是心智功能與神經結構出現問題，還包括了病者的自我調適、家庭支持系統、鄰人功能與居家環境的功能與障礙。這些包含身體功能、活動參與與環境功能的整體，才是一個完整的疾病經驗（Lived experience of illness）。| archive-url=https://archive.today/20180308074237/http://www.letchildrenbe.org/archives/1838%23more-1838#more-1838| archive-date=2018-03-08| deadurl=yes| accessdate=2017-06-24| archiveurl=https://archive.today/20180308074237/http://www.letchildrenbe.org/archives/1838%23more-1838#more-1838| archivedate=2018-03-08}}</ref>

[[台灣兒童青少年精神醫學會|台灣兒童青少年精神醫學會]]指出：「治療ADHD核心症狀時，藥物是絕對不能忽略的治療選項。<ref name="tscap1" />」台灣兒童青少年精神醫學會另指出，對於18歲後才獲得第一次ADHD診斷的患者，台灣健保僅給付短效中樞神經刺激劑（利他能），但患者若認為有使用其他長效中樞神經刺激劑或者長效型非中樞神經刺激劑藥物的需求，應勇於跟醫生討論，不要因而忌諱就醫，延誤治療時機。<ref name="全國法規資料庫入口網站 II">{{cite web | title=全民健康保險藥物給付項目及支付標準§83 | website=全國法規資料庫入口網站 | url=http://law.moj.gov.tw/LawClass/LawSingleIf.aspx?Pcode=L0060035&FLNO=83 | language=zh | access-date=2018-07-16 | page=1680-1681 | date=2018-09-19}}</ref>{{R|找回專注力}}{{RP|105}}

研究顯示，ADHD的藥物治療能顯著降低患者發生交通事故的機率。<ref name="Chang Quinn Hur Gibbons p=597">{{cite journal | last=Chang | first=Zheng | last2=Quinn | first2=Patrick D. | last3=Hur | first3=Kwan | last4=Gibbons | first4=Robert D. | last5=Sjölander | first5=Arvid | last6=Larsson | first6=Henrik | last7=D’Onofrio | first7=Brian M. | title=Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes | journal=JAMA psychiatry | publisher=American Medical Association (AMA) | volume=74 | issue=6 | date=2017-06-01 | issn=2168-622X | pmid=28492937 | pmc=5539840 | doi=10.1001/jamapsychiatry.2017.0659 | page=597}}</ref>
研究也顯示，ADHD的治療可能大幅降低ADHD患者被[[霸凌|霸凌]]或霸凌他人的機率<ref name="Liu Guo Hsiao Hu 2017 pp. 59–66">{{cite journal | last=Liu | first=Tai-Ling | last2=Guo | first2=Nai-Wen | last3=Hsiao | first3=Ray C. | last4=Hu | first4=Huei-Fan | last5=Yen | first5=Cheng-Fang | title=Relationships of bullying involvement with intelligence, attention, and executive function in children and adolescents with attention-deficit/hyperactivity disorder | journal=Research in Developmental Disabilities | publisher=Elsevier BV | volume=70 | year=2017 | issn=0891-4222 | doi=10.1016/j.ridd.2017.08.004 | pages=59–66}}</ref><ref name="Yeh Huang Wu Hu p=108705471772451">{{cite journal | last=Yeh | first=Yi-Chun | last2=Huang | first2=Mei-Feng | last3=Wu | first3=Yu-Yu | last4=Hu | first4=Huei-Fan | last5=Yen | first5=Cheng-Fang | title=Pain, Bullying Involvement, and Mental Health Problems Among Children and Adolescents With ADHD in Taiwan | journal=Journal of attention disorders | publisher=SAGE Publications | date=2017-08-24 | issn=1087-0547 | pmid=28836888 | doi=10.1177/1087054717724514 | page=108705471772451}}</ref><ref name="Hu Chou Yen 2016 pp. 103–109">{{cite journal | last=Hu | first=Huei-Fan | last2=Chou | first2=Wen-Jiun | last3=Yen | first3=Cheng-Fang | title=Anxiety and depression among adolescents with attention-deficit/hyperactivity disorder: The roles of behavioral temperamental traits, comorbid autism spectrum disorder, and bullying involvement | journal=The Kaohsiung journal of medical sciences | publisher=Elsevier BV | volume=32 | issue=2 | year=2016 | issn=1607-551X | pmid=26944330 | doi=10.1016/j.kjms.2016.01.002 | pages=103–109}}</ref><ref name="Chou Liu Yang Yen 2018 pp. 25–34">{{cite journal | last=Chou | first=Wen-Jiun | last2=Liu | first2=Tai-Ling | last3=Yang | first3=Pinchen | last4=Yen | first4=Cheng-Fang | last5=Hu | first5=Huei-Fan | title=Bullying Victimization and Perpetration and Their Correlates in Adolescents Clinically Diagnosed With ADHD | journal=Journal of attention disorders | publisher=SAGE Publications | volume=22 | issue=1 | date=2014-11-17 | year=2018 | issn=1087-0547 | pmid=25403369 | doi=10.1177/1087054714558874 | pages=25–34}}</ref>（包含遭受[[網路霸凌|網路霸凌]]或在網路上霸凌別人<ref name="Yen Chou Liu Ko 2014 pp. 3543–3553">{{cite journal | last=Yen | first=Cheng-Fang | last2=Chou | first2=Wen-Jiun | last3=Liu | first3=Tai-Ling | last4=Ko | first4=Chih-Hung | last5=Yang | first5=Pinchen | last6=Hu | first6=Huei-Fan | title=Cyberbullying among male adolescents with attention-deficit/hyperactivity disorder: Prevalence, correlates, and association with poor mental health status | journal=Research in developmental disabilities | publisher=Elsevier BV | volume=35 | issue=12 | year=2014 | issn=0891-4222 | pmid=25241113 | doi=10.1016/j.ridd.2014.08.035 | pages=3543–3553}}</ref><ref name="Chou Liu Hu Yen 2016 pp. 86–94">{{cite journal | last=Chou | first=Wen-Jiun | last2=Liu | first2=Tai-Ling | last3=Hu | first3=Huei-Fan | last4=Yen | first4=Cheng-Fang | title=Suicidality and its relationships with individual, family, peer, and psychopathology factors among adolescents with attention-deficit/hyperactivity disorder | journal=Research in Developmental Disabilities | publisher=Elsevier BV | volume=53-54 | year=2016 | issn=0891-4222 | doi=10.1016/j.ridd.2016.02.001 | pages=86–94}}</ref>）。<ref name="Unnever Cornell 2003 pp. 129–147">{{cite journal | last=Unnever | first=James D. | last2=Cornell | first2=Dewey G. | title=Bullying, Self-Control, and Adhd | journal=Journal of Interpersonal Violence | publisher=SAGE Publications | volume=18 | issue=2 | year=2003 | issn=0886-2605 | doi=10.1177/0886260502238731 | pages=129–147}}</ref><ref name="suppress">{{youtube|uTvVcYDs2z8|m=13|s=14|language=zh|title=20180811自閉症青少年親職講座}}</ref>

==非藥物治療==
{{main article|注意力不足過動症的非藥物治療}}
{{:注意力不足過動症的非藥物治療}}

==藥物治療==
      參見：[[Template:ADHD_pharmacotherapies|ADHD的治療藥物、藥品一覽表]]、[[注意力不足過動症多重治療模式研究#行為治療|注意力不足過動症多重治療模式研究§藥物治療]]

{{Pie chart
 | caption=2011年，全美「有ADHD診斷的兒童與青少年（4-17歲）且被診斷數年後至少仍符合ADHD診斷最低標準的患者」之用藥比例。
<ref name="Visser Danielson Bitsko Holbrook 2014 pp. 34–46.e2">{{cite journal | last=Visser | first=Susanna N. | last2=Danielson | first2=Melissa L. | last3=Bitsko | first3=Rebecca H. | last4=Holbrook | first4=Joseph R. | last5=Kogan | first5=Michael D. | last6=Ghandour | first6=Reem M. | last7=Perou | first7=Ruth | last8=Blumberg | first8=Stephen J. | title=Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003–2011 | journal=Journal of the American Academy of Child and Adolescent Psychiatry | publisher=Elsevier BV | volume=53 | issue=1 | year=2014 | issn=0890-8567 | pmid=24342384 | pmc=4473855  | doi=10.1016/j.jaac.2013.09.001 | pages=34–46.e2}}</ref><ref name="NIMH » Home 2017 Last update November 2017">{{cite web | title=NIMH » Attention-Deficit/Hyperactivity Disorder (ADHD) | website=NIMH » Home | date=2017-11-01 | url=https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd.shtml | access-date=2018-07-20 | accessdate=2018-07-20 | archiveurl=https://web.archive.org/web/20180709200248/https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd.shtml | archivedate=2018-07-09 | deadurl=no }}</ref>{{NoteTag|name=|1=全美國ADHD的用藥率從2007-2011年成長了4%，其中男性青少年用藥比率是相對其他族群來說，成長最快的。<ref name="Visser Danielson Bitsko Holbrook 2014 pp. 34–46.e2"/><ref name="NIMH » Home 2017 Last update November 2017"/>}}
 | other = 
 | label1 =正在接受藥物治療者
 | value1 = 69.3 | color1 =  #008
 | label2 = 沒有正在接受藥物治療者
 | value2 = 30.7 | color2 =silver
 | label3 =
 | value3 = | color3 =
 }}
 {{Pie chart
 | caption=2016年，全台灣「有ADHD的兒童與青少年（4-17歲）」之用藥比例。 
<ref name="Thomas Sanders Doust Beller 2015 pp. e994–e1001">{{cite journal | last=Thomas | first=R. | last2=Sanders | first2=S. | last3=Doust | first3=J. | last4=Beller | first4=E. | last5=Glasziou | first5=P. | title=Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis | type=secondary source or tertiary source| journal=PEDIATRICS | publisher=American Academy of Pediatrics (AAP) | volume=135 | issue=4 | year=2015 | pages=e994–e1001 | url=https://doi.org/10.1542%2Fpeds.2014-3482 | doi=10.1542/peds.2014-3482 | accessdate=2017-04-21|quote=7.2% (95% confidence interval: 6.7 to 7.8)}}</ref><ref>{{cite journal| url=http://www.tscap.org.tw/TW/ImgTscapOrg/20160806140723.pdf | journal=Child & Adolescent Psychiatry Newsletter | volume=15 | issue=2 | date=2016-06 |author=[[高淑芬|Susan Gau]] | title=兒童青少年精神醫學通訊-主題：拒學行為}}</ref><ref name="zhen 2016 p. ">{{cite book |author=陳錦宏 |author2= 高淑芬| title=ADHD注意力不足過動症家長手冊 A parenting guide for ADHD | publisher=台灣兒童青少年精神醫學會  | publication-place=Taipei City | year=2016-08 | isbn=978-986-93509-1-4 | oclc=982650259 | language=zh-tw | page=}}</ref><ref name="Pingtung Hospital">
{{cite news
|url = http://news.ltn.com.tw/news/life/breakingnews/1937245
|title = 家有頑童？ 屏東醫院籲把握ADHD黃金治療期
|pages = 生活
|newspaper = 自由時報電子報
|author =
|date = 2016
|location = 中華民國台灣 屏東縣屏東市
|language = zh-tw
|deadurl = no
|archiveurl = https://web.archive.org/web/20170108190949/http://news.ltn.com.tw/news/life/breakingnews/1937245
|archivedate = 2017-01-08}}</ref><ref name="陳鈞凱 2018">{{cite web | author=陳鈞凱 | title=【有影】從白目衝動變拿文學、美術獎 台灣醫師靠這招解除過動兒「封印」 | website=匯流新聞網 | archive-url=https://web.archive.org/web/20181215161219/https://cnews.com.tw/003180817a04/ | archive-date=2018-12-16 | date=2018-08-17 | url=https://cnews.com.tw/003180817a04/ | language=zh | access-date=2018-12-15 | quote=根據統計，台灣ADHD盛行率約為7.5至9%，但健保資料研究顯示，只有近2%的孩子尋求診斷，更只有1%接受完整治療。超過7成的ADHD青少年有其他合併症狀，陳錦宏說，包括5成有學習障礙、4成感到焦慮、3成發生物質濫用行為、2成有憂鬱情形，且在學業、工作、身體意外傷害、家庭關係、車禍、藥酒癮的負面影響機率全都是一般人的2到3倍，而專業治療可以降低這些意外及藥酒癮50%的風險。治療非常的重要，陳錦宏強調，因ADHD是一種腦生理功能發展延遲的問題，大腦一半區域發展速度明顯較慢，美國國家衛生研究院花了10年追蹤更發現，ADHD兒童大腦皮質發展比正常兒童慢3年，部分更會持續到青春期或成年之後。}}</ref>

 | other = 
 | label1 = 正在接受藥物治療者
 | value1 = 4.8 | color1 = red

 | label2 = 沒有正在接受藥物治療者
 | value2 = 95.2 | color2 = green
 | label3 = 
 | value3 = | color3 = 
 }}
藥物可以減少「過動—衝動」、分心等核心症狀，提升孩子的自制力，讓他們有足夠的能力追尋自己的夢想。另外一方面，藥物<!--並非控制過動症狀，而-->是治療腦部先天性功能缺陷。在醫療用途上，ADHD藥物的副作用均輕微，副作用透過調整藥物配方（停藥、減少劑量、加入Clonidine等緩[[心悸|心悸]]藥物）即可改善。在[[醫學|醫學]]與[[藥學|藥學]]（[[藥理學|藥理學]]、[[藥劑學|藥劑學]]）知識的把關下，中樞神經刺激劑等藥物都是安全的。{{#tag:ref| <ref name="Arnold Hodgkins Caci Kahle">
{{cite journal | last=Arnold | first=L. Eugene | last2=Hodgkins | first2=Paul | last3=Caci | first3=Hervé | last4=Kahle | first4=Jennifer | last5=Young | first5=Susan | title=Effect of Treatment Modality on Long-Term Outcomes in Attention-Deficit/Hyperactivity Disorder: A Systematic Review | journal=PLoS ONE | volume=10 | issue=2| pmid=25714373 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791/ | doi=10.1371/journal.pone.0116407 | accessdate=2017-05-15}}</ref>
<ref name="Millichap: onset, peak, and duration">
{{cite book 
| author = Millichap JG 
|  editor = Millichap JG 
| title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD 
| year = 2010 
| publisher = Springer 
| location = New York, USA 
| isbn = 9781441913968 
| pages = 112 
| edition = 2nd 
| chapter = Chapter 9: Medications for ADHD 
| quote = <br />Table 9.2 Dextroamphetamine formulations of stimulant medication<br />Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...<br />Adderall [Peak:2–3 h] [Duration:5–7 h]<br />Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...<br />Adderall XR [Peak:7–8 h] [Duration:12 h]<br />Vyvanse [Peak:3–4 h] [Duration:12 h]}}</ref>
<ref name="Long-Term Outcomes Medications">{{cite journal |vauthors=Huang YS, Tsai MH | title = Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge | journal = CNS Drugs | volume = 25 | issue = 7 | pages = 539–554 |date=2011-07  | pmid = 21699268 | doi = 10.2165/11589380-000000000-00000}}</ref><!--參考自[[苯丙胺|Amphetamine]]條目。--><ref name="Long-term 2015">{{cite journal|title=Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review|date=2015-02|journal=PLoS ONE|issue=2|doi=10.1371/journal.pone.0116407|volume=10|pages=e0116407|pmc=4340791|pmid=25714373|quote=The highest proportion of improved outcomes was reported with combination treatment (83% of outcomes). Among significantly improved outcomes, the largest effect sizes were found for combination treatment. The greatest improvements were associated with academic, self-esteem, or social function outcomes.|vauthors=Arnold LE, Hodgkins P, Caci H, Kahle J, Young S}}</ref><ref name="Dexedrine FDA">{{cite web | title = Dexedrine Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017078s047lbl.pdf | publisher = Amedra Pharmaceuticals LLC | work = United States Food and Drug Administration | date =  2013-10 | accessdate = 2013-11-04 | deadurl = no | archiveurl = https://web.archive.org/web/20160304085041/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017078s047lbl.pdf | archivedate = 2016-03-04 }}</ref><ref>{{cite web | title=Adderall IR Prescribing Information | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011522s042lbl.pdf | publisher=Teva Pharmaceuticals USA, Inc. | work=United States Food and Drug Administration | date=2015-10 | accessdate=2016-05-18 | deadurl=no | archiveurl=https://web.archive.org/web/20160418103847/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011522s042lbl.pdf | archivedate=2016-04-18 }}</ref><ref>{{cite web | title = Adderall XR Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | publisher = Shire US Inc | work = United States Food and Drug Administration | date =  2013-12 | accessdate = 2013-12-30 | deadurl = no | archiveurl = https://web.archive.org/web/20131230233702/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | archivedate = 2013-12-30 }}</ref><ref name="Department of Health">{{cite web | title=The amphetamine withdrawal syndrome | website=Department of Health | url=http://www.health.gov.au/internet/publications/publishing.nsf/Content/drugtreat-pubs-modpsy-toc~drugtreat-pubs-modpsy-3~drugtreat-pubs-modpsy-3-7~drugtreat-pubs-modpsy-3-7-aws#amp | accessdate=2017-05-09 | deadurl=no | archiveurl=https://web.archive.org/web/20170208102025/http://health.gov.au/internet/publications/publishing.nsf/Content/drugtreat-pubs-modpsy-toc~drugtreat-pubs-modpsy-3~drugtreat-pubs-modpsy-3-7~drugtreat-pubs-modpsy-3-7-aws#amp | archivedate=2017-02-08 }}</ref>|group="references"}}
{{#tag:ref|<ref name="NIMH » Home 2018">{{cite web | title=NIMH » Attention Deficit Hyperactivity Disorder | website=NIMH » Home | url=https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | access-date=2018-07-21 | quote=Stimulants. The most common type of medication used for treating ADHD is called a “stimulant.” Although it may seem unusual to treat ADHD with a medication that is considered a stimulant, it works because it increases the brain chemicals dopamine and norepinephrine, which play essential roles in thinking and attention. Under medical supervision, stimulant medications are considered safe. However, there are risks and side effects, especially when misused or taken in excess of the prescribed dose.For example, stimulants can raise blood pressure and heart rate and increase anxiety. Therefore, a person with other health problems, including high blood pressure, seizures, heart disease, glaucoma, liver or kidney disease, or an anxiety disorder should tell their doctor before taking a stimulant. | accessdate=2016-12-27 | archiveurl=https://web.archive.org/web/20161225231931/https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | archivedate=2016-12-25 | deadurl=no }}</ref><ref name="Overview of palpitations in adults">{{cite web | title=Overview of palpitations in adults | website=UpToDate | url=https://www.uptodate.com/contents/overview-of-palpitations-in-adults?search=palpitations&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 | access-date=2018-08-14 | archive-url=https://web.archive.org/web/20180814232700/https://www.uptodate.com/contents/overview-of-palpitations-in-adults?search=palpitations&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 | archive-date=2018-08-14 | dead-url=no }}</ref><ref name="Approach to the child with palpitations">{{cite web | title=Approach to the child with palpitations | website=UpToDate | url=https://www.uptodate.com/contents/approach-to-the-child-with-palpitations?search=palpitations&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 | access-date=2018-08-14 | archive-url=https://web.archive.org/web/20180814232722/https://www.uptodate.com/contents/approach-to-the-child-with-palpitations?search=palpitations&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 | archive-date=2018-08-14 | dead-url=no }}</ref><ref name="UpToDate 2016 Asthma comorbidity"/><ref name="UpToDate Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents
">{{cite web | title=Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents | website=UpToDate | url=https://www.uptodate.com/contents/pharmacology-of-drugs-used-to-treat-attention-deficit-hyperactivity-disorder-in-children-and-adolescents?sectionName=ALPHA-2-ADRENERGIC%20AGONISTS&topicRef=17158&anchor=H1130293854&source=see_link#H1130293854 | access-date=2018-09-12 | quote= Clonidine may be useful in overaroused, easily frustrated, highly active, or aggressive individuals [3]. Although there are few randomized controlled trials with multiple drugs, the addition of clonidine to stimulant therapy may help offset some of the common stimulant side effects.}}</ref><ref name="Pliszka 2007 pp. 894–921">{{cite journal | last=Pliszka | first=Steven | title=Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder | journal=Journal of the American Academy of Child and Adolescent Psychiatry | publisher=Elsevier BV | volume=46 | issue=7 | year=2007 | issn=0890-8567 | pmid=17581453 | doi=10.1097/chi.0b013e318054e724 | pages=894–921}}</ref>
|group="references"}}

ADHD有時可能出現忘記吃藥的情形{{noteTag|name=|1=藥物不會成癮且ADHD患者往往不易維持生活組織及時間等。<ref name="Medscape Education 2010 reviewed">{{cite web | title=Medscape Log In | website=Medscape Education | date=2010-01-01 | url=https://www.medscape.org/viewarticle/734449 | access-date=2018-06-14 | quote=Short-acting stimulants have been available for decades, but their use as first-line treatment is not advised. These agents require 3-4 daily doses to sustain effectiveness throughout the day. This is a tall order for patients with preexisting struggles with time management and organization. Furthermore, because behavioral response is linked to drug metabolism and these agents have a therapeutic effect that wanes within hours of administration, it is difficult for a clinician to assess efficacy in patients with rapidly shifting blood levels. For these reasons, the use of short-acting stimulants delays significant and consistent improvements in symptoms.[12] | deadurl=no | archiveurl=https://web.archive.org/web/20180614124021/https://www.medscape.org/viewarticle/734449 | archivedate=2018-06-14 }}</ref>}}，且短效藥物在[[血漿|血漿]]內的濃度變化很快，故不易維持穩定的療效，所以中長效型的藥物，對於患者來說是較為適合的。<ref name="Medscape Education 2010 reviewed II">{{cite web | title=Medscape Log In | website=Medscape Education | date=2010-01-01 | url=https://www.medscape.org/viewarticle/734449 | access-date=2018-06-14 | quote=Using pharmacy data of 60,010 patients taking ADHD medications (41.6% adults), researchers found that adherence and persistence were best with long-acting stimulants, with long-acting amphetamines having the advantage over long-acting methylphenidate.[21]A long-acting drug and a higher therapeutic dose may make a marked difference. If the patient is resistant to one agent, then trying a different medication might be more effective and elicit better adherence. In most cases, long-acting ADHD medications are best because they can provide a more rapid response, which further increases the likelihood of medication adherence. | deadurl=no | archiveurl=https://web.archive.org/web/20180614124021/https://www.medscape.org/viewarticle/734449 | archivedate=2018-06-14 }}</ref><ref name="U S Food and Drug Administration Home Page 1999 validated source">{{cite web | title=FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides | website=U S Food and Drug Administration Home Page | date=2016-11-07 | url=https://www.fda.gov/Drugs/DrugSafety/ucm107918.htm | access-date=2017-12-09}}</ref> 除此之外，中樞神經刺激劑的劑量如果不足，會導致「治療ADHD的療效打折」或「藥效只出現一下下（later loss of effectiveness）」<ref>{{Cite journal|last=Stevens|first=Jonathan R.|last2=Wilens|first2=Timothy E.|last3=Stern|first3=Theodore A.|date=2013|title=Using Stimulants for Attention-Deficit/Hyperactivity Disorder: Clinical Approaches and Challenges|journal=The Primary Care Companion for CNS Disorders|volume=15|issue=2|doi=10.4088/PCC.12f01472|issn=2155-7772|pmc=3733520|pmid=23930227}}</ref>。中樞神經刺激劑的劑量不足的情況曾經發生在成人及青少年患者身上且未來也有可能發生，因為美國食品藥物管理局批准的劑量主要是適用於學齡兒童。為此，有些臨床醫師選擇改以體重或{{tsl|en|clinical judgement|臨床判斷|臨床療效}}作為處方藥物的劑量的基準。<ref>{{Cite web|url=http://www.medscape.org/viewarticle/734449|title=Individualizing Treatment for Adult ADHD: An Evidence-Based Guideline|last=Young|first=Joel L.|date=2010|website=Medscape|publisher=|access-date=2016-06-19|deadurl=no|archiveurl=https://web.archive.org/web/20150508075829/http://www.medscape.org/viewarticle/734449|archivedate=2015-05-08}}</ref><ref>{{Cite web|url=http://www.medscape.com/viewarticle/464377_print|title=New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder|last=Biederman|first=Joseph|date=2003|website=Medscape|publisher=|access-date=2016-06-19|quote=As most treatment guidelines and prescribing information for stimulant medications relate to experience in school-aged children, prescribed doses for older patients are lacking. Emerging evidence for both methylphenidate and Adderall indicate that when weight-corrected daily doses, equipotent with those used in the treatment of younger patients, are used to treat adults with ADHD, these patients show a very robust clinical response consistent with that observed in pediatric studies. These data suggest that older patients may require a more aggressive approach in terms of dosing, based on the same target dosage ranges that have already been established – for methylphenidate, 1–1.5–2 mg/kg/day, and for D,L-amphetamine, 0.5–0.75–1 mg/kg/day.... <br />In particular, adolescents and adults are vulnerable to underdosing, and are thus at potential risk of failing to receive adequate dosage levels. As with all therapeutic agents, the efficacy and safety of stimulant medications should always guide prescribing behavior: careful dosage titration of the selected stimulant product should help to ensure that each patient with ADHD receives an adequate dose, so that the clinical benefits of therapy can be fully attained.|deadurl=no|archiveurl=https://web.archive.org/web/20031207063556/http://www.medscape.com/viewarticle/464377_print|archivedate=2003-12-07}}</ref><ref>{{Cite journal|last=Kessler|first=S.|date=1996|title=Drug therapy in attention-deficit hyperactivity disorder|journal=Southern Medical Journal|volume=89|issue=1|pages=33–38|issn=0038-4348|pmid=8545689|doi=10.1097/00007611-199601000-00005}}</ref><ref name="Kienle Kiene 2018 p. ">{{cite journal | last=Kienle | first=Gunver S | last2=Kiene | first2=Helmut | title=Clinical judgement and the medical profession | journal=Journal of Evaluation in Clinical Practice | volume=17 | issue=4 | date=2018-12-14 | pmid=20973873 | doi=10.1111/j.1365-2753.2010.01560.x | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170707/ | access-date=2018-12-14 | page=}}</ref>

「[[中樞神經刺激劑|中樞神經刺激劑]]」{{noteTag|又名中樞神經活化劑、中樞神經興奮劑、興奮劑}}被列為第三級別『管制藥品』的原因在於<!--此藥的的[[藥理學|藥理學]]作用是增加[[多巴胺|多巴胺]]在腦部中的濃度，而長期過多的多巴胺濃度將使得大腦逐漸對刺激源產生「生理依賴」。管制的目的在於限制患者能取得的[[注意力不足過動症|中樞神經刺激劑]]數量並且-->避免民眾尚未經醫師處方就錯誤地使用<ref name="NIMH » Home 2018"/><ref>{{cite web| url=http://www.nzsmr.kh.edu.tw/upload/news/news_2_17848.ppt| author=顏正芳| archive-date=2018-03-15| website=[[高雄市立楠梓特殊教育學校|高雄市立楠梓特殊教育學校]] (www.nzsmr.kh.edu.tw/)| title=注意力不足過動症(ADHD)的評估和治療| archive-url=https://archive.today/20180315174410/http://www.nzsmr.kh.edu.tw/upload/news/news_2_17848.ppt| date=| deadurl=yes| accessdate=2018-03-15| archiveurl=https://archive.today/20180315174410/http://www.nzsmr.kh.edu.tw/upload/news/news_2_17848.ppt| archivedate=2018-03-15}}</ref>。

管制藥品雖具有醫療用途，但也可能因不當流用、濫用後而導致成癮，為了使管制藥品不致於淪為非法毒品，台灣的《[[wikisource:zh:管制藥品管理條例|管制藥品管理條例]]》規定，醫師必須領有管制藥品使用執照，才能開立第1~3級管制藥品專用處方箋；而藥師也必須依「管制藥品專用處方箋」才可調劑此類藥品；除此之外，患者領藥時，必須出具[[健保卡|身分證明]]，並在專用處方箋上[[簽名|簽名]]，確保用藥安全<ref name="衛生福利部食品藥物管理署 2018">{{cite web | title=管制藥品層層把關，防濫用成癮 | publisher=衛生福利部食品藥物管理署 | journal=藥物食品安全週報 | volume= 第683期 | date=2018/10/19| url=https://www.fda.gov.tw/TC/publishotherepaperContent.aspx?id=1216&tid=2512 | language=zh | access-date=2019-01-04 | archive-url=https://web.archive.org/web/20190104074318/https://www.fda.gov.tw/TC/publishotherepaperContent.aspx?id=1216&tid=2512 | archive-date=2019-01-04 | access-date=2019-01-04 }}</ref>。而患者領藥後應依據醫師開立的管制藥品處方箋，遵循醫囑，正確地服用<ref name="衛生福利部食品藥物管理署 2018"/>。如果管制藥品不是由醫師診斷、開立，甚至來路不明，民眾切勿服用，以免無法改善病情，還可能上癮或造成更嚴重的傷害<ref name="衛生福利部食品藥物管理署 2018"/>。

雖然個案可能常看似已興奮過頭，且治療藥物被歸納為興奮劑類{{noteTag|也就是中樞神經刺激劑類}}，但是興奮劑類藥物確實有幫助患者們保持平靜的效果。<ref>{{cite web
 |url         = https://medlineplus.gov/ency/article/001551.htm
 |title       = Medical Encyclopedia → Attention deficit hyperactivity disorder
 |date        = 2017-01-05
 |website     = medlineplus.gov
 |access-date = 2017-01
 |quote       = Psychostimulants (also known as stimulants) are the most commonly used medicines. Although these drugs are called stimulants, they actually have a calming effect in people with ADHD.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170126193043/https://medlineplus.gov/ency/article/001551.htm
 |archivedate = 2017-01-26
}}</ref><ref name="NIMH » Home 2018"/>
每個人或多或少都會有分心、過動或衝動等症狀，但這些症狀在ADHD患者上會更為頻繁的出現、症狀的嚴重度更高且影響生活、學業、工作等。一個現象是否達到疾病等級，必須考量到頻率及程度。<ref>{{cite web
 |url         = https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml
 |title       = Signs and symptoms of Attention Deficit Hyperactivity Disorder, National Institute of Mental Health.
 |date        =  2013-03
 |website     = nimh.nih.gov
 |publisher   = National Institute of mental health
 |access-date = 2017-01
 |quote       = It is normal to have some inattention, unfocused motor activity and impulsivity, but for people with ADHD, these behaviors/are more severe, occur more often, interfere with or reduce the quality of how they functions socially, at school, or in a job.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20161229084207/https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml
 |archivedate = 2016-12-29
}}</ref>

有些家長或孩童會以為使用藥物即可解決相關問題，因此對於藥物過度依賴，卻忽略需配合藥物使用的時期，讓孩子學習與接受指導，建立起人際互動、行為管理等技巧。這也讓孩子有機會可以不靠藥物自我管理。<ref>衛生福利部精神疾病衛教叢書 注意力不足過動症，第19至20頁<!--quote內容-->「反之，有些家長或孩童會以為使用藥物就像吃了「聰明藥」一切都解決了，而對於藥物過度依賴。卻忽略藥物只是提供孩子學習與接受指導的最佳時機，藉由此時建立起學習策略、人際互動、行為管理的技巧，才是孩子一生受用的能力，也有機會不靠藥物自我管理。」</ref><ref name="National Institute of Neurological Disorders and Stroke 2018"/>

一般來說，以藥物治療ADHD的效果相當顯著。
<ref name="ChanFogler2016"/>
<ref name="Yen">{{cite web|url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=1&hidNewsID=118|title=孩子和家長接受專業醫療協助的權利，是需要被維護的|author=顏正芳|date=2016/05|access-date=2017-02-27|publisher=台灣兒童青少年精神醫學會|deadurl=no|archiveurl=https://web.archive.org/web/20161129224139/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=1&hidNewsID=118|archivedate=2016-11-29}}</ref>
使用此類藥品的患者，長期治療的預後，幾乎都可以改善其注意力不集中、衝動與人際衝突的症狀；而且患者的社會性互動及人際關係乃至{{tsl|en|reading comprehension|閱讀理解|閱讀能力}}也都會有改善。<ref name="ChanFogler2016"/><ref name="Gray Climie p. ">{{cite journal | last=Gray | first=Christina | last2=Climie | first2=Emma A. | title=Children with Attention Deficit/Hyperactivity Disorder and Reading Disability: A Review of the Efficacy of Medication Treatments | journal=Frontiers in Psychology | publisher=Frontiers Media SA | volume=07 | date=2016-07-05 | issn=1664-1078 | doi=10.3389/fpsyg.2016.00988 | page=}}</ref> 文獻另指出，針對ADHD的{{le|個人化醫療|Personalized medicine}}可能包含較新的ADHD藥物配方、組合。<ref name="Leahy 2018 p. ">{{cite journal | last=Leahy | first=Laura G. | title=Diagnosis and Treatment of ADHD in Children vs Adults: What Nurses Should Know | journal=Archives of Psychiatric Nursing | publisher=Elsevier BV | year=2018 | issn=0883-9417 | doi=10.1016/j.apnu.2018.06.013 | page=}}</ref>醫師藉由{{tsl|en|Dosing|藥劑量滴定}}協助病人找到對病人來說最適合、最有效的{{tsl|en|Dose (biochemistry)||藥物劑量}}<ref name="Goodman Starr Ma Rostain pp. 105–114">{{cite journal | last=Goodman | first=David W. | last2=Starr | first2=H. Lynn | last3=Ma | first3=Yi-Wen | last4=Rostain | first4=Anthony L. | last5=Ascher | first5=Steve | last6=Armstrong | first6=Robert B. | title=Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder | journal=The Journal of Clinical Psychiatry | publisher=Physicians Postgraduate Press, Inc | volume=78 | issue=01 | date=2016-08-02 | issn=0160-6689 | doi=10.4088/jcp.15m10348 | pages=105–114}}</ref>，而不同的ADHD子類型所適用的{{tsl|en|Effective_dose_(pharmacology)||最小有效劑量}}可能不同<ref name="Barkley DuPaul McMurray 1991 pp. 519–31">{{cite | last=Barkley | first=RA | last2=DuPaul | first2=GJ | last3=McMurray | first3=MB | title=Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. | journal=Pediatrics | volume=87 | issue=4 | year=1991 | issn=0031-4005 | pmid=2011430 | pages=519–31}}</ref>。

近年來，多項國際大型研究表明適當的注意力不足過動症藥物治療可以減少未來[[意外|意外傷害]]、[[交通事故|交通事故]]的機會、降低頭部外傷的風險並且減少物質使用和濫用的機率。<ref name="tscap1" />
<ref name="Bone Fracture"/>
<ref name="NIDAAAS" />
<ref name="ChangLichtenstein2014">{{cite journal|last1=Chang
|first1=Zheng
|last2=Lichtenstein
|first2=Paul
|last3=Halldner
|first3=Linda
|last4=D'Onofrio
|first4=Brian
|last5=Serlachius
|first5=Eva
|last6=Fazel
|first6=Seena
|last7=Långström
|first7=Niklas
|last8=Larsson
|first8=Henrik
|title=Stimulant ADHD medication and risk for substance abuse|journal=Journal of Child Psychology and Psychiatry
|volume=55
|issue=8
|year=2014
|pages=878–885
|issn=00219630
|doi=10.1111/jcpp.12164
|quote=Results_ADHD medication was not associated with increased rate of substance abuse. Actually, the rate during 2009 was 31% lower among those prescribed ADHD medication in 2006, even after controlling for medication in 2009 and other covariates (hazard ratio: 0.69; 95% confidence interval: 0.57–0.84). Also, the longer the duration of medication, the lower the rate of substance abuse. Similar risk reductions were suggested among children and when investigating the association between stimulant ADHD medication and concomitant short-term abuse.}}</ref>
<ref name="ChangLichtenstein2014_2">{{cite journal
|last1=Chang
|first1=Zheng
|last2=Lichtenstein
|first2=Paul
|last3=Halldner
|first3=Linda
|last4=D'Onofrio
|first4=Brian
|last5=Serlachius
|first5=Eva
|last6=Fazel
|first6=Seena
|last7=Långström
|first7=Niklas
|last8=Larsson
|first8=Henrik
|title=Stimulant ADHD medication and risk for substance abuse|journal=Journal of Child Psychology and Psychiatry
|volume=55
|issue=8
|year=2014
|pages=878–885
|issn=00219630
|doi=10.1111/jcpp.12164
|quote=Conclusions：We found no indication of increased risks of substance abuse among individuals prescribed stimulant ADHD medication; if anything, the data suggested a long-term protective effect on substance abuse. Although stimulant ADHD medication does not seem to increase the risk for substance abuse, clinicians should remain alert to the potential problem of stimulant misuse and diversion in ADHD patients.}}</ref>
<ref>{{Cite journal
 | author = Soren Dalsgaard, James F. Leckman, Preben Bo Mortensen, Helena Skyt Nielsen & Marianne Simonsen
 | title = Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study
 | journal = The lancet. Psychiatry
 | volume = 2
 | issue = 8
 | pages = 702–709
 | date =2015-08
 | doi = 10.1016/S2215-0366(15)00271-0
 | pmid = 26249301
 |quote=INTERPRETATION: Children with ADHD had an increased risk of injuries compared with other children. Treatment with ADHD drugs reduced the risk of injuries by up to 43% and emergency ward visits by up to 45% in children with ADHD. Taken together with previous findings of accidents being the most common cause of death in individuals with ADHD, these results are of major public health importance.
}}</ref>
<ref>{{Cite journal
 | author = Rafael Mikolajczyk, Johannes Horn, Niklas Schmedt, Ingo Langner, Christina Lindemann & Edeltraut Garbe
 | title = Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study
 | journal = JAMA pediatrics
 | volume = 169
 | issue = 4
 | pages = 391–395
 | date = 2015-04
 | doi = 10.1001/jamapediatrics.2014.3275
 | pmid = 25686215
 |quote = CONCLUSIONS AND RELEVANCE: No significant risk reduction for hospitalizations with injury diagnoses was observed during periods of ADHD medication, but there was a preventive effect on the risk of brain injuries (34% risk reduction). The effects were controlled for time-invariant characteristics of the patients by the study design.
}}</ref>
<ref name="efficacy of vitamins on ADHD treatment reported by BBC ">
{{cite web
 |author2     = the journal JAMA Psychiatry
 |url         = http://www.bbc.com/news/health-25946116
 |title       = Vitamins ‘effective in treating ADHD symptoms’
 |website     = BBC News
 |author      = Helen Briggs
 |date        = 2014-01-30
 |access-date = 2017-04-13
 |quote       = Scientists from the Karolinska Institute studied 17,000 individuals with ADHD over a period of four years using data from health registers. They found individuals with ADHD had a higher risk of being involved in serious transport accidents, such as car or motorcycle crashes, compared with those without ADHD. Transport accidents were lower among men with ADHD who were on medication than among men with ADHD who did not take medication. Calculations showed 41% of transport accidents involving men with ADHD could have been avoided if they had received medication and carried on taking it during the course of the study.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170414000342/http://www.bbc.com/news/health-25946116
 |archivedate = 2017-04-14
}}</ref>{{R|affecting}}<ref name="Man Ip Chan Law 2017 pp. 1043–1055">{{cite journal | last=Man | first=Kenneth K. C. | last2=Ip | first2=Patrick | last3=Chan | first3=Esther W. | last4=Law | first4=Siew-ling | last5=Leung | first5=Miriam T. Y. | last6=Ma | first6=Evelyn X. Y. | last7=Quek | first7=Wan-ting | last8=Wong | first8=Ian C. K. | title=Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies | journal=CNS Drugs | publisher=Springer Nature | volume=31 | issue=12 | year=2017 | issn=1172-7047 | doi=10.1007/s40263-017-0485-1 | pages=1043–1055}}</ref><ref name="Chang Quinn Hur Gibbons p=597">{{cite journal | last=Chang | first=Zheng | last2=Quinn | first2=Patrick D. | last3=Hur | first3=Kwan | last4=Gibbons | first4=Robert D. | last5=Sjölander | first5=Arvid | last6=Larsson | first6=Henrik | last7=D’Onofrio | first7=Brian M. | title=Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes | journal=JAMA psychiatry | publisher=American Medical Association (AMA) | volume=74 | issue=6 | date=2017-06-01 | issn=2168-622X | pmid=28492937 | pmc=5539840 | doi=10.1001/jamapsychiatry.2017.0659 | page=597}}</ref>

[[PloS_One|PloS One]]期刊中一篇文獻指出，對臨床醫師而言，應向患者及家屬傳達「持續藥物治療對於減少身體傷害有其重要性」。研究發現，相較於從未接受藥物治療的患者，接受藥物治療超過180天的ADHD族群，其[[骨折|骨折]]風險顯著較低，低了將近23%。有接受藥物治療，但總期間不超過180天的患者，其骨折風險與未接受藥物的族群比較起來並無明顯差異，凸顯了藥物治療持續時間的影響。<ref name="Bone Fracture">
{{Cite journal
 | author = Vincent Chin-Hung Chen, Yao-Hsu Yang, Yin-To Liao, Ting-Yu Kuo, Hsin-Yi Liang, Kuo-You Huang, Yin-Cheng Huang, Yena Lee, Roger S. McIntyre & Tzu-Chin Lin
 | title = The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan
 | journal = PloS one
 | volume = 12
 | issue = 3
 | pages = e0173762
 | year = 2017
 | month = 
 | doi = 10.1371/journal.pone.0173762
 | pmid = 28296941
}}</ref>

[[台灣兒童青少年精神醫學會|台灣兒童青少年精神醫學會]]指出：「治療ADHD核心症狀時，藥物是絕對不能忽略的治療選項。<ref name="tscap1" />」台灣兒童青少年精神醫學會理事長高淑芬另指出，對於18歲後才獲得第一次ADHD診斷的患者，台灣健保僅給付短效利他能，但患者若認為有使用其他藥物需求，應勇於跟醫生討論，不要因而忌諱就醫。<ref name="全國法規資料庫入口網站">{{cite web | title=全民健康保險藥物給付項目及支付標準§83-全國法規資料庫入口網站 | website=全國法規資料庫入口網站 | url=http://law.moj.gov.tw/LawClass/LawSingleIf.aspx?Pcode=L0060035&FLNO=83 | language=zh | access-date=2018-07-16 | page=1680-1681}}</ref>{{R|找回專注力}}

[[File:ADHD藥物治療能減少傷害.png|thumb]]
=== 中樞神經刺激劑 ===
{{see also|苯丙胺#醫療}}

[[兴奋剂|中樞神經刺激劑]]藥物是治療ADHD的藥物選擇之一。<ref name="CNS09"/><ref name="Castells Blanco-Silvente Cunill p=CD007813">{{cite journal | last=Castells | first=X | last2=Blanco-Silvente | first2=L | last3=Cunill | first3=R | title=Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. | journal=The Cochrane database of systematic reviews | volume=8 | date=2018-08-09 | issn=1469-493X | pmid=30091808 | doi=10.1002/14651858.CD007813.pub3 | page=CD007813}}</ref> 中樞神經刺激劑至少能在14個月內，改善部分ADHD的症狀。<ref name=May2008>{{cite journal | vauthors = Mayes R, Bagwell C, Erkulwater J | title = ADHD and the rise in stimulant use among children | journal = Harvard Review of Psychiatry | volume = 16 | issue = 3 | pages = 151–66 | date = 2008 | pmid = 18569037 | doi = 10.1080/10673220802167782 }}</ref><ref name="Long-term 36">{{cite journal | vauthors = Parker J, Wales G, Chalhoub N, Harpin V | title = The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials | journal = Psychology Research and Behavior Management | volume = 6 | issue =  | pages = 87–99 | date = September 2013 | pmid = 24082796 | pmc = 3785407 | doi = 10.2147/PRBM.S49114 | quote = Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.22 }}</ref><ref name="Cochrane Amphetamines ADHD" /> 

一些家長和老師回報[[哌甲酯|哌甲酯]]似乎能改善ADHD的症狀。<ref name="Long-term 36" /><ref name=May2008 /><ref>{{cite journal | vauthors = Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C | display-authors = 6 | title = Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) | journal = The Cochrane Database of Systematic Reviews | volume = 11 | issue = 11 | pages = CD009885 | date = November 2015 | pmid = 26599576 | doi = 10.1002/14651858.CD009885.pub2 }}</ref> 中樞神經刺激劑似乎也能降低ADHD遭遇意外事故傷害的風險。<ref name=Ruiz2017>{{cite journal | vauthors = Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, Magallón S, Alvarez Zallo N, Luis EO, de Castro-Manglano P, Soutullo C, Arrondo G | title = Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis | journal = Neuroscience and Biobehavioral Reviews | volume = 84 | pages = 63–71 | date = January 2018 | pmid = 29162520 | doi = 10.1016/j.neubiorev.2017.11.007 }}</ref>[[核磁共振成像|核磁共振成像]]學研究表明長期以安非他命或哌甲酯能降低ADHD患者腦部中的結構和功能的異常。<ref name="Neuroplasticity 1">{{cite journal | vauthors = Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K | title = Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects | journal = JAMA Psychiatry | volume = 70 | issue = 2 | pages = 185–98 | date = February 2013 | pmid = 23247506 | doi = 10.1001/jamapsychiatry.2013.277 }}</ref><ref name="Neuroplasticity 2">{{cite journal | vauthors = Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J | title = Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies | journal = The Journal of Clinical Psychiatry | volume = 74 | issue = 9 | pages = 902–17 | date = September 2013 | pmid = 24107764 | pmc = 3801446 | doi = 10.4088/JCP.12r08287 }}</ref><ref name="Neuroplasticity 3">{{cite journal | vauthors = Frodl T, Skokauskas N | title = Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects | journal = Acta Psychiatrica Scandinavica | volume = 125 | issue = 2 | pages = 114–26 | date = February 2012 | pmid = 22118249 | doi = 10.1111/j.1600-0447.2011.01786.x | quote = Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure. }}</ref> 一篇2018年的系統性回顧發現以哌甲酯治療兒童、以安非他命治療成人能帶給他們最大的短期療效。<ref>{{cite journal |last1=Cortese |first1=Samuele |last2=Adamo |first2=Nicoletta |last3=Del Giovane |first3=Cinzia |last4=Mohr-Jensen |first4=Christina |last5=Hayes |first5=Adrian J |last6=Carucci |first6=Sara |last7=Atkinson |first7=Lauren Z |last8=Tessari |first8=Luca |last9=Banaschewski |first9=Tobias |last10=Coghill |first10=David |last11=Hollis |first11=Chris |last12=Simonoff |first12=Emily |last13=Zuddas |first13=Alessandro |last14=Barbui |first14=Corrado |last15=Purgato |first15=Marianna |last16=Steinhausen |first16=Hans-Christoph |last17=Shokraneh |first17=Farhad |last18=Xia |first18=Jun |last19=Cipriani |first19=Andrea |title=Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis |journal=The Lancet Psychiatry |date=September 2018 |volume=5 |issue=9 |pages=727–738 |doi=10.1016/S2215-0366(18)30269-4}}</ref> 中樞神經刺激劑{{tsl|en|drug holiday|藥物假期|必須定期暫停使用或降低藥劑量}}以評估ADHD患者是否還需要繼續用藥、即便ADHD患者仍需要繼續用藥，定期暫停使用或降低藥劑量的作法能降低患者可能身高發展延遲和腦部神經開始習慣藥劑量（[[Drug_tolerance|耐受性]]）的風險。<ref name="pmid21530185">{{cite journal | vauthors = van de Loo-Neus GH, Rommelse N, Buitelaar JK | title = To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? | journal = European Neuropsychopharmacology | volume = 21 | issue = 8 | pages = 584–99 | date = August 2011 | pmid = 21530185 | doi = 10.1016/j.euroneuro.2011.03.008 }}</ref><ref>{{cite journal | vauthors = Ibrahim K, Donyai P | title = Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades | journal = Journal of Attention Disorders | volume = 19 | issue = 7 | pages = 551–68 | date = July 2015 | pmid = 25253684 | doi = 10.1177/1087054714548035 | url = https://www.researchgate.net/publication/266151922 | archive-url = https://web.archive.org/web/20160630122316/https://www.researchgate.net/profile/Kinda_Ibrahim2/publication/266151922_Drug_Holidays_From_ADHD_Medication_International_Experience_Over_the_Past_Four_Decades/links/56a5ec7408ae1b651134629a.pdf | df = dmy-all | deadurl = no | archive-date = 30 June 2016 }}</ref> 長期以「遠高於治療用劑量」的中樞神經刺激劑治療ADHD，可能會導致[[成癮|成癮]]和[[物質依賴|物質依賴]]。<ref name="NHM therapeutic stim addiction liability" /><ref>{{Cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK47127/|title=Black box warnings of ADHD drugs approved by the US Food and Drug Administration|year=2009|author=Oregon Health & Science University|location=Portland, Oregon|publisher=United States National Library of Medicine|access-date=17 January 2014|deadurl=no|archive-url=https://web.archive.org/web/20170908135126/https://www.ncbi.nlm.nih.gov/books/NBK47127/|archive-date=8 September 2017}}</ref> 然而，若ADHD未被妥善治療，患者在往後容易出現[[物質濫用|物質濫用]]和行為問題（conduct disorders）的風險。<ref name="NHM therapeutic stim addiction liability" /> 使用中樞神經刺激劑治療ADHD，至少能不同程度的降低這些風險。<ref name="Kooij-2010">{{cite journal | vauthors = Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P | display-authors = 6 | title = European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD | journal = BMC Psychiatry | volume = 10 | issue =  | pages = 67 | date = September 2010 | pmid = 20815868 | pmc = 2942810 | doi = 10.1186/1471-244X-10-67 }}</ref><ref name="ADHD 2015 review" /><ref name="NHM therapeutic stim addiction liability">{{cite book | vauthors = Malenka RC, Nestler EJ, Hyman SE | veditors = Sydor A, Brown RY | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2009 | publisher = McGraw-Hill Medical | location = New York | isbn = 978-0-07-148127-4 | pages = 323, 368 | edition = 2nd |quote = supervised use of stimulants at therapeutic doses may decrease risk of experimentation with drugs to self-medicate symptoms. Second, untreated ADHD may lead to school failure, peer rejection, and subsequent association with deviant peer groups that encourage drug misuse. ... amphetamines and methylphenidate are used in low doses to treat attention deficit hyperactivity disorder and in higher doses to treat narcolepsy (Chapter 12). Despite their clinical uses, these drugs are strongly reinforcing, and their long-term use at high doses is linked with potential addiction}}</ref>

治療注意力不足過動症的第一线药物为[[中樞神經刺激劑|中樞神經刺激劑]]（又名為中樞神經興奮劑，簡稱為兴奋剂），其中包括<ref name="UpToDate Patient education: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)
">{{cite web | title=Patient education: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)| website=UpToDate | url=https://www.uptodate.com/contents/treatment-of-attention-deficit-hyperactivity-disorder-in-children-beyond-the-basics | access-date=2019-01-04}}</ref>：

{{-}}
{| class="wikitable sortable"
|-
! style="width: 96px;"|藥物名 !!style="width: 100px;"| 藥物（主成分/有效成分）學名 !!style="width: 90px;"| 作用時間 !!style="width: 90px;"| 生效時間 !! 備註
|-
| 利他能（Ritalin） || [[哌甲酯|哌甲酯]]{{noteTag|又稱為「派醋甲酯」}} || 短：3.5小時左右 || 約服用後30分鐘 ||
* 在藥物動力學上，食物可能增加立即釋放型哌甲酯的[[生物利用度|口服吸收率]]，因此建議使用者於餐前30-45分鐘用藥。<ref name="UpToDate Methylphenidate: Drug information">{{cite web | title=Methylphenidate: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/methylphenidate-drug-information?search=methylphenidate&source=search_result&selectedTitle=1~120&usage_type=default&display_rank=1#F195292 | access-date=2018-07-26 | archive-url=https://web.archive.org/web/20180726170302/https://www.uptodate.com/contents/methylphenidate-drug-information?search=methylphenidate&source=search_result&selectedTitle=1~120&usage_type=default&display_rank=1#F195292#F195292 | archive-date=2018-07-26 | dead-url=no }}</ref>
* 安保美喜錠為利他能的副廠藥品。 副廠名：{{tsl|en|Apotex|Apotex Incorporation|安保美喜公司}}
*研究發現，[[胎兒|胎兒]]在[[子宮|子宮]]接觸到[[哌甲酯|哌甲酯]]，有相對控制組來說，較高的風險在出生後帶有[[先天性心臟病|先天性心臟病]]，而[[安非他命|安非他命]]則無此風險。<ref name="Huybrechts Bröms Christensen Einarsdóttir p=167"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加哌甲酯的[[生物利用度|口服吸收率]]<ref name="UpToDate Methylphenidate: Drug information II">{{cite web | title=Methylphenidate: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/methylphenidate-drug-information?search=methylphenidate&source=search_result&selectedTitle=1~117&usage_type=default&display_rank=1#F195265 | access-date=2018-09-09 | quote=Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. Risk C: Monitor therapy}}</ref>。
|-
| [[阿得拉尔|Adderall]] || [[右旋苯丙胺|右旋苯丙胺]]和[[左旋苯丙胺|左旋苯丙胺]] || 
*短效型：4-5小時<ref name="Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences">{{cite web | title=ADHD Medication Chart | website=Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences | url=http://naceonline.com/article-medications-for-adhd.php | access-date=2018-08-19 | archive-url=https://web.archive.org/web/20180203153102/http://naceonline.com/article-medications-for-adhd.php | archive-date=2018-02-03 | dead-url=no }}</ref>

*長效型：10-12小時<ref name="Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences"/>

 || 
*短效型：30-60分鐘<ref name="Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences"/>

*長效型：60-90分鐘或更短<ref name="Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences"/>

 || 
*為[[安非他命|安非他命]]产品
*尚未引進台灣
*在[[歐美|歐美]]與[[紐澳|紐澳]]皆為合法的處方藥及管制藥品。
*對於哌甲酯之{{tsl|en|Dose–response_relationship||藥物反應}}不佳時，可換成此藥物。<ref name="Ben Amor Sikirica Cloutier Lachaine 2014 pp. 157–66">{{cite journal | last=Ben Amor | first=L | last2=Sikirica | first2=V | last3=Cloutier | first3=M | last4=Lachaine | first4=J | last5=Guerin | first5=A | last6=Carter | first6=V | last7=Hodgkins | first7=P | last8=van Stralen | first8=J | title=Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec. | journal=Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent | volume=23 | issue=3 | year=2014 | issn=1719-8429 | pmid=25320609 | pmc=4197516 | pages=157–66}}</ref>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加安非他命的[[生物利用度|口服吸收率]]及藥物釋放速度<ref name="Dextroamphetamine and amphetamine: Drug information">{{cite web | title=Dextroamphetamine and amphetamine: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information?search=adderall&source=search_result&selectedTitle=1~22&usage_type=default&display_rank=1 | access-date=2018-09-09}}</ref>。
|-
| Desoxyn || [[甲基苯丙胺|甲基苯丙胺]] || N/A || N/A || 
*為{{tsl|en|substituted amphetamine|安非他命衍伸物}}
*尚未引進台灣
*在[[歐美|歐美]]與[[紐澳|紐澳]]皆為合法的處方藥及管制藥品。
*對於哌甲酯之{{tsl|en|Dose–response_relationship||藥物反應}}不佳時，可換成此藥物。<ref name="Ben Amor Sikirica Cloutier Lachaine 2014 pp. 157–66"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加安非他命的[[生物利用度|口服吸收率]]<ref name="Dextroamphetamine and amphetamine: Drug information">{{cite web | title=Dextroamphetamine and amphetamine: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information?search=adderall&source=search_result&selectedTitle=1~22&usage_type=default&display_rank=1 | access-date=2018-09-09}}</ref>。
|-
|Tyvense || [[甲磺酸赖氨酸安非他命|甲磺酸赖氨酸安非他命]] || 12小時 || 2 小時 || 
*為{{tsl|en|substituted amphetamine|安非他命衍伸物}}
*尚未引進台灣
*在[[歐美|歐美]]與[[紐澳|紐澳]]皆為合法的處方藥及管制藥品。
*對於哌甲酯之{{tsl|en|Dose–response_relationship||藥物反應}}不佳時，可換成此藥物。<ref name="Ben Amor Sikirica Cloutier Lachaine 2014 pp. 157–66"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加安非他命的[[生物利用度|口服吸收率]]及藥物釋放速度。<ref name="Dextroamphetamine and amphetamine: Drug information">{{cite web | title=Dextroamphetamine and amphetamine: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information?search=adderall&source=search_result&selectedTitle=1~22&usage_type=default&display_rank=1 | access-date=2018-09-09}}</ref>。
|-
|Dexedrine || [[右旋安非他命|右旋安非他命]] || 
*立即釋放型：3-7小時
*長效型：12小時
 || 
*立即釋放型：0.5-1.5小時
*長效型：1.5-2小時
||
*為{{tsl|en|substituted amphetamine|安非他命衍伸物}}
*尚未引進台灣
*在[[歐美|歐美]]與[[紐澳|紐澳]]皆為合法的處方藥及管制藥品。
*對於哌甲酯之{{tsl|en|Dose–response_relationship||藥物反應}}不佳時，可換成此藥物。<ref name="Ben Amor Sikirica Cloutier Lachaine 2014 pp. 157–66"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加安非他命的[[生物利用度|口服吸收率]]及藥物釋放速度。<ref name="Dextroamphetamine and amphetamine: Drug information">{{cite web | title=Dextroamphetamine and amphetamine: Drug information | website=UpToDate | url=https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information?search=adderall&source=search_result&selectedTitle=1~22&usage_type=default&display_rank=1 | access-date=2018-09-09}}</ref>。
|-
| 利他(長)能LA <br/>（Ritalin LA/利長能） || 哌甲酯 || 中：8小時左右 || 約服用後30分鐘 || 
*[[生物半衰期|藥物之半衰期]]介於利他能與專思達之間。有10MG、20MG、30MG、40MG及60MG等劑型。
*研究發現，[[胎兒|胎兒]]在[[子宮|子宮]]接觸到[[哌甲酯|哌甲酯]]，有相對控制組來說，較高的風險在出生後帶有[[先天性心臟病|先天性心臟病]]，而[[安非他命|安非他命]]則無此風險。<ref name="Huybrechts Bröms Christensen Einarsdóttir p=167"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會造成Ritalin LA 比原先設計的時間更快的釋出藥物並且可能會增加哌甲酯的[[生物利用度|口服吸收率]]。<ref name="UpToDate Methylphenidate: Drug information II"/>
|-
| [[專思達|專思達/專注達]]  || 哌甲酯 || 長：12小時左右 || 約服用後30分鐘 || 
*台灣譯作專思達，有18MG、27MG、36MG、54MG等數種劑量。
*中華民國中央健康保險署已經核定醫師可將此藥物作為十八歲以下患者的第一線處方。<ref name="New Approval">{{cite web| url =http://www.nhi.gov.tw/Information/bbs_detail.aspx?menu=9&menu_id=545&bulletin_ID=2651| title =衛生福利部中央健康保險署　公告| date =2017-02-06| website =衛生福利部中央健康保險署| publisher =衛生福利部中央健康保險署| access-date =2017-04-10| deadurl =no| archiveurl =https://web.archive.org/web/20170410132941/http://www.nhi.gov.tw/Information/bbs_detail.aspx?menu=9&menu_id=545&bulletin_ID=2651| archivedate =2017-04-10}}</ref><ref>{{cite web| url =http://www.nhi.gov.tw/Resource/bulletin/6838_1060034854-1.pdf| title =「藥品給付規定」修正規定| date =2017-02-06| website =衛生福利部中央健康保險署| publisher =衛生福利部中央健康保險署| access-date =2017-04-10| deadurl =no| archiveurl =https://web.archive.org/web/20170410132954/http://www.nhi.gov.tw/Resource/bulletin/6838_1060034854-1.pdf| archivedate =2017-04-10}}</ref>
*中國大陸翻譯為專注達。
*研究發現，[[胎兒|胎兒]]在[[子宮|子宮]]接觸到[[哌甲酯|哌甲酯]]，有相對控制組來說，較高的風險在出生後帶有[[先天性心臟病|先天性心臟病]]，而[[安非他命|安非他命]]則無此風險。<ref name="Huybrechts Bröms Christensen Einarsdóttir p=167"/>
*與[[質子泵抑制劑|質子泵抑制劑]]共服可能會增加哌甲酯的[[生物利用度|口服吸收率]]<ref name="UpToDate Methylphenidate: Drug information II"/>。
|}
<ref name="找回專注力">{{cite book|author=[[高淑芬|高淑芬]] |title=找回專注力：成人ADHD全方位自助手冊 |publisher=心靈工坊|language =zh-tw|location=台北 |isbn=9789863570592 |date=2016-05-09 |accessdate=2016-12-12|url=http://books.google.com/books?id=0h8qnQAACAAJ }}</ref>
<ref name="label of Ritalin LA">{{cite web
 |title       = Label of Ritalin LA
 |date        =2015
 |url         = https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ritalin_la.pdf
 |publisher   = Novartis
 |access-date = 2017-01
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170830025139/https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ritalin_la.pdf
 |archivedate = 2017-08-30
}}</ref>
<ref name="new release of label of Ritalin LA">{{cite web
 |title       = Label of Ritalin LA
 |date        = 2017-01-05
 |url         = https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 |publisher   = Novartis Pharmaceuticals Corporation
 |access-date = 2017-01
 |quote       = Ritalin LA 10, 20, 30, 40, and 60 mg capsules provide in a single dose the same amount of methylphenidate as dosages of 5, 10, 15, 20, or 30 mg of Ritalin tablets given b.i.d.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170326230529/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 |archivedate = 2017-03-26
}}</ref>
<ref name="leaflet of Concerta">
{{cite web
 |url         = http://www.concerta.net/pdfs/Prescribing_Info-short.pdf
 |title       = Label of Concerta
 |date        = 2013
 |website     = concerta.net
 |publisher   = Jassen Cilag
 |access-date = 2017-01
 |deadurl     = yes
 |archiveurl  = https://web.archive.org/web/20170117135801/http://www.concerta.net/pdfs/Prescribing_Info-short.pdf
 |archivedate = 2017-01-17
}}</ref>
<ref name="guidelines for Ritalin">{{cite web
 |url         = https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 |title       = Label of Ritalin
 |date        = 2017-01-05
 |website     = DailyMed
 |publisher   = Novartis
 |access-date = 2017-03
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170320052349/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 |archivedate = 2017-03-20
}}</ref>

*必須避免於藥物作用期間攝取[[乙醇|乙醇]]和[[醇|醇]]，因為這兩種物質很可能會導致血漿中的methylphenidate濃度急速升高<ref name="UpToDate Methylphenidate: Drug information"/>。
-----
利他能<ref name="guidelines for Ritalin"/>、利長能<ref name="label of Ritalin LA"/>、專思達<ref name="leaflet of Concerta"/>、安保美喜錠<ref name="label of Apo-Methylphenidate">
{{Citation
 |contribution-url = http://www.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=02025016
 |location         = Canada
 |title            = Information for the patient
 |contribution     = 安保美喜錠 10 毫克 衛署藥輸字第 025016 號
 |editor           = 鴻汶醫藥實業有限公司
 |author           = Apotex Incorporation.
 |date             = 2006-03-27
 |year             = 
 |url              = https://www.apotex.com/ca/en/products/downloads/di/0263_PIL.pdf
 |access-date      = 2017-03-19
 |deadurl          = no
 |archiveurl       = https://web.archive.org/web/20091122124123/http://www.apotex.com/ca/en/products/downloads/di/0263_PIL.pdf
 |archivedate      = 2009-11-22
}}</ref>
，所含之有效成分皆為哌甲酯，各自在[[藥效學|藥效動力學]]上具有相同屬性；在[[藥物代謝動力學|藥物代謝動力學]]上的作用則有些微差異。<ref name="Lopez Silva Pestreich Muniz 2003 pp. 545–55">{{cite | last=Lopez | first=F | last2=Silva | first2=R | last3=Pestreich | first3=L | last4=Muniz | first4=R | title=Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. | journal=Paediatric drugs | volume=5 | issue=8 | year=2003 | issn=1174-5878 | pmid=12895137 | pages=545–55| quote =While both Ritalin LA and Concerta were shown to be effective, the different release profiles of each formulation can result in distinct differences between the effects on measures of attention and deportment.}}</ref><ref name="Coghill Banaschewski Zuddas Pelaz p. correction addition">{{cite journal | last=Coghill | first=David | last2=Banaschewski | first2=Tobias | last3=Zuddas | first3=Alessandro | last4=Pelaz | first4=Antonio | last5=Gagliano | first5=Antonella | last6=Doepfner | first6=Manfred | title=Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | journal=BMC Psychiatry | publisher=Springer Nature | volume=15 | issue=1 | date=2015-08-25 | issn=1471-244X | pmid=26302778 | pmc=4549088 | doi=10.1186/s12888-015-0581-z | page=}}</ref><ref name="Coghill Banaschewski Zuddas Pelaz p. ">{{cite journal | last=Coghill | first=David | last2=Banaschewski | first2=Tobias | last3=Zuddas | first3=Alessandro | last4=Pelaz | first4=Antonio | last5=Gagliano | first5=Antonella | last6=Doepfner | first6=Manfred | title=Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | journal=BMC Psychiatry | publisher=Springer Nature | volume=13 | issue=1 | date=2013-09-27 | issn=1471-244X | pmid=24074240 | pmc=3852277 | doi=10.1186/1471-244x-13-237 | page=}}</ref>醫師可依患者的需求，視各種藥品之藥物動力學的特性，調整處方藥物，實現{{le|個人化醫療|Personalized medicine}}<ref name="Coghill Banaschewski Zuddas Pelaz p. II">{{cite journal | last=Coghill | first=David | last2=Banaschewski | first2=Tobias | last3=Zuddas | first3=Alessandro | last4=Pelaz | first4=Antonio | last5=Gagliano | first5=Antonella | last6=Doepfner | first6=Manfred | title=Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | journal=BMC Psychiatry | publisher=Springer Nature | volume=13 | issue=1 | date=2013-09-27 | issn=1471-244X | doi=10.1186/1471-244x-13-237 | page=}}</ref>{{#tag:ref|
<ref name=Product>{{cite web | title=Biphentin Product Monograph. | url=http://purdue.ca/wp-content/uploads/2015/12/Biphentin-PM-EN1.pdf | website=Purdue Pharma. | date=2017-04-12 | deadurl=no | archiveurl=https://web.archive.org/web/20180714085012/http://purdue.ca/wp-content/uploads/2015/12/Biphentin-PM-EN1.pdf | archivedate=2018-07-14 | df= }}</ref><ref name="Adjei Teuscher Kupper Chang 2014 pp. 570–578">{{cite journal | last=Adjei | first=Akwete | last2=Teuscher | first2=Nathan S. | last3=Kupper | first3=Robert J. | last4=Chang | first4=Wei-Wei | last5=Greenhill | first5=Laurence | last6=Newcorn | first6=Jeffrey H. | last7=Connor | first7=Daniel F. | last8=Wigal | first8=Sharon | title=Single-Dose Pharmacokinetics of Methylphenidate Extended-Release Multiple Layer Beads Administered as Intact Capsule or Sprinkles Versus Methylphenidate Immediate-Release Tablets (Ritalin®) in Healthy Adult Volunteers | journal=Journal of child and adolescent psychopharmacology | publisher=Mary Ann Liebert Inc | volume=24 | issue=10 | year=2014 | issn=1044-5463 | pmid=25514542 | pmc=4268571 | doi=10.1089/cap.2013.0135 | pages=570–578}}</ref><ref name="Concerta Product Monograph">{{cite web | title=Concerta Product Monograph. | publisher=Janssen Inc. | url=https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/concerta_cpm.pdf | date=2017-11-27 | deadurl=no | archiveurl=https://web.archive.org/web/20180422104051/http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/concerta_cpm.pdf | archivedate=2018-04-22 | df= }}</ref><ref name="Ritalin Summary of Product Characteristics">{{ cite web | title=Ritalin Summary of Product Characteristics. | url=https://www.medicines.org.uk/emc/product/1035/smpc | publisher=Novartis Pharmaceuticals UK Ltd. | date=26 Apr 2018 | deadurl=no | archiveurl=https://web.archive.org/web/20180714085012/https://www.medicines.org.uk/emc/product/1035/smpc | archivedate=2018-07-14 | df= }}</ref><ref name="Medikent Summary of Product Characteristics">{{cite web | title=Medikinet Summary of Product Characteristics. | publisher=Flynn Pharma Ltd. | date=20 March 2017 | url=https://www.medicines.org.uk/emc/product/328/smpc | deadurl=no | archiveurl=https://web.archive.org/web/20180714085012/https://www.medicines.org.uk/emc/product/328/smpc | archivedate=2018年7月14日 | df= }}</ref><ref name="Wang Lee Somma Thompson 2004 pp. 91–98">{{cite journal | last=Wang | first=Yanfeng | last2=Lee | first2=Lucy | last3=Somma | first3=Russell | last4=Thompson | first4=Glenn | last5=Bakhtiar | first5=Ray | last6=Lee | first6=James | last7=Rekhi | first7=Gurvinder Singh | last8=Lau | first8=Henry | last9=Sedek | first9=Greg | last10=Hossain | first10=Mohammad | title=In vitro dissolution andin vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers | journal=Biopharmaceutics & drug disposition | publisher=Wiley | volume=25 | issue=2 | date=2004-02-05 | issn=0142-2782 | pmid=14872557 | doi=10.1002/bdd.390 | pages=91–98}}</ref>
|group="sources"}}{{#tag:ref|<ref name="Dexedrine Product Monograph">{{cite web | title=Dexedrine Product Monograph. | publisher=Paladin Labs Inc. | date=Last updated 21 March 2016. | url=http://www.paladin-labs.com/our_products/dexedrine_en.pdf?ver=9.0 | deadurl=no | archiveurl=https://web.archive.org/web/20160418091424/http://www.paladin-labs.com/our_products/dexedrine_en.pdf?ver=9.0 | archivedate=2016年4月18日 | df= }}</ref><ref name="Wong Wang Hartman Simcoe 1998 pp. 971–8">{{cite | last=Wong | first=YN | last2=Wang | first2=L | last3=Hartman | first3=L | last4=Simcoe | first4=D | last5=Chen | first5=Y | last6=Laughton | first6=W | last7=Eldon | first7=R | last8=Markland | first8=C | last9=Grebow | first9=P | title=Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. | journal=Journal of clinical pharmacology | volume=38 | issue=10 | year=1998 | issn=0091-2700 | pmid=9807980 | pages=971–8}}</ref><ref name="(eMC) 2018">{{cite web | title=Elvanse 20mg Capsules, hard - Summary of Product Characteristics (SmPC) | website=(eMC) | date=2018-04-03 | url=https://www.medicines.org.uk/emc/product/2979/smpc | access-date=2018-07-18 | accessdate=2018-07-18 | archiveurl=https://web.archive.org/web/20180718174414/https://www.medicines.org.uk/emc/product/2979/smpc | archivedate=2018-07-18 | deadurl=no }}</ref><ref name="(eMC) 2017">{{cite web | title=Elvanse Adult 30mg Capsules, hard - Summary of Product Characteristics (SmPC) | website=(eMC) | date=2017-11-03 | url=https://www.medicines.org.uk/emc/product/6828/smpc | access-date=2018-07-18 | accessdate=2018-07-18 | archiveurl=https://web.archive.org/web/20180718174400/https://www.medicines.org.uk/emc/product/6828/smpc | archivedate=2018-07-18 | deadurl=no }}</ref><ref name="Krishnan Zhang 2008 pp. 293–302">{{cite journal | last=Krishnan | first=Suma | last2=Zhang | first2=Yuxin | title=Relative Bioavailability of Lisdexamfetamine 70-mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single-Dose, Crossover Pharmacokinetic Study | journal=Journal of clinical pharmacology | publisher=Wiley | volume=48 | issue=3 | year=2008 | issn=0091-2700 | pmid=18285619 | doi=10.1177/0091270007310381 | pages=293–302}}</ref><ref>{{cite web| title=Adderall XR Canadian Product Monograph. | url=https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/adderall-xr-pm-en.pdf | date= Last updated 23 September 2015. | website=shirecanada.com}}</ref>|group="sources"}}{{#tag:ref|<ref>Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53-63.</ref><ref>Intuniv Summary of Product Characteristics. Last updated 10 December 2015.</ref><ref>Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007; 29: 617-625.</ref><ref>Amfexa Summary of Product Characteristics. Flynn Pharma Ltd. Last updated 06 June 2016.</ref><ref>Dexamfetamine Sulphate Summary of Product Characteristics. Auden Mckenzie (Pharma Division) Ltd. Last updated 01 August 2016.</ref><ref>Matoride XL Summary of Product Characteristics. Sandoz Ltd. Last updated 02 December 2015.</ref>|group="sources"}}{{#tag:ref|<ref>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009; 121: 11-19.</ref><ref>Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002; 40: 175-184.</ref><ref>Equasym XL Summary of Product Characteristics. Shire Pharmaceuticals Ltd. Last updated 10 March 2014.</ref><ref>Medikinet XL Summary of Product Characteristics. Flynn Pharma Ltd. Last updated 17 June 2014.</ref><ref>Haessler F, Tracik F, Dietrich H, et al. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 2008; 46: 466-476.</ref><ref>Ritalin LA Summary of Product Characteristics. Novartis Pharmaceuticals Corporation. Last updated 29 June 2015.</ref>|group="sources"}}{{#tag:ref|<ref name="Heal Pierce 2006 pp. 713–38">{{cite journal | last=Heal | first=DJ | last2=Pierce | first2=DM | title=Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. | journal=CNS drugs | volume=20 | issue=9 | year=2006 | issn=1172-7047 | pmid=16953648 | pages=713–38}}</ref><ref name="Wolraich Doffing 2004 pp. 243–50">{{cite journal | last=Wolraich | first=ML | last2=Doffing | first2=MA | title=Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. | journal=CNS drugs | volume=18 | issue=4 | year=2004 | issn=1172-7047 | pmid=15015904 | pages=243–50}}</ref><ref>Strattera Summary of Product Characteristics. Eli Lilly and Company Ltd. Last updated 08 June 2015.</ref><ref>Focalin XR US Prescribing Information. Novartis Pharmaceuticals Corporation. Last updated June 2015.</ref><ref>Tuerck D, Wang Y, Maboudian M, et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 2007; 45: 662-668.</ref><ref>{{cite |title=Pharmacokinetic data for the ADHD treatments: methylphenidate, dexamfetamine, lisdexamfetamine sulphate, mixed amfetamine salts, atomoxetine and guanfacine | date= January 2017 | website=ADHD Instituite }}</ref> |group="sources"}}{{#tag:ref|
<ref name="Coghill Banaschewski Zuddas Pelaz p.II">{{cite journal | last=Coghill | first=David | last2=Banaschewski | first2=Tobias | last3=Zuddas | first3=Alessandro | last4=Pelaz | first4=Antonio | last5=Gagliano | first5=Antonella | last6=Doepfner | first6=Manfred | title=Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | journal=BMC psychiatry | publisher=Springer Nature | volume=13 | issue=1 | date=2013-09-27 | issn=1471-244X | pmid=24074240 | pmc=3852277 | doi=10.1186/1471-244x-13-237 | page=}}</ref><ref name="Heal Pierce 2006 pp. 713–38">{{cite journal | last=Heal | first=DJ | last2=Pierce | first2=DM | title=Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. | journal=CNS drugs | volume=20 | issue=9 | year=2006 | issn=1172-7047 | pmid=16953648 | pages=713–38}}</ref><ref name="JS Al. 2018">{{cite web | last=JS | first=Markowitz | last2=Al. | first2=Et | title=Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. - PubMed | website=NCBI | date=2018-09-27 | url=https://www.ncbi.nlm.nih.gov/pubmed/12648029 | access-date=2018-09-27 | archive-url=https://web.archive.org/web/20180927204017/https://www.ncbi.nlm.nih.gov/pubmed/12648029 | archive-date=2018-09-27 | dead-url=no }}</ref><ref name="Huss Duhan Gandhi Chen 2017 pp. 1741–1751"/><ref name="Sikirica Lu Greven Zhong 2014 p=1543"/><ref name="Fredriksen Dahl Martinsen Klungsøyr 2014 pp. 1873–1884"/><ref name="Esposito Azhari Borelli 2018 p. "/>|group="sources"}}。

常見的專思達，其12歲以下的使用者每日最大劑量上限為54毫克；13到17歲的使用者之每日''建議'' 最大劑量上限為72毫克<ref>{{cite web
 |url         = http://epaper.ntuh.gov.tw/health/201209/project_3.html
 |title       = 過動兒與藥物治療
 |website     = 台大醫院
 |access-date = 2018-04-06
 |author      = 江雅暄
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170313063637/http://epaper.ntuh.gov.tw/health/201209/project_3.html
 |archivedate = 2017-03-13
}}</ref><ref>{{cite journal | last=Newcorn | first=Jeffrey H | last2=Ivanov | first2=Iliyan | title=Psychopharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders | journal=Pediatric Annals 2007 | volume=36 | issue=9 | date=2007-09-01 | doi=10.3928/0090-4481-20070901-08 | page=564-574 | url=https://www.healio.com/pediatrics/journals/pedann/2007-9-36-9/%7B6bc30397-acb9-418e-bd9d-f8c81b3f92b4%7D/psychopharmacologic-treatment-of-attention-deficithyperactivity-disorder-and-disruptive-behavior-disorders | quote=The labeled daily maximum dose of d,l-MPH is 60 mg, with the exception of OROS-MPH, which is approved for 54 mg in children and 72 mg in adolescents | deadurl=no | archiveurl=https://web.archive.org/web/20180406163538/https://www.healio.com/pediatrics/journals/pedann/2007-9-36-9/%7B6bc30397-acb9-418e-bd9d-f8c81b3f92b4%7D/psychopharmacologic-treatment-of-attention-deficithyperactivity-disorder-and-disruptive-behavior-disorders | archivedate=2018-04-06 }}</ref>。若患者早上服用的中長效劑型藥物之藥效在傍晚開始消退，患者可視需要再服用短效劑型藥物，彌補隨著長效型藥物藥效退去後產生的療效落差。<ref name="幫助ADHD孩子快樂成長">{{cite book|author=高淑芬 |title=家有過動兒：幫助ADHD孩子快樂成長 |publisher=心靈工坊 |location=台北 |isbn=9789866112805 |date=2013-08-28 |accessdate=2016-12-09|url= }}</ref><ref name="Wolraich Brown Brown DuPaul 2011 pp. 1007–22">{{cite journal | last=Wolraich | first=M | last2=Brown | first2=L | last3=Brown | first3=RT | last4=DuPaul | first4=G | last5=Earls | first5=M | last6=Feldman | first6=HM | last7=Ganiats | first7=TG | last8=Kaplanek | first8=B | last9=Meyer | first9=B | last10=Perrin | first10=J | last11=Pierce | first11=K | last12=Reiff | first12=M | last13=Stein | first13=MT | last14=Visser | first14=S | title=ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. | journal=Pediatrics | volume=128 | issue=5 | year=2011 | issn=0031-4005 | pmid=22003063 | pmc=4500647701937 | doi=10.1542/peds.2011-2654 | pages=1007–22}}</ref>

雖中樞神經刺激劑藥效約於服用後半小時左右開始，並不表示症狀會在服用後半小時就消失，如同其他疾病的治療一樣，病情的改善需要一定（段）時間的持續治療（時間長度因人而異）。藥物（包含：中樞神經刺激劑、非中樞神經刺激劑、......）會在這些患者的背後推他們一把，助他們一臂之力<ref name="auto">{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=125 |title=青少年ADHD的治療-一系統性回顧 |doi=10.1001/jama.2016.5453 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161129210346/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=125 |archivedate=2016-11-29 }}</ref>。然而，即便如此，患者本身仍需認真努力地改變自己。藥物是注意力不足過動症整體治療的其中一環。<ref name="找回專注力"/><ref name="books2000">{{cite book|author=Edward M. Hallowell & John J. Ratey|title=分心不是我的錯（增訂版）：正確診療ADD，重建有計畫的生活方式 Driven to Distraction|url=http://books.google.com/books?id=5OVyCgAAQBAJ|date=2015-09-01|publisher=遠流出版|isbn=978-957-32-7700-2|accessdate=2017-06-27}}</ref><ref>{{cite web|url=http://www.concerta.net/contact-us.html|title=CONCERTA® - Contact Us|author=|date=|publisher=Janssen Cilag|access-date=2017-01|deadurl=no|archiveurl=https://web.archive.org/web/20171006212033/https://www.concerta.net/contact-us.html|archivedate=2017-10-06}}</ref>

根據[[世界反運動禁藥組織|世界反運動禁藥組織]]，中樞神經刺激劑在未事先申請醫療許可及非醫療所需的情況下服用都將被視同違規行為。<ref>{{cite web |url=https://wada-main-prod.s3.amazonaws.com/resources/files/2016-09-29_-_wada_prohibited_list_2017_eng_final.pdf |title=THE PROHIBITED LIST Updated annually, the List identifies the substances and methods prohibited to athletes in- and out-of-competition |publisher=Wada-main-prod.s3.amazonaws.com |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161220073305/https://wada-main-prod.s3.amazonaws.com/resources/files/2016-09-29_-_wada_prohibited_list_2017_eng_final.pdf |archivedate=2016-12-20 }}</ref>

部分用來治療注意力不足過動症的藥品（例如：中樞神經刺激劑）在美国食品藥物管理局划分为二级[[管制藥品|管制藥品]]（Schedule II，即指有滥用可能性的药品），在台灣則列為第三級管制藥品。<ref name="NIDAAAS" /><ref name="medlineplus1">{{cite web |url=https://medlineplus.gov/attentiondeficithyperactivitydisorder.html |title=Home of MedlinePlus→ Health Topics → Attention Deficit Hyperactivity Disorder Attention Deficit Hyperactivity Disorder Also called: ADHD |publisher=Medlineplus.gov |date= |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20161225115235/https://medlineplus.gov/attentiondeficithyperactivitydisorder.html |archivedate=2016-12-25 }}</ref><ref name="Taiwan_FDA_on_controlled_medications">{{cite web |url=http://www.fda.gov.tw/TC/site.aspx?sid=41 |title=衛生福利部-食品藥物管理署-管制藥品 |publisher=Fda.gov.tw |date=2013-12-30 |accessdate=2016-12-27 |deadurl=no |archiveurl=https://web.archive.org/web/20170120033551/http://www.fda.gov.tw/TC/site.aspx?sid=41 |archivedate=2017-01-20 }}</ref><ref name="Taiwan_FDA_on_controlled_medications_2">{{cite web|url=http://www.fda.gov.tw/TC/siteList.aspx?sid=50|title=衛生福利部-食品藥物管理署-管制藥品的管理|publisher=Fda.gov.tw|date=|accessdate=2016-12-27|deadurl=no|archiveurl=https://web.archive.org/web/20161226221334/http://www.fda.gov.tw/TC/siteList.aspx?sid=50|archivedate=2016-12-26}}</ref>

中樞神經刺激劑即便正確依照藥物動力學及藥效動力學知識下使用，仍''強烈'' 建議用藥者應定期追蹤自己的體重、心跳與血壓等{{NoteTag|name=teen height| 1=兒童或青少年服用中樞神經刺激劑者則應額外監測身高。}}<ref name="U S Food and Drug Administration Home Page 2011"/><ref name="UpToDate long-term cardiovascular effect associated with long-term use of stimulants">{{cite web | title=Pharmacotherapy for adult attention deficit hyperactivity disorder | website=UpToDate | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | quote=Cardiovascular effects — Blood pressure and heart rate should be monitored when initiating stimulants for adult ADHD and ''over the course of treatment'', due to stimulants' potential for causing cardiovascular side effects....... | access-date=2018-02-27 | deadurl=no | archiveurl=https://web.archive.org/web/20180227034338/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | archivedate=2018-02-27 }}</ref><ref name="Wender 1998 pp. 76–9">{{cite journal | last=Wender | first=PH | title=Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. | journal=The Journal of clinical psychiatry | volume=59 Suppl 7 | year=1998 | issn=0160-6689 | pmid=9680056 | pages=76–9}}</ref>，研究顯示中樞神經刺激劑造成的心血管作用與其攝取劑量多寡有關<ref name="Wender 1998 pp. 76–9"/><ref name="Wilens Hammerness Biederman Kwon 2005 pp. 253–9">{{cite | last=Wilens | first=TE | last2=Hammerness | first2=PG | last3=Biederman | first3=J | last4=Kwon | first4=A | last5=Spencer | first5=TJ | last6=Clark | first6=S | last7=Scott | first7=M | last8=Podolski | first8=A | last9=Ditterline | first9=JW | last10=Morris | first10=MC | last11=Moore | first11=H | title=Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. | journal=The Journal of clinical psychiatry | volume=66 | issue=2 | year=2005 | issn=0160-6689 | pmid=15705013 | pages=253–9}}</ref>（中樞神經刺激劑可能產生的副作用有：[[食欲不振|食慾降低]]、[[雷诺氏综合征|雷诺氏综合征]]、[[心率|心跳]]與[[血壓|血壓]]上升等；<!--而輕度、中度的[[心悸|心悸]]及-->[[高血壓|高血壓]]可能不會被人覺察到，然而血壓長期超越正常範圍可能會導致許多健康問題；食慾降低可能不自覺地引起[[低血糖|低血糖]]，導致[[心悸|心悸]]等副作用<ref name="hypoglycemia ">{{cite web | title=Hypoglycemia: MedlinePlus | website=MedlinePlus | date=2017-11-07 | url=https://medlineplus.gov/hypoglycemia.html | access-date=2017-12-23 | quote=You can also have low blood sugar without having diabetes. Causes include certain medicines or diseases, hormone or enzyme deficiencies, and tumors. Laboratory tests can help find the cause. The kind of treatment depends on why you have low blood sugar. | deadurl=no | archiveurl=https://web.archive.org/web/20171222134524/https://medlineplus.gov/hypoglycemia.html | archivedate=2017-12-22 }}</ref><ref name="National Institute of Diabetes and Digestive and Kidney Diseases 2016">{{cite web | title=Low Blood Glucose (Hypoglycemia) | website=National Institute of Diabetes and Digestive and Kidney Diseases | date=2016-08-11 | url=https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia | access-date=2017-12-23 | quote=Fast or irregular heart beat | deadurl=no | archiveurl=https://web.archive.org/web/20170728180001/https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia | archivedate=2017-07-28 }}</ref>；食欲降低也可能讓服藥者在空腹的時候卻不覺得[[飢餓|餓]]，使得其三餐未定時定量，再者，中樞神經刺激劑本身會刺激[[胃酸|胃酸]]分泌，多重因素交織，長期下來，容易引起{{tsl|en|Abdominal_distension|消化道不舒服|腸道不適}}或[[胃潰瘍|胃潰瘍]]<ref name="UpToDate Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis">{{cite web | title=Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis | website=UpToDate | url=https://www.uptodate.com/contents/peptic-ulcer-disease-genetic-environmental-and-psychological-risk-factors-and-pathogenesis?topicRef=25&source=see_link#H5 | access-date=2018-07-15 | archive-url=https://web.archive.org/web/20180715211029/https://www.uptodate.com/contents/peptic-ulcer-disease-genetic-environmental-and-psychological-risk-factors-and-pathogenesis?topicRef=25&source=see_link#H5#H5 | archive-date=2018-07-15 | dead-url=no }}</ref>）。<ref name="American College of Cardiology 2015 long-term cardiovascular effects on people treated with stimulants">{{cite web | type=tertiary source | title=The Safety of Stimulant Medication Use in Cardiovascular and Arrhythmia Patients | website=American College of Cardiology | date=2015-04-28 | url=http://www.acc.org/latest-in-cardiology/articles/2015/04/28/10/06/the-safety-of-stimulant-medication-use-in-cardiovascular-and-arrhythmia-patients | access-date=2017-12-08 | deadurl=no | archiveurl=https://web.archive.org/web/20171209100055/http://www.acc.org/latest-in-cardiology/articles/2015/04/28/10/06/the-safety-of-stimulant-medication-use-in-cardiovascular-and-arrhythmia-patients | archivedate=2017-12-09 }}</ref><ref name="U S Food and Drug Administration Home Page 2011">{{cite web | title=FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults | website=U S Food and Drug Administration Home Page | date=2011-11-01 | url=https://www.fda.gov/Drugs/DrugSafety/ucm277770.htm | access-date=2018-09-30 | archive-url=https://web.archive.org/web/20180726005518/https://www.fda.gov/Drugs/DrugSafety/ucm277770.htm | archive-date=2018-07-26 | dead-url=no }}</ref><ref name="Biederman Mick Surman Doyle 2006 pp. 829–835">{{cite journal | last=Biederman | first=Joseph | last2=Mick | first2=Eric | last3=Surman | first3=Craig | last4=Doyle | first4=Robert | last5=Hammerness | first5=Paul | last6=Harpold | first6=Theresa | last7=Dunkel | first7=Stephanie | last8=Dougherty | first8=Meghan | last9=Aleardi | first9=Megan | last10=Spencer | first10=Thomas | title=A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder | journal=Biological psychiatry | publisher=Elsevier BV | volume=59 | issue=9 | date=2006-05-01 | issn=0006-3223 | pmid=16373066 | doi=10.1016/j.biopsych.2005.09.011 | pages=829–835}}</ref><ref name="Hammerness Wilens Mick Spencer 2009 pp. 84–89.e1">{{cite journal | last=Hammerness | first=Paul | last2=Wilens | first2=Timothy | last3=Mick | first3=Eric | last4=Spencer | first4=Thomas | last5=Doyle | first5=Robert | last6=McCreary | first6=Michelle | last7=Becker | first7=Judith | last8=Biederman | first8=Joseph | title=Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder | journal=The Journal of pediatrics | publisher=Elsevier BV | volume=155 | issue=1 | year=2009 | issn=0022-3476 | pmid=19394037 | doi=10.1016/j.jpeds.2009.02.008 | pages=84–89.e1}}</ref><ref name="Adler Orman Starr Silber 2011 pp. 108–114">{{cite journal | last=Adler | first=Lenard A. | last2=Orman | first2=Camille | last3=Starr | first3=H. Lynn | last4=Silber | first4=Steve | last5=Palumbo | first5=Joseph | last6=Cooper | first6=Kimberly | last7=Berwaerts | first7=Joris | last8=Harrison | first8=Diane D. | title=Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder | journal=Journal of clinical psychopharmacology | publisher=Ovid Technologies (Wolters Kluwer Health) | volume=31 | issue=1 | year=2011 | issn=0271-0749 | pmid=21192153 | doi=10.1097/jcp.0b013e318203ea0a | pages=108–114}}</ref><ref name="Weisler Biederman Spencer Wilens 2005 pp. 35–43">{{cite journal | last=Weisler | first=RH | last2=Biederman | first2=J | last3=Spencer | first3=TJ | last4=Wilens | first4=TE | title=Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. | journal=CNS spectrums | volume=10 | issue=12 Suppl 20 | year=2005 | issn=1092-8529 | pmid=16344839 | pages=35–43}}</ref><ref name="Simpson Plosker 2004 pp. 205–222">{{cite journal | last=Simpson | first=Dene | last2=Plosker | first2=Greg L | title=Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. | journal=Drugs | publisher=Springer Nature | volume=64 | issue=2 | year=2004 | issn=0012-6667 | pmid=14717619 | doi=10.2165/00003495-200464020-00005 | pages=205–222}}</ref><ref name="Wernicke Faries Girod Brown 2003 pp. 729–740">{{cite journal | last=Wernicke | first=Joachim F | last2=Faries | first2=Douglas | last3=Girod | first3=Donald | last4=Brown | first4=Jeffrey W | last5=Gao | first5=Haitao | last6=Kelsey | first6=Douglas | last7=Quintana | first7=Humberto | last8=Lipetz | first8=Robert | last9=Michelson | first9=David | last10=Heiligenstein | first10=John | title=Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults | journal=Drug safety | publisher=Springer Nature | volume=26 | issue=10 | year=2003 | issn=0114-5916 | pmid=12862507 | doi=10.2165/00002018-200326100-00006 | pages=729–740}}</ref><ref name="Adler Spencer Williams Moore 2008 pp. 248–253">{{cite journal | last=Adler | first=Lenard A. | last2=Spencer | first2=Thomas J. | last3=Williams | first3=David W. | last4=Moore | first4=Rodney J. | last5=Michelson | first5=David | title=Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD | journal=Journal of attention disorders | publisher=SAGE Publications | volume=12 | issue=3 | date=2008-04-30 | issn=1087-0547 | pmid=18448861 | doi=10.1177/1087054708316250 | pages=248–253}}</ref><ref name="Habel Cooper Sox Chan p=2673">{{cite journal | last=Habel | first=Laurel A. | last2=Cooper | first2=William O. | last3=Sox | first3=Colin M. | last4=Chan | first4=K. Arnold | last5=Fireman | first5=Bruce H. | last6=Arbogast | first6=Patrick G. | last7=Cheetham | first7=T. Craig | last8=Quinn | first8=Virginia P. | last9=Dublin | first9=Sascha | last10=Boudreau | first10=Denise M. | last11=Andrade | first11=Susan E. | last12=Pawloski | first12=Pamala A. | last13=Raebel | first13=Marsha A. | last14=Smith | first14=David H. | last15=Achacoso | first15=Ninah | last16=Uratsu | first16=Connie | last17=Go | first17=Alan S. | last18=Sidney | first18=Steve | last19=Nguyen-Huynh | first19=Mai N. | last20=Ray | first20=Wayne A. | last21=Selby | first21=Joe V. | title=ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults | journal=JAMA | publisher=American Medical Association (AMA) | volume=306 | issue=24 | date=2011-12-28 | issn=0098-7484 | pmid=22161946 | pmc=3350308370952 | doi=10.1001/jama.2011.1830 | page=2673}}</ref>

患者第一次用藥前必須先進行全面的心血管功能檢查，以確保患者沒有重度的[[先天性心臟病|先天性心臟病]]或存有任何嚴重的心血管問題。<ref name="U S Food and Drug Administration Home Page 2011"/><ref name="U S Food and Drug Administration Home Page 2011"/><ref name="UpToDate 2017">{{cite web | title=Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder | website=UpToDate | date=2017-08-01 | url=https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | access-date=2017-12-22 | quote=Evaluation of children with ADHD prior to initiation of medication should include a comprehensive, cardiovascular (CV)-focused patient history, family history, and physical examination | deadurl=no | archiveurl=https://web.archive.org/web/20171223042839/https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | archivedate=2017-12-23 }}</ref>有研究指出ADHD用藥可能會引起[[血管硬化|血管硬化]]，然而尚需更多研究確認，並且也要再確認此現象是否有到臨床上界定需要治療的程度<ref name="affecting & sentimental">{{cite web | title=Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder | website=UpToDate | date=2017-08-01 | url=https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | access-date=2017-12-22 | quote=One small study suggested that there may be evidence of arterial stiffness, but further investigation is needed to confirm and determine any clinically significant effect | deadurl=no | archiveurl=https://web.archive.org/web/20171223042839/https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | archivedate=2017-12-23 }}</ref><ref name="Kelly Rudser Dengel Kaufman 2014 pp. 755–759">{{cite journal | last=Kelly | first=Aaron S. | last2=Rudser | first2=Kyle D. | last3=Dengel | first3=Donald R. | last4=Kaufman | first4=Christopher L. | last5=Reiff | first5=Michael I. | last6=Norris | first6=Anne L. | last7=Metzig | first7=Andrea M. | last8=Steinberger | first8=Julia | title=Cardiac Autonomic Dysfunction and Arterial Stiffness among Children and Adolescents with Attention Deficit Hyperactivity Disorder Treated with Stimulants | journal=The Journal of pediatrics | publisher=Elsevier BV | volume=165 | issue=4 | year=2014 | issn=0022-3476 | pmid=25015574 | doi=10.1016/j.jpeds.2014.05.043 | pages=755–759}}</ref><ref name="MyHealth.Alberta.ca 2019">{{cite web | title=How High Blood Pressure Damages Arteries | website=MyHealth.Alberta.ca | date=2019-01-04 | url=https://myhealth.alberta.ca/Health/Pages/conditions.aspx?hwid=zm6282 | access-date=2019-01-04}}</ref><ref name="Mayo Clinic 2018">{{cite web | author=Rekha Mankad, M.D. | title=Coronary artery spasm: Cause for concern? | website=Mayo Clinic | date=2018-10-13 | url=https://www.mayoclinic.org/diseases-conditions/angina/expert-answers/coronary-artery-spasm/faq-20058316 | access-date=2019-01-04}}</ref><ref name="Mayo Clinic 2016">{{cite web | title=High blood pressure dangers: Hypertension's effects on your body | website=Mayo Clinic | date=2016-11-23 | url=https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/high-blood-pressure/art-20045868 | access-date=2019-01-04}}</ref>。

中樞神經刺激劑藥物可能的副作用包含[[口乾|口乾]]、[[失眠|失眠]]、[[应激性|急躁/急性子/靜不下來]]、[[煩躁|煩躁]]、[[食慾|食慾]]降低、[[基礎代謝率|基礎代謝率]]增加{{noteTag|name=|1=[[中樞神經|中樞神經]]過度刺激或心跳增加都可能推升基礎代謝率。}}、[[體重下降|體重下降]]、[[頭痛|頭痛]]、[[顫抖|抖動]]、[[抽动综合症|抽动综合症]]、[[尿液滯留|尿液滯留]]{{noteTag| name=|1=尿液滯留或[[膀胱|膀胱]]已經蓄積足量[[尿液|尿液]]卻不自覺，同樣可能導致心悸}}等<ref name="Hubel Jass Marcus Laessle 2006 pp. 139–146">{{cite journal | last=Hubel | first=R. | last2=Jass | first2=J. | last3=Marcus | first3=A. | last4=Laessle | first4=R. G. | title=Overweight and basal metabolic rate in boys with attention-deficit/hyperactivity disorder | journal=Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity | publisher=Springer Nature | volume=11 | issue=3 | year=2006 | issn=1124-4909 | doi=10.1007/bf03327559 | pages=139–146}}</ref><ref name="WW (Weight Watchers Reimagined) 2018">{{cite web | title=Increasing Metabolism | website=WW (Weight Watchers Reimagined) | date=2018-11-27 | url=https://signup.weightwatchers.co.uk/util/art/index_art.aspx?tabnum=1&art_id=22061&sc=801 | access-date=2018-11-27 | quote=A person's heart rate has an impact on metabolism – the higher the heart rate, the more calories burned. Stimulants, whether from a prescribed medication, dietary supplement, or a caffeine-containing beverage, all work to increase the heart rate and fire up the nervous system. | archive-url=https://web.archive.org/web/20181127111054/https://signup.weightwatchers.co.uk/util/art/index_art.aspx?tabnum=1&art_id=22061&sc=801 | archive-date=2018-11-27 | dead-url=no }}</ref><ref name="Acheson Zahorska-Markiewicz Pittet Anantharaman 1980 pp. 989–997">{{cite journal | last=Acheson | first=K J | last2=Zahorska-Markiewicz | first2=B | last3=Pittet | first3=P | last4=Anantharaman | first4=K | last5=Jéquier | first5=E | title=Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals | journal=The American Journal of Clinical Nutrition | volume=33 | issue=5 | date=1980-05-01 | issn=0002-9165 | doi=10.1093/ajcn/33.5.989 | pages=989–997 | url=https://academic.oup.com/ajcn/article/33/5/989/4692739 | access-date=2018-11-27 | author= | archive-url=https://web.archive.org/web/20181113181831/https://academic.oup.com/ajcn/article/33/5/989/4692739 | archive-date=2018-11-13 | dead-url=no }}</ref><ref>{{cite journal | title=A CLINICAL STUDY OF THE ACTION OF 10 COMMONLY USED DRUGS ON CARDIAC OUTPUT, WORK AND SIZE; ON RESPIRATION, ON METABOLIC RATE AND ON THE ELECTROCARDIOGRAM | date=1937 | author=ISAAC STARR, C. J. GAMBLE, A. MARGOLIES, J. S.,DONAL, JR., N. JOSEPH AND E. EAGLE | location=Departments of Research Therapeutics, and of Pharmacology, the Robinette Foundation, and the Medical Division of the Hospital of the University of Pennsylvania., Philadelphia | journal= Am Soc Clin Investig}}</ref><ref name="UpToDate edginess">{{cite web | title=Pharmacotherapy-for-Adult-Attention-Deficit-Hyperactivity-Disorder | website=UpToDate | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | access-date=2018-02-26 | deadurl=no | archiveurl=https://web.archive.org/web/20180227034338/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | archivedate=2018-02-27 }}</ref>{{NoteTag|name=|1=See {{tsl|en|Obsessive–compulsive_spectrum#Tic_disorders}} }}<!--為什麼此NoteTag無法放進前面的refernce的quote中?--><ref name="Santosh Sattar Canagaratnam 2011 pp. 737–763">{{cite journal | last=Santosh | first=Paramala J. | last2=Sattar | first2=Sanjida | last3=Canagaratnam | first3=Myooran | title=Efficacy and Tolerability of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder in Adults | journal=CNS drugs | publisher=Springer Nature | volume=25 | issue=9 | date=2011-09-01 | issn=1172-7047 | pmid=21870887 | doi=10.2165/11593070-000000000-00000 | pages=737–763}}</ref>
<ref name="UpToDate jitteriness">{{cite web | title=Pharmacotherapy-for-Adult-Attention-Deficit-Hyperactivity-Disorder | website=[[UpToDate|UpToDate]] | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | access-date=2018-02-26 | quote=An uncontrolled follow-up of 96 adults with ADHD who experienced improvement while taking extended release methylphenidate in a randomized trial found that improvement in ADHD symptoms was sustained at 30 weeks on the medication. Only 39 subjects (40.6 percent) completed the long-term follow-up period. Participants continued to experience decreased appetite, insomnia, and jitteriness | deadurl=no | archiveurl=https://web.archive.org/web/20180227034338/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | archivedate=2018-02-27 }}</ref><ref name="Biederman Mick Surman Doyle 2010 pp. 549–553">{{cite journal | last=Biederman | first=Joseph | last2=Mick | first2=Eric | last3=Surman | first3=Craig | last4=Doyle | first4=Robert | last5=Hammerness | first5=Paul | last6=Kotarski | first6=Meghan | last7=Spencer | first7=Thomas | title=A Randomized, 3-Phase, 34-Week, Double-Blind, Long-Term Efficacy Study of Osmotic-Release Oral System-Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder | journal=Journal of clinical psychopharmacology | publisher=Ovid Technologies (Wolters Kluwer Health) | volume=30 | issue=5 | year=2010 | issn=0271-0749 | pmid=20814332 | doi=10.1097/jcp.0b013e3181ee84a7 | pages=549–553}}</ref>；而在不超量使用中樞神經刺激劑藥物的情況下，其引發[[幻覺|幻覺]]<!--delusion-->、[[偏執|偏執]]<!--paranoid-->、[[心血管疾病|心血管問題]]等嚴重副作用的機率極低，大約千分之一到萬分之一，而且發生的機率和沒有服用藥物的人沒有差異。<!--Quoted from [[苯丙胺|苯丙胺#心理]]--><ref name="U S Food and Drug Administration Home Page 2011"/><ref name="FDA Abuse & OD">{{cite web | title = Adderall XR Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | page = 11 | publisher = Shire US Inc | work = United States Food and Drug Administration | date = 2013-12 | accessdate = 2013-12-30 | deadurl = no | archiveurl = https://web.archive.org/web/20131230233702/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | archivedate = 2013-12-30 }}</ref><ref name="FDA Effects">{{cite web | title = Adderall XR Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | pages = 4–8 | publisher = Shire US Inc | work = United States Food and Drug Administration | date = 2013-12 | accessdate = 2013-12-30 | deadurl = no | archiveurl = https://web.archive.org/web/20131230233702/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | archivedate = 2013-12-30 }}</ref><ref name="Shoptaw Kao Ling p=CD003026">{{cite journal | last=Shoptaw | first=SJ | last2=Kao | first2=U | last3=Ling | first3=W | title=Treatment for amphetamine psychosis. | journal=The Cochrane database of systematic reviews | issue=1 | date=2009-01-21 | issn=1469-493X | pmid=19160215 | doi=10.1002/14651858.CD003026.pub3 | page=CD003026 | quote=A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention ...
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983) ...
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.}}</ref><ref name="FDA Abuse & OD" /><ref name="FDA Effects" /><ref name="Stimulant Misuse">{{cite web | author = Greydanus D | title=Stimulant Misuse: Strategies to Manage a Growing Problem | type=Review Article | url=http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf | archiveurl=https://web.archive.org/web/20131103155156/http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf | work=American College Health Association | publisher=ACHA Professional Development Program | accessdate=2013-11-02 | archivedate=2013-11-03 | page=20}}</ref><!--Quoted from [[苯丙胺|苯丙胺#心理]]-->
因此期刊整理過去 185個研究（達一萬兩千多人），得到的研究結論是：注意力不足過動症的治療藥物並未增加嚴重副作用風險的機會。相對而言，常被家長忽略的是，限制或延遲患有ADHD的兒童及早接受有效的治療可能導致往後出現的嚴重後果，例如''顯著'' 增加孩子在其[[青少年|青少年]]時期衍生[[物質濫用|物質濫用]]、中途輟學、學業挫敗（academic failure）、[[意外事故|意外事故]]等風險<ref name="affecting">{{cite web | title=Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder | website=UpToDate | date=2017-08-01 | url=https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | access-date=2017-12-22 | quote=What is clear, however, is limiting or delaying children's access to effective treatment for ADHD could have serious implications (such as increased risk of adolescent substance use disorder, academic failure, and accidents) in patients who are not effectively treated. | deadurl=no | archiveurl=https://web.archive.org/web/20171223042839/https://www.uptodate.com/contents/cardiac-evaluation-of-patients-receiving-pharmacotherapy-for-attention-deficit-hyperactivity-disorder | archivedate=2017-12-23 }}</ref>（陳錦宏醫師指出，發生[[意外|意外]]及[[成癮|藥物成癮]]或[[酒精成癮|酒精成癮]]的[[風險|風險]]約達到50%）<ref name="陳鈞凱 2018"/>。{{noteTag|nam3=|1=[[愛思唯爾|Elsevier BV]]曾經出版一篇文獻指出，未經治療的ADHD可能在往後的人生中直接或間接衍生出以下共伴疾病（已忽略重複項目）：[[吸菸|吸菸]]、[[性成癮|性成癮]]（包含：從事{{tsl|en|Risky sexual behavior|高風險性愛}}、罹患[[性感染疾病|性感染疾病]]）。間接：[[體適能|體適能]]不足、醫療費用及就醫次數增加。極間接：[[糖尿病|糖尿病]]、[[高血壓|高血壓]]。<ref name="Nigg 2013 pp. 215–228">{{cite journal | last=Nigg | first=JT | title=Attention-deficit/hyperactivity disorder and adverse health outcomes | journal=Clinical psychology review | publisher=Elsevier BV | volume=33 | issue=2 | year=2013 | issn=0272-7358 | pmid=23298633 | pmc=4322430 | doi=10.1016/j.cpr.2012.11.005 | pages=215–228}}</ref>}}<ref name="risk of untreated ADHD">{{cite web
 |url          = http://www.tc-adhd.com/?p=1565
 |title        = 心動家族協會理事長專文：問ADHD藥物有無風險，不如問「不治療和治療的風險哪一個高」
 |date         = 2016-04-18
 |website      = 心動家族協會
 |author       = 陳錦宏
 |access-date  = 2017-01
 |archive-url  = https://archive.today/20170103064140/http://www.tc-adhd.com/?p=1565
 |archive-date = 2017-01-03
 |deadurl      = yes
 |accessdate   = 2017-01-01
 |archiveurl   = https://archive.today/20170103064140/http://www.tc-adhd.com/?p=1565
 |archivedate  = 2017-01-03
}}</ref>不過[[考科藍協作組織|考科藍協作組織]]於2015年發表的系統性文獻回顧指出，使用中樞神經刺激劑後，像[[失眠|失眠]]、[[食慾不振|食慾不振]]等較不嚴重的副作用常出現在服用者身上，並衍生出長期預後的不確定因素<ref name="Storebø Ramstad Krogh Nilausen p. ">{{cite | last=Storebø | first=Ole Jakob | last2=Ramstad | first2=Erica | last3=Krogh | first3=Helle B. | last4=Nilausen | first4=Trine Danvad | last5=Skoog | first5=Maria | last6=Holmskov | first6=Mathilde | last7=Rosendal | first7=Susanne | last8=Groth | first8=Camilla | last9=Magnusson | first9=Frederik L | last10=Moreira-Maia | first10=Carlos R | last11=Gillies | first11=Donna | last12=Buch Rasmussen | first12=Kirsten | last13=Gauci | first13=Dorothy | last14=Zwi | first14=Morris | last15=Kirubakaran | first15=Richard | last16=Forsbøl | first16=Bente | last17=Simonsen | first17=Erik | last18=Gluud | first18=Christian | editor-last=Storebø | editor-first=Ole Jakob | title=Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) | journal=The Cochrane database of systematic reviews | publisher=John Wiley & Sons, Ltd | publication-place=Chichester, UK | issue=11 | date=2015-11-25 | pmid=26599576 | doi=10.1002/14651858.cd009885.pub2 | page=| quote = Within the short follow-up periods typical of the included trials, there is some evidence that methylphenidate is associated with increased risk of non-serious adverse events, such as sleep problems and decreased appetite, but no evidence that it increases risk of serious adverse events.Better designed trials are needed to assess the benefits of methylphenidate. Given the frequency of non-serious adverse events associated with methylphenidate, the particular difficulties for blinding of participants and outcome assessors point to the advantage of large, 'nocebo tablet' controlled trials.|type = systematic review}}</ref>。

所有用來治療注意力不足過動症的藥物只要依照醫師基於藥物動力學及藥效動力學所做成的醫囑用藥，都是相當安全的。<ref name="NIDAAAS">{{cite web
 |url         = https://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-methylphenidate-amphetamines
 |title       = Stimulant ADHD Medications: Methylphenidate and Amphetamines
 |first       = National Institute on Drug
 |last        = Abuse
 |date        = 
 |publisher   = 
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170710220805/https://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-methylphenidate-amphetamines
 |archivedate = 2017-07-10
}}</ref><ref name="medlineplus1"/>
<ref name="NHS">
{{cite web
 |url         = http://www.nhs.uk/chq/Pages/1391.aspx?CategoryID=73
 |title       = What is a controlled medicine (drug)? - Health questions - NHS Choices
 |first       = N. H. S.
 |last        = Choices
 |date        = 2016-12-12
 |publisher   = 
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170503060547/http://www.nhs.uk/chq/Pages/1391.aspx?CategoryID=73
 |archivedate = 2017-05-03
}}</ref>
而藥物成分為哌甲酯的中樞神經刺激劑，例如：利他能與專思達，可能導致：心悸、頭痛、胃痛、喪失食慾、失眠、因相對專注而變得冷淡（面無表情）等副作用，因此6歲以下的兒童不適宜將藥物當成第一線療法服用。（副作用產生與否因人而異）
<ref>{{cite web
 |title       = Methylphenidate
 |url         = https://medlineplus.gov/druginfo/meds/a682188.html
 |website     = Home of MedlinePlus → Drugs, Herbs and Supplements → Methylphenidate Methylphenidate pronounced as (meth'' il fen' i date)
 |date        = 2016-02-15
 |access-date = 2017-02-27
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170704210652/https://medlineplus.gov/druginfo/meds/a682188.html
 |archivedate = 2017-07-04
}}</ref>

隨著時間推進與各方的努力，中樞神經刺激劑的相關副作用{{NoteTag|name=adverse effect|1=「常見副作用」的定義為：在臨床試驗中，實驗組中至少5%的人出現此症狀，且在實驗組中出現此反應的比例為安慰組的兩倍。}}{{NoteTag|name=less common side effects|1=「較少見的副作用」的定義為：在臨床試驗中，實驗組中至少2%的人出現此症狀，且在實驗組中出現此反應的比例多於安慰組。}}已可藉由包括但不限於劑量調整、服藥時間、飯前飯後服用、服藥頻率等服藥模式之改變以及改變藥物組合等方式獲得相當程度的減少。<ref name="NIDAAAS" />
<ref name="Science_daily">{{cite web
 |url          = https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |title        = Combining medications could offer better results for ADHD patients
 |archive-url  = https://web.archive.org/web/20170102050323/https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |archive-date = 2017-01-02
 |date         = 2016-08-01
 |website      = Science News
 |publisher    = Elsevier
 |access-date  = 2017-01
 |quote        = "Three studies to be published in the August 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) report that combining two standard medications could lead to greater clinical improvements for children with attention-deficit/hyperactivity disorder (ADHD) than either ADHD therapy alone.", August, 2016
 |deadurl      = no
 |accessdate   = 2017-01-01
 |archiveurl   = https://web.archive.org/web/20170102050323/https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |archivedate  = 2017-01-02
}}</ref>
<ref>{{cite book
 |title       = Adults with ADHD
 |publisher   = NATIONAL LIBRARY OF MEDICINE at the NATIONAL INSTITUTES OF HEALTH
 |series      = MedlinePlus the Magazine
 |volume      = 9
 |ISSN        = 1937-4712
 |date        = 2014
 |location    = 8600 Rockville Pike • Bethesda, MD 20894, United States of America
 |pages       = 19
 |language    = en-us
 |url         = https://medlineplus.gov/magazine/issues/spring14/articles/spring14pg19.html
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170715030133/https://medlineplus.gov/magazine/issues/spring14/articles/spring14pg19.html
 |archivedate = 2017-07-15
}}</ref>
<ref>{{cite web
 |url         = https://medlineplus.gov/ency/article/001551.htm
 |title       = Attention deficit hyperactivity disorder
 |date        = 2016-05-25
 |website     = Home → Medical Encyclopedia → Attention deficit hyperactivity disorder
 |publisher   = NATIONAL LIBRARY OF MEDICINE at the NATIONAL INSTITUTES OF HEALTH
 |access-date = 2017-02-27
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170126193043/https://medlineplus.gov/ency/article/001551.htm
 |archivedate = 2017-01-26
}}</ref>
<ref>
{{cite web
 |url         = http://www.ninds.nih.gov/disorders/adhd/adhd.htm
 |title       = All Disorders
 |website     = National Institute of Neurological Disorders and Stroke
 |access-date = February twenty seventh, 2017
 |quote       = 
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20161202230225/http://www.ninds.nih.gov/disorders/adhd/adhd.htm
 |archivedate = 2016-12-02
}}</ref>
<ref name="UpToDate over palpitations">{{cite web | title=Overview of palpitations in adults | website=UpToDate | url=https://www.uptodate.com/contents/overview-of-palpitations-in-adults?search=palpitation&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 | access-date=2018-07-15 | accessdate=2018-07-15 | archiveurl=https://web.archive.org/web/20180716044648/https://www.uptodate.com/contents/overview-of-palpitations-in-adults?search=palpitation&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 | archivedate=2018-07-16 }}</ref><ref name="UpToDate regarding palpitations">{{cite web | title=Approach to the child with palpitations | website=UpToDate | url=https://www.uptodate.com/contents/approach-to-the-child-with-palpitations?search=palpitation&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 | access-date=2018-07-15 | accessdate=2018-07-15 | archiveurl=https://web.archive.org/web/20180716044648/https://www.uptodate.com/contents/approach-to-the-child-with-palpitations?search=palpitation&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 | archivedate=2018-07-16 }}</ref><ref name="NIMH » Home bothersome side effects from stimulants">{{cite web | title=NIMH » Attention Deficit Hyperactivity Disorder | website=NIMH » Home | url=https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | access-date=2018-07-21 | quote=Although not approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ADHD, some antidepressants are sometimes used alone or in combination with a stimulant to treat ADHD. Antidepressants may help all of the symptoms of ADHD and can be prescribed if a patient has bothersome side effects from stimulants. Antidepressants can be helpful in combination with stimulants if a patient also has another condition, such as an anxiety disorder, depression, or another mood disorder. | accessdate=2016-12-27 | archiveurl=https://web.archive.org/web/20161225231931/https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | archivedate=2016-12-25 | deadurl=no }}</ref>

UpToDate指出，使用者於中斷使用中樞神經刺激劑後恢復使用之，可能需要重新從較低的劑量開始逐步增加至理想劑量。<ref name="UpToDate edginess and drug holidays">{{cite web | title=Pharmacotherapy-for-Adult-Attention-Deficit-Hyperactivity-Disorder | website=UpToDate | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | access-date=2018-02-26 | quote=Progressive titration, as tolerated, to an optimally effective dose is an important means of minimizing side effects. Re-titration may be necessary after drug holidays. | deadurl=no | archiveurl=https://web.archive.org/web/20180227034338/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | archivedate=2018-02-27 }}</ref><ref name="Castells Cunill Capellà 2013 pp. 347–356">{{cite journal | last=Castells | first=Xavier | last2=Cunill | first2=Ruth | last3=Capellà | first3=Dolors | title=Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials | journal=European journal of clinical pharmacology | publisher=Springer Nature | volume=69 | issue=3 | date=2012-09-16 | year=2013 | issn=0031-6970 | pmid=22983311 | doi=10.1007/s00228-012-1390-7 | pages=347–356}}</ref>

近年來美國正值可受孕期的女性（15-44歲）服用中樞神經刺激劑治療成人注意力不足過動症的人數大幅增加，截至2015年此類女性已佔全美國女性的4%<ref name="Anderson Ailes Danielson Lind pp. 66–70">{{cite journal | last=Anderson | first=Kayla N. | last2=Ailes | first2=Elizabeth C. | last3=Danielson | first3=Melissa | last4=Lind | first4=Jennifer N. | last5=Farr | first5=Sherry L. | last6=Broussard | first6=Cheryl S. | last7=Tinker | first7=Sarah C. | title=Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15–44 Years — United States, 2003–2015 | journal=MMWR. Morbidity and mortality weekly report | publisher=Centers for Disease Control MMWR Office | volume=67 | issue=2 | date=2018-01-19 | issn=0149-2195 | pmid=29346342 | pmc=5772805 | doi=10.15585/mmwr.mm6702a3 | pages=66–70}}</ref>。然而研究初步發現，[[胎兒|胎兒]]在[[子宮|子宮]]接觸到[[哌甲酯|哌甲酯]]，有相對控制組來說，較高的風險在出生後帶有[[先天性心臟病|先天性心臟病]]，而[[安非他命|安非他命]]則無此風險。<ref name="Huybrechts Bröms Christensen Einarsdóttir p=167">{{cite journal | last=Huybrechts | first=Krista F. | last2=Bröms | first2=Gabriella | last3=Christensen | first3=Lotte Brix | last4=Einarsdóttir | first4=Kristjana | last5=Engeland | first5=Anders | last6=Furu | first6=Kari | last7=Gissler | first7=Mika | last8=Hernandez-Diaz | first8=Sonia | last9=Karlsson | first9=Pär | last10=Karlstad | first10=Øystein | last11=Kieler | first11=Helle | last12=Lahesmaa-Korpinen | first12=Anna-Maria | last13=Mogun | first13=Helen | last14=Nørgaard | first14=Mette | last15=Reutfors | first15=Johan | last16=Sørensen | first16=Henrik Toft | last17=Zoega | first17=Helga | last18=Bateman | first18=Brian T. | title=Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations | journal=JAMA psychiatry | publisher=American Medical Association (AMA) | volume=75 | issue=2 | date=2018-02-01 | issn=2168-622X | pmid=29238795 | pmc=5838573  | doi=10.1001/jamapsychiatry.2017.3644 | page=167}}</ref>因此當醫生處方哌甲酯給孕婦（包含不知自己已經懷孕的女性）前，應該權衡此舉對患者的利弊得失。<ref name="Huybrechts Bröms Christensen Einarsdóttir p=167"/>

食物可能延遲[[Adderal|Adderal XR]]的生效時間並增加安非他命在血漿中的最高濃度；Concerta 則無此特性<ref name="Auiler Liu Lynch Gelotte 2002 pp. 311–316">{{cite journal | last=Auiler | first=J. F. | last2=Liu | first2=K. | last3=Lynch | first3=J. M. | last4=Gelotte | first4=C. K. | title=Effect of Food on Early Drug Exposure from Extended-Release Stimulants: Results from the Concerta®, Adderall XR™ Food Evaluation (CAFÉ) Study | journal=Current medical research and opinion | publisher=Informa Healthcare | volume=18 | issue=5 | year=2002 | issn=0300-7995 | pmid=12240794 | doi=10.1185/030079902125000840 | pages=311–316 | quote= The food effect on early drug exposure and the pharmacokinetic profiles up to 8 h after dosing of the two extended-release stimulants were directly compared using partial area (AUC(p4h), AUC(p6h) and AUC(p8h)) fed/fasted ratios. Amphetamine concentrations were markedly lower when the subjects had eaten breakfast, resulting in lower early drug exposures (p < 0.0001). By contrast, methylphenidate concentrations over the same 8 h were unaffected by breakfast, providing consistent levels of early drug exposure. Therefore, as a child's or adult's eating pattern varies, methylphenidate exposure over the first 8 h would be expected to have less day-to-day variation compared with amphetamine exposure. The osmotic-controlled OROS tablet provides a reliable and consistent delivery of methylphenidate HCI, independent of food, for patients with ADHD.}}</ref>。

{{For2|更多中樞神經刺激劑和其藥物<!--：派醋甲酯、[[安非他命|安非他命]]-->|[[中樞神經刺激劑|中樞神經刺激劑]]、[[哌甲酯|哌甲酯]]、和[[安非他命|安非他命]]尤其[[安非他命#醫療|安非他命§醫療]]乙節}}

{| style="margin: 0 auto;"  | [[File:Ritalin_LA_exterior、outward_appearance、藥罐外觀.jpg|left]]LA（Ritalin LA）藥罐外觀]]
| [[File:Dextroamphetamine.jpg|center]]]]
| [[File:Lilly_Strattera_60mg_Capsule.jpg|center]]60毫克膠囊（Lilly Strattera 60mg Capsule）]]
| [[File:Strattera_atomoxetin.jpg|center]]
|}

====第一線中樞神經刺激劑====
{| class="wikitable sortable"
|+ 專思達（Concerta）仿單（說明書）上的建議劑量
|-
! 患者年紀 !! 建議起始劑量 !! 建議劑量範圍
|-
| 6-12歲 || 18 [[毫克|毫克]]/每天 （mg/Kg）|| 18 - 54 毫克/每天 （mg/Kg）
|-
| 13-17歲  || 18 毫克/每天 || 18 - 72 毫克/每天 每天每公斤不可超過2毫克。{{NoteTag|name=|1=舉例：一個三十公斤的服藥者每天不可服用超過60毫克的專思達}}
|-
| 18-65歲  || 18  或 36 毫克/每天   || 18 - 72 毫克/每天 （{{tsl|en|clinical studies||藥物臨床試驗}}中記載的{{tsl|en|Therapeutic_index#Maximum_tolerated_dose||安全}}且{{tsl|en|Effective_dose_(pharmacology)||有效的劑量範圍}}為：36 - 108 毫克/每天 <ref name="DailyMed 2018 least effective dosage">{{cite web | title=CONCERTA- methylphenidate hydrochloride tablet, extended release | website=DailyMed | date=2018-10-09 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd | access-date=2018-10-18 | quote=14.3 Adults<br/>Two double-blind, placebo-controlled studies were conducted in 627 adults aged 18 to 65 years. The controlled studies compared CONCERTA® administered once daily and placebo in a multicenter, parallel-group, 7-week dose-titration study (Study 5) (36 to 108 mg/day) and in a multicenter, parallel-group, 5-week, fixed-dose study (Study 6) (18, 36, and 72 mg/day). <br/> Study 5 demonstrated the effectiveness of CONCERTA® in the treatment of ADHD in adults aged 18 to 65 years at doses from 36 mg/day to 108 mg/day based on the change from baseline to final study visit on the Adult ADHD Investigator Rating Scale (AISRS). Of 226 patients who entered the 7-week trial, 110 were randomized to CONCERTA® and 116 were randomized to placebo. Treatment was initiated at 36 mg/day and patients continued with incremental increases of 18 mg/day (36 to 108 mg/day) based on meeting specific improvement criteria with acceptable tolerability. At the final study visit, mean change scores (LS Mean, SEM) for the investigator rating on the AISRS demonstrated that CONCERTA®was statistically significantly superior to placebo. <br/> Study 6 was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study (5-week duration) with 3 fixed-dose groups (18, 36, and 72 mg). Patients were randomized to receive CONCERTA® administered at doses of 18 mg (n=101), 36 mg (n=102), 72 mg/day (n=102), or placebo (n=96). All three doses of CONCERTA® were statistically significantly more effective than placebo in improving CAARS (Conners' Adult ADHD Rating Scale) total scores at double-blind end point in adult subjects with ADHD. | archive-url=https://web.archive.org/web/20170326230808/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd | archive-date=2017-03-26 | dead-url=no }}</ref>）
|}
<ref name="Concerta's clinical trial for adolescent">
{{cite web
 |url         = https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 |title       = Label of Concerta
 |date        = 2013
 |website     = DailyMed.gov
 |publisher   = Jassen Cilag
 |access-date = January, 2017.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170326230808/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 |archivedate = 2017-03-26
}}</ref>
註解：
# 在專思達的藥物試驗過程中發現，13-17歲的青年試驗組中，專思達的最低有效劑量為： 每天每公斤1.4毫克 (1.4 mg/kg/day)。<ref name="Concerta's clinical trial for adolescent" />
# 18歲以上的兩個成人試驗組中，發現每天18-72毫克的劑量皆可達到在統計學上具顯著意義的療效。（然而以每天36毫克以上進而達到統計學上具顯著意義的療效的臨床試驗者為大多數。）<ref name="Concerta's clinical trials for people older than 18">
{{cite web
 |url         = https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 |title       = Label of Concerta
 |date        = 2013
 |website     = DailyMed.gov
 |publisher   = Jassen Cilag
 |access-date = January, 2017.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170326230808/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 |archivedate = 2017-03-26
}}</ref>

至今為止的「藥劑量最佳化（Dose-optimization）」的成人組臨床試驗揭示：成分為methylphenidate的藥品，無論為短效或長效，每日最高的上限劑量總和為120毫克{{nowrap|（120 mg / day）}}<ref name="Huss Duhan Gandhi Chen 2017 pp. 1741–1751">{{cite journal | last=Huss | first=Michael | last2=Duhan | first2=Praveen | last3=Gandhi | first3=Preetam | last4=Chen | first4=Chien-Wei | last5=Spannhuth | first5=Carsten | last6=Kumar | first6=Vinod | title=Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity | journal=Neuropsychiatric Disease and Treatment | publisher=Dove Medical Press Ltd. | volume=Volume 13 | date=2017-07-04 | issn=1178-2021 | pmid=28740389 | pmc=5505611 | doi=10.2147/ndt.s130444 | pages=1741–1751 | type=Systematic review (Secondary source) | quote=Fredriksen et al conducted a naturalistic study to assess the 1-year efficacy of ADHD treatment regimens in adults with ADHD.59 All patients received MPH as the first-line pharmacological treatment in addition to psychosocial interventions. The study was conducted at a specialized outpatient clinic in Norway and involved a 6-week MPH titration phase (up to 60 mg/day) followed by a dose-optimization phase (maximum dose 120 mg/day).}}</ref><ref name="Sikirica Lu Greven Zhong 2014 p=1543">{{cite journal | last=Sikirica | first=Vanja | last2=Lu | first2=Mei | last3=Greven | first3=Peter | last4=Zhong | first4=Yichen | last5=Qin | first5=Paige | last6=Xie | first6=Jipan | last7=Gajria | first7=Kavita | title=Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review | journal=Neuropsychiatric Disease and Treatment | publisher=Dove Medical Press Ltd. | volume=10 | date=2014-08-22 | issn=1178-2021 | pmid=25187718 | pmc=4149449 | doi=10.2147/ndt.s65721 | page=1543}}</ref><ref name="Fredriksen Dahl Martinsen Klungsøyr 2014 pp. 1873–1884">{{cite journal | last=Fredriksen | first=Mats | last2=Dahl | first2=Alv A. | last3=Martinsen | first3=Egil W. | last4=Klungsøyr | first4=Ole | last5=Haavik | first5=Jan | last6=Peleikis | first6=Dawn E. | title=Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity | journal=European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | publisher=Elsevier BV | volume=24 | issue=12 | year=2014 | issn=0924-977X | pmid=25453480 | doi=10.1016/j.euroneuro.2014.09.013 | pages=1873–1884}}</ref><ref name="Esposito Azhari Borelli 2018 p. ">{{cite journal | last=Esposito | first=Gianluca | last2=Azhari | first2=Atiqah | last3=Borelli | first3=Jessica L. | title=Gene × Environment Interaction in Developmental Disorders: Where Do We Stand and What’s Next? | journal=Frontiers in psychology | publisher=Frontiers Media SA | volume=9 | date=2018-10-26 | issn=1664-1078 | pmid=30416467 | pmc=6212589 | doi=10.3389/fpsyg.2018.02036 | page=}}</ref>。

=== 非中樞神經刺激劑 ===

數種非中樞神經刺激劑，例如：[[阿托莫西汀|阿托莫西汀]]、[[可樂定|可樂定]]、[[安非他酮|安非他酮]]和{{tsl|en|guanfacine|胍法辛}}，可與中樞神經刺激劑一起使用，也可以作為中樞神經刺激劑的替代方案。<ref name=CNS09>{{cite journal 
|author=Wigal SB 
|title=Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults |journal=CNS Drugs|volume=23 Suppl 1 |pages=21–31 |year=2009 |pmid=19621975 |doi=10.2165/00023210-200923000-00004 |url=}}</ref><ref name="Cochrane Amphetamines ADHD">{{cite journal |vauthors=Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M |title=Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults |journal=Cochrane Database Syst. Rev. |volume= |issue=6 |pages=CD007813 |year=2011 |pmid=21678370 |doi=10.1002/14651858.CD007813.pub2 |url= |editor=Castells X}}</ref><ref>{{Cite journal|last=Childress|first=A. C.|last2=Sallee|first2=F. R.|date=2012|title=Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder|journal=Drugs of Today (Barcelona, Spain: 1998)|volume=48|issue=3|pages=207–217|doi=10.1358/dot.2012.48.3.1750904|issn=1699-3993|pmid=22462040|quote=There are a number of non-stimulant medications, such as [[阿托莫西汀|atomoxetine]], [[安非他酮|bupropion]], guanfacine, and [[可乐定|clonidine]] that may be used as alternatives, or added to stimulant therapy.}}</ref> 當前並無高品質的文獻比較過這些藥物的優劣，然而這些非中樞神經刺激劑藥物之間的副作用似乎大同小異。<ref name=McD2011>{{cite journal | vauthors =  McDonagh MS, Peterson K, Thakurta S, Low A | title = Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder | date = December 2011 | pmid = 22420008 | url = https://www.ncbi.nlm.nih.gov/books/NBK84419 | publisher = United States Library of Medicine | archive-url = https://web.archive.org/web/20160831152630/http://www.ncbi.nlm.nih.gov/books/NBK84419/ | df = dmy-all | deadurl = no | archive-date = 31 August 2016 | series = Drug Class Reviews }}</ref> 中樞神經刺激劑似乎能改善用藥者的學業表現，阿托莫西汀則否。<ref name="pmid23179416">{{cite journal | vauthors = Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K | title = How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis | journal = European Child & Adolescent Psychiatry | volume = 22 | issue = 4 | pages = 203–16 | date = April 2013 | pmid = 23179416 | doi = 10.1007/s00787-012-0346-x }}</ref> 阿托莫西汀，受惠於自身對於用藥者的成癮性或依賴性較低的屬性，所以適用於使用於那些有極高可能把中樞神經刺激劑用於娛樂用途或因為衝動而大量用藥使得中樞神經刺激劑的劑量遠高於醫療用劑量的患者。<ref name="Kooij-2010"/> 當前有些許證據表明這些藥物能改善患者的社交行為能力。<ref name=McD2011/><!--Pending review: There is little evidence on the effects of medication on social behaviors.<ref name=McD2011/>--> {{As of|2015|6}}，ADHD藥物的長期療效尚未被完全評定。<ref name="ADHD 2015 review">{{cite journal | vauthors = Kiely B, Adesman A | title = What we do not know about ADHD… yet | journal = Current Opinion in Pediatrics | volume = 27 | issue = 3 | pages = 395–404 | date = June 2015 | pmid = 25888152 | doi = 10.1097/MOP.0000000000000229 | quote = In addition, a consensus has not been reached on the optimal diagnostic criteria for ADHD. Moreover, the benefits and long-term effects of medical and complementary therapies for this disorder continue to be debated. These gaps in knowledge hinder the ability of clinicians to effectively recognize and treat ADHD. }}</ref><ref name="pmid21519262">{{cite journal | vauthors = Hazell P | title = The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder | journal = Current Opinion in Psychiatry | volume = 24 | issue = 4 | pages = 286–90 | date = July 2011 | pmid = 21519262 | doi = 10.1097/YCO.0b013e32834742db  }}</ref>

[[禮來公司|禮來公司]]（Eli Lilly）的[[思銳|思銳]]（Strattera），有效成份為阿托莫西汀<ref name="Strattera label"/>，與中樞神經刺激劑同樣為治療ADHD的第一線藥物。思銳為非[[中樞神經|中樞神經]]刺激藥物（非興奮劑），且歸類於[[配體_(生物化學)|選擇性]][[去甲腎上腺素再回收抑制劑|正腎上腺素再回收抑制劑]]。思銳有六種劑量型，分別為：18MG、25MG、40MG、60MG、80MG和100MG。<ref name="Strattera label"/>
「對於年齡小於18歲且體重小於70公斤」的使用者來說「總計每天服用劑量的上限為每公斤1.4 毫克（mg/day）」；對於「年齡大於或等於18歲或年齡小於18歲且體重大於70公斤」的使用者來說「總計每天服用劑量的上限為每天100毫克（mg/day）」。<ref name="Strattera label_2">

{{cite web
 | url = https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb&type=pdf&name=309de576-c318-404a-bc15-660c2b1876fb
 | title = Label of Strattera consisting of atomoxetine
 | date =  2015-06
 | website = DailyMed.gov
 | publisher =Eli Lilly Company
 | access-date =2017-02
 | quote =DOSAGE AND ADMINISTRATION 2.1 Acute Treatment Dosing of children and adolescents up to 70 kg body weight......No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day [see Clinical Studies (14)]. 'The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg, whichever is less'. Dosing of children and adolescents over 70 kg body weight and adults......The maximum recommended total daily dose in children and adolescents over 70 kg and adults is 100 mg. }}</ref>

思銳的副作用相較於中樞神經刺激劑來得輕微許多。思銳主要的副作用有：<!-- 胃腸不適、食慾不振、 -->疲倦<!-- 、情緒變化 -->、口乾（唾液分泌減少）等<ref name="Strattera label"/>。（副作用產生與否因人而異）<ref name="Strattera label">{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb|title=DailyMed - STRATTERA- atomoxetine hydrochloride capsule  STRATTERA- atomoxetine hydrochloride|author=|date=2015-06|publisher=Eli Lilly|website=DailyMed.com|deadurl=no|archiveurl=https://web.archive.org/web/20170902005439/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb|archivedate=2017-09-02}}</ref>患者如果對中樞神經刺激劑沒有反應、反應不佳或過敏，可考慮使用阿托莫西汀。患者可向醫生詢問，共同制定一個漸進的劑量法。

思銳的藥效可以持續24小時<ref name="UpToDate 2017 in regard to atomoxetine">{{cite web | title=Atomoxetine: Drug information | date=2017-12-28 | website=[[UpToDate|UpToDate]] | url=https://www.uptodate.com/contents/atomoxetine-drug-information#F137783 | access-date=2017-12-28 | quote=Duration of action: Up to 24 hours (Jain 2017) | deadurl=no | archiveurl=https://web.archive.org/web/20171228172248/https://www.uptodate.com/contents/atomoxetine-drug-information#F137783 | archivedate=2017-12-28 }}</ref>。<!--根據NAMI Minnesota提供的資料，-->思銳從第一天服用開始約需持續服用28至56天（4週到8週）才會完全生效。<ref name="Maudsley">{{cite book | isbn = 978-0-470-97948-8 | title = The Maudsley prescribing guidelines in psychiatry | last1 = Taylor | first1 = D |author2=Paton, C |author3=Shitij, K | year = 2012 | publisher = Wiley-Blackwell | location = West Sussex  | pages =  }}</ref><ref>{{cite book|title=Adult ADHD Diagnostic Assessment and Treatment|isbn=978-1-4471-4137-2|doi=10.1007/978-1-4471-4138-9|author=Kooij, JJS|year=2013|url=https://link.springer.com/content/pdf/10.1007%2F978-1-4471-4138-9|format=PDF|publisher=Springer London}}</ref>
然而患者或患者周遭的人在這期間便可能逐漸感受到藥效
<ref name="How long for Strattera to start working">{{cite web
 |url         = http://www.namihelps.org/assets/PDFs/fact-sheets/Medications/Strattera.pdf
 |title       = How long for Strattera to start working?
 |website     = Minnesota National Allianceof Mental Illness
 |access-date = 2017-02
 |quote       = It may take 4 - 8 weeks after an effective dose is reached for atomoxetine to reach maximum effectiveness.  However, improvements in some symptoms may occur sooner.
 |deadurl     = yes
 |archiveurl  = https://web.archive.org/web/20151224013453/http://www.namihelps.org/assets/PDFs/fact-sheets/Medications/Strattera.pdf
 |archivedate = 2015-12-24
}}</ref>
<ref name="How long does Strattera take to work?">{{cite web
 |url         = http://www.strattera.com/parent/faqs.html
 |title       = Frequently Asked Questions
 |date        =  2016-09
 |website     = Official website for Strattera
 |publisher   = Strattera-Eli Lilly
 |access-date =  2017-02
 |quote       = Strattera works gradually, so improvements are seen over time. When your child starts treatment with Strattera, it's important to set some small goals. Remember to be patient—some people notice small changes within 2 weeks, and by 4 to 6 weeks at target dose you should see significant improvement in your child's symptoms.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170109184607/http://www.strattera.com/parent/faqs.html
 |archivedate = 2017-01-09
}}</ref><ref name="Biological Psychiatry 2003 pp. 112–120">{{cite journal | title=Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies | journal=Biological Psychiatry | volume=53 | issue=2 | date=2003-01-15 | issn=0006-3223 | doi=10.1016/S0006-3223(02)01671-2 | pages=112–120 | url=http://www.sciencedirect.com/science/article/pii/S0006322302016712 | access-date=2017-12-28}}</ref><ref name = "MSR"/>。服用者建議定期追蹤監測[[心律|心律]]、[[血壓|血壓]]、{{tsl|en|liver function||肝功能}}<ref name="UpToDate Drug information for atomoxetine">{{cite web | title=Drug information for atomoxetine | website=UpToDate | url=https://www.uptodate.com/contents/atomoxetine-drug-information | access-date=2018-02-26 | deadurl=no | archiveurl=https://web.archive.org/web/20171228172248/https://www.uptodate.com/contents/atomoxetine-drug-information | archivedate=2017-12-28 }}</ref>，患者第一次用藥前建議先進行全面的[[心血管|心血管功能]]檢查，以確保患者沒有[[先天性心臟病|先天性心臟病]]或存有任何嚴重的心血管問題<ref name="UpToDate Drug information for atomoxetine"/>。

縱然阿托莫西汀與中樞神經刺激劑同樣為治療ADHD的第一線藥物，然而其對特定症狀改善的程度可能與中樞神經刺激劑不同（兩類藥物各有其長處）。阿托莫西汀在改善「過動-衝動」的症狀上，略優於派甲酯；派甲酯則在改善「分心」的症狀上，略優於阿托莫西汀。<ref>{{Cite journal
 | author = Chi-Yung Shang, Yi-Lei Pan, Hsiang-Yuan Lin, Lin-Wan Huang & Susan Shur-Fen Gau
 | title = An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder
 | journal = Journal of child and adolescent psychopharmacology
 | volume = 25
 | issue = 7
 | pages = 566–573
 | date =  2015-09
 | doi = 10.1089/cap.2015.0035
 | pmid = 26222447
 | quote = At week 24, mean changes in ADHD-RS-IV Inattention scores were 13.58 points (Cohen's d, -3.08) for OROS-methylphenidate and 12.65 points (Cohen's d, -3.05) for atomoxetine; and mean changes in ADHD-RS-IV Hyperactivity-Impulsivity scores were 10.16 points (Cohen's d, -1.75) for OROS-methylphenidate and 10.68 points (Cohen's d, -1.87) for atomoxetine.
}}</ref><ref>衛生福利部精神疾病衛教叢書 注意力不足過動症，第22頁<!--quote內容-->「atomoxetine，用在病情 較為複雜、或是無法忍受MPH副作用的患者，然而一般發現其對於專注度的改善沒有MPH明顯」</ref>
<ref>{{Cite journal
 | author = Myriam Harfterkamp, Jan K. Buitelaar, Ruud B. Minderaa, Gigi van de Loo-Neus, Rutger-Jan van der Gaag & Pieter J. Hoekstra
 | title = Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study
 | journal = Journal of child and adolescent psychopharmacology
 | volume = 23
 | issue = 3
 | pages = 194–199
 | doi = 10.1089/cap.2012.0012
 | pmid = 23578015
|date=2013-04}}</ref>
<ref>{{Cite journal
 | author = L. Eugene Arnold, Michael G. Aman, Amelia M. Cook, Andrea N. Witwer, Kristy L. Hall, Susan Thompson & Yaser Ramadan
 | title = Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
 | journal = Journal of the American Academy of Child and Adolescent Psychiatry
 | volume = 45
 | issue = 10
 | pages = 1196–1205
 | doi = 10.1097/01.chi.0000231976.28719.2a
 | pmid = 17003665
|date=2006-10}}</ref>
<ref>
{{cite book
 |author      = Matthew Siegel, MD.,Craig Erickson, MD., MS, Jean A. Frazier, MD., Toni Ferguson, Autism Society of America., Eric Goepfert, MD., Gagan Joshi, MD., Quentin Humberd, MD., Bryan H. King, MD., Amy Lutz, EASI Foundation: Ending Aggression and Self-Injury in the Developmentally Disabled., Louis Kraus, MD., Alice Mao, MD., Adelaide Robb, MD., Jeremy Veenstra-VanderWeele, MD, PhD., Paul Wang, MD, Autism SpeaksCarmen J. Head, MPH, CHES, Director, Research, Development, & WorkforceEve, Bender, Scientific Editor.
 |title       = Autism_Spectrum_Disorder_Parents_Medication_Guide
 |publisher   = American Academy of Child and Adolescent Psychiatry
 |series      = 
 |volume      = 
 |edition     = 
 |date        = 2016
 |location    = 3615 Wisconsin Avenue, NW, Washington, DC 20016-3007
 |pages       = 13
 |language    =en
 |url         = https://www.aacap.org/App_Themes/AACAP/Docs/resource_centers/autism/Autism_Spectrum_Disorder_Parents_Medication_Guide.pdf
 |doi         = 
 |id          = 
 |isbn        = 
 |quote       = Atomoxetine (Strattera) has also been researched in controlled studies for treatment of ADHD in children with autism, and showed some improvements,particularly for hyperactivity and impulsivity.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170411220740/https://www.aacap.org/App_Themes/AACAP/Docs/resource_centers/autism/Autism_Spectrum_Disorder_Parents_Medication_Guide.pdf
 |archivedate = 2017-04-11
}}</ref>

而阿托莫西汀與哌甲酯併服的處方尚未經[[美國食品藥物管理局|美國食品藥物管理局]]核可，但醫師會視個案的情況（如共病、預後等）以開{{tsl|en|off-label use|仿單標示外使用}}的方式處方之。<ref>{{cite web
 |archive-url  = https://web.archive.org/web/20170202064443/https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |type         = Guidelines (Tertiary source)
 |archive-date = 2017-02-02
 |url          = https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |title        = Parent's Medication Guide: ADHD
 |date         = 2013-06
 |website      = American Psychiatric Association
 |publisher    = American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP)
 |access-date  = 2017-01
 |quote        = Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.
 |deadurl      = no
 |accessdate   = 2017-01-01
 |archiveurl   = https://web.archive.org/web/20170202064443/https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |archivedate  = 2017-02-02
}}</ref><ref>{{cite web
 |url         = https://medlineplus.gov/ency/article/001551.htm
 |title       = Medical Encyclopedia → Attention deficit hyperactivity disorder
 |date        = 2017-01-05
 |website     = MedlinePlus.gov
 |access-date = 2017-01
 |quote       = Medicine combined with behavioral treatment often works best. Different ADHD medicines can be used alone or combined with each other. The doctor will decide which medicine is right, based on the person's symptoms and needs.
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170126193043/https://medlineplus.gov/ency/article/001551.htm
 |archivedate = 2017-01-26
}}</ref><ref name="pmid23560600">{{cite journal
 | author=Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M et al.
 | title=A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. 
 | journal=Journal of Child and Adolescent Psychopharmacology 
 | type= systematic review (Secondary source)
 | year= 2013 
 | volume= 23 
 | issue= 3 
 | pages= 179-93 
 | pmid=23560600 
 | doi=10.1089/cap.2012.0093 
 | pmc=3696926 
 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23560600 
 |quote=Existing evidence suggests, but does not confirm, that this drug combination may benefit some, but not all, patients who have tried several ADHD medications without success. }}</ref><ref name="pmid26364896">{{cite journal 
 | author=Perugi G, Vannucchi G| title=The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. 
 | journal=Expert Opin Pharmacother 
 | year= 2015 
 | volume= 16 
 | issue= 14 
 | pages= 2193-204 
 | pmid=26364896 
 | doi=10.1517/14656566.2015.1079620 
 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26364896 
 |quote=Although systematic trials on the use of stimulants and ATX in ADHD-BD comorbidity in adulthood are necessary, both treatments should be considered possible options to be carefully evaluated once the patient has been stabilized.}}</ref>在臨床試驗中，並未發現兩者併服後產生加乘的心血管副作用。換言之，兩者併服之心血管作用，與單獨服用哌甲酯所產生的心血管作用相同。<ref name="Strattera label_3">{{cite web
 | url = https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb&type=pdf&name=309de576-c318-404a-bc15-660c2b1876fb
 | type= Leaflet/label (Tertiary source)
 | title = Label of Strattera consisting of atomoxetine
 | date = 2015-06
 | website = DailyMed.gov
 | publisher =Eli Lilly Company
 | access-date = 2017-02
 | quote =7.7 Methylphenidate\ Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone. }}</ref><ref name="NIMH » Home combination">{{cite web | title=NIMH » Attention Deficit Hyperactivity Disorder | website=NIMH » Home | url=https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | access-date=2018-07-21 | quote=Non-stimulants. A few other ADHD medications are non-stimulants. These medications take longer to start working than stimulants, but can also improve focus, attention, and impulsivity in a person with ADHD. Doctors may prescribe a non-stimulant: when a person has bothersome side effects from stimulants; when a stimulant was not effective; or in combination with a stimulant to increase effectiveness. | accessdate=2016-12-27 | archiveurl=https://web.archive.org/web/20161225231931/https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml | archivedate=2016-12-25 | deadurl=no }}</ref>

[[可樂定|可樂定]]與{{tsl|en|guanfacine|胍法新}}皆為非中樞神經刺激劑、{{tsl|en|alpha-2 adrenergic receptor|α2腎上腺素受體}}刺激劑/促進劑/活化劑 的一員；與哌甲酯併用或單獨服用都有顯著療效，其中兩藥物併服：可樂定或胍法新與哌甲酯或安非他命合併使用的療效優於單獨服用任意一者。{{NoteTag|name=Adrenergic receptor|1=延伸閱讀：[[腎上腺素受體|腎上腺素受體]]、α<sub>2</sub>腎上腺素受體}}
<ref name="Science_daily"/>
<ref name="AACAP">{{cite web
 |archive-url  = https://web.archive.org/web/20170202064443/https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |archive-date = 2017-02-02
 |url          = https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |title        = Parent's Medication Guide: ADHD
 |date         = 2013-06
 |website      = American Psychiatric Association
 |publisher    = American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP)
 |access-date  = 2017-02
 |quote        = Extended release guanfacine (Intuniv) and extended release clonidine (Kapvay) are approved to be added to stimulant treatment when the stimulant doesn’t fully reduce the ADHD symptoms.
 |deadurl      = no
 |accessdate   = 2017-01-01
 |archiveurl   = https://web.archive.org/web/20170202064443/https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 |archivedate  = 2017-02-02
}}</ref>
<ref name="pmid27453081">{{cite journal
| author=Loo SK, Bilder RM, Cho AL, Sturm A, Cowen J, Walshaw P et al.
| title=Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder. 
| journal=J Am Acad Child Adolesc Psychiatry 
| year= 2016 
| volume= 55 
| issue= 8 
| pages= 674-682.e1 
| pmid=27453081 
| doi=10.1016/j.jaac.2016.04.020 
| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27453081  }}</ref>
<ref name="pmid27453079">{{cite journal
| author=McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J et al.
| title=Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. 
| journal=J Am Acad Child Adolesc Psychiatry 
| year= 2016 
| volume= 55 
| issue= 8 
| pages= 657-666.e1 
| pmid=27453079 
| doi=10.1016/j.jaac.2016.05.015 
| pmc=4976782 
| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27453079  }}</ref>
<ref name="pmid27453080">{{cite journal
| author=Bilder RM, Loo SK, McGough JJ, Whelan F, Hellemann G, Sugar C et al.
| title=Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder. 
| journal=J Am Acad Child Adolesc Psychiatry 
| year= 2016 
| volume= 55 
| issue= 8 
| pages= 667-73
| pmid=27453080 
| doi=10.1016/j.jaac.2016.05.016 
| pmc=4964604 
| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27453080  }}</ref>
<ref>{{cite web
 |url          = https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |title        = Combining medications could offer better results for ADHD patients
 |archive-url  = https://web.archive.org/web/20170102050323/https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |archive-date = 2017-01-02
 |date         = 2016-08-01
 |website      = Science News
 |publisher    = Elsevier
 |access-date  = 2017-01
 |quote        = Summary:Three studies report that combining two standard medications could lead to greater clinical improvements for children with attention-deficit/hyperactivity disorder (ADHD) than either ADHD therapy alone. At present, studies show that the use of several ADHD medications result in significant reductions in ADHD symptoms. However, so far there is no conclusive evidence that these standard drug treatments also improve long-term academic, social, and clinical outcomes.
 |deadurl      = no
 |accessdate   = 2017-01-01
 |archiveurl   = https://web.archive.org/web/20170102050323/https://www.sciencedaily.com/releases/2016/08/160801093232.htm
 |archivedate  = 2017-01-02
}}</ref>

請注意：
# 美國食品藥物管理局已證明數起曾因為併服：可樂定、胍法新、哌甲酯或安非他命而致命的個案群與四种药物本身並無關聯。<ref>{{cite web
 |url         = http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM317388.pdf
 |title       = Death with the concomitant use of clonidine or guanfacine and amphetamine／dextroamphetamine or dexmethylphenidate or dextroamphetamine or lisdexamfetamine or methylphenidate.
 |date        = 2010-07-06
 |website     = American Psychiatric Association
 |publisher   = Department of Health and Human Services & Public Health Service & Food and Drug Administration & Center for Drug Evaluation and Research & Office of Surveillance and Epidemiology
 |access-date = 2017-01
 |deadurl     = no
 |archiveurl  = https://web.archive.org/web/20170215194550/http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/pediatricadvisorycommittee/ucm317388.pdf
 |archivedate = 2017-02-15
}}</ref>
# 《{{tsl|en|Journal of the American Academy of Child and Adolescent Psychiatry|美國兒童青少年精神醫學會期刊}}》所刊登之論文，「<font color="#000000">可樂定或胍法新與哌甲酯或安非他命合併使用的療效優於單獨服用任意一者</font>」的結論是立基於使用「長效可樂定或胍法新」作為臨床實驗過程中的試驗物。<ref name="Science_daily"/><ref name="AACAP"/><ref name="pmid27453079"/><ref name="pmid27453080"/>

{| class="wikitable"
|-
! 藥品學名 !! 藥物類別（屬性）!! 作用時間 !! 備註
|-
| [[阿托莫西汀|阿托莫西汀]] {{nowrap|（思銳）}}{{NoteTag|name=Strattera's officially approved guidance|1=膠囊必須整顆與開水或其他液體一起吞服。其他注意事項請詳閱藥品說明書。<ref>{{cite web | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb | title=LABEL: STRATTERA- atomoxetine hydrochloride capsule STRATTERA- atomoxetine hydrochloride | website=DailyMed | date=2017-03-16 | access-date=2017-24-23 | quote=Swallow STRATTERA capsules whole with water or other liquids. | deadurl=no | archiveurl=https://web.archive.org/web/20170902005439/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb | archivedate=2017-09-02 }}</ref>}} || [[配體_(生物化學)|選擇性]]正腎上腺素[[再回收抑制劑|再回收抑制劑]]、非中樞神經刺激劑（非興奮劑）|| {{nowrap|5.2小時}} <ref name=MSR>{{cite web|title=atomoxetine (Rx) – Strattera|work=Medscape Reference|publisher=WebMD|accessdate=2013-11-10|url=http://reference.medscape.com/drug/strattera-atomoxetine-342994|deadurl=no|archiveurl=https://web.archive.org/web/20131110153513/http://reference.medscape.com/drug/strattera-atomoxetine-342994|archivedate=2013-11-10}}</ref><ref>{{Cite journal
 | author = John-Michael Sauer, Barbara J. Ring & Jennifer W. Witcher
 | title = Clinical pharmacokinetics of atomoxetine
 | journal = Clinical pharmacokinetics
 | volume = 44
 | issue = 6
 | pages = 571–590
 | year = 2005
 | month = 
 | doi = 10.2165/00003088-200544060-00002
 | pmid = 15910008
 | quote=After single oral dose, atomoxetine reaches maximum plasma concentration within about 1-2 hours of administration. In extensive metabolisers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolisers, atomoxetine has a plasma half-life of 21.6 hours.
}}</ref><ref name=TGA>{{cite web|title=STRATTERA® (atomoxetine hydrochloride)|work=TGA eBusiness Services|publisher=Eli Lilly Australia Pty. Limited|date=2013-08-21|accessdate=2013-11-10|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04269-3|deadurl=no|archiveurl=https://web.archive.org/web/20170406152455/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04269-3|archivedate=2017-04-06}}</ref><ref name=DM>{{cite web|title=ATOMOXETINE HYDROCHLORIDE capsule [Mylan Pharmaceuticals Inc.]|work=DailyMed|publisher=Mylan Pharmaceuticals Inc.|date=2011-10|accessdate=2013-11-10|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdab7205-d0ff-41c3-8430-2d399dfaa759|deadurl=no|archiveurl=https://web.archive.org/web/20131110152856/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdab7205-d0ff-41c3-8430-2d399dfaa759|archivedate=2013-11-10}}</ref>|| 

*美國食品藥物管理局已經批准用於治療兒童、青少年及成人患者<ref name="National Institute of Neurological Disorders and Stroke 2018">{{cite web | title=Attention Deficit-Hyperactivity Disorder Information Page | website=National Institute of Neurological Disorders and Stroke | date=2018-06-15 | url=https://www.ninds.nih.gov/Disorders/All-Disorders/Attention-Deficit-Hyperactivity-Disorder-Information-Page | access-date=2018-07-13 | quote=The usual course of treatment may include medications such as methylphenidate (Ritalin) or dextroamphetamine (Dexedrine), which are stimulants that decrease impulsivity and hyperactivity and increase attention. The U.S. Food and Drug Administration has approved the generic versions of Strattera (atomoxetine) to treat ADHD in pediatric and adult individuals. Most experts agree that treatment for ADHD should address multiple aspects of the individual's functioning and should not be limited to the use of medications alone. Treatment should include structured classroom management, parent education (to address discipline and limit-setting), and tutoring and/or behavioral therapy for the child. | deadurl=no | archiveurl=https://web.archive.org/web/20180423080345/https://www.ninds.nih.gov/Disorders/All-Disorders/Attention-Deficit-Hyperactivity-Disorder-Information-Page | archivedate=2018-04-23 | df= }}</ref>。
<!--語法保留供往後有需要的時候使用： <div style="text-align: center;"> - </div> -->
|-
| [[可樂定|可樂定]] {{NoteTag|name=What should I avoid while taking Clonidine tablets|1=請注意（仿單標註）：
* 除非經醫師評估後允許，否則在服用Clonidine期間切勿攝取酒精及其他與clonidine藥效相似皆會增加睡意的物質、藥物。
* 不要在服用Clonidine期間駕車、操作機械或從事具危險性的活動，除非服藥者已明白且熟悉Clonidine對自己帶來的各種影響。 
* 避免讓自己脫水及中暑。
: clonidine常見的副作用為：
:# 較低的血壓及心跳速率 
:# 想睡覺。 <ref name="What are possible side effects of Clonidine hydrochloride tablet">{{cite web | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8e0edbe-f25f-4c90-8774-4a9c04de9070 | title=LABEL: CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE- clonidine hydrochloride tablet, extended release | website=DailyMed | date=2016-09-30 | access-date=2017-04-23 | deadurl=no | archiveurl=https://web.archive.org/web/20170423064823/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8e0edbe-f25f-4c90-8774-4a9c04de9070 | archivedate=2017-04-23 }}</ref>}} || alpha <sub>2</sub> 腎上腺素受體[[激動劑|刺激劑/促進劑/激動劑/激活劑/活化劑]]、非中樞神經刺激劑（非興奮劑）|| 2-4 小時 <ref name="Attention deficit and hyperkinetic disorders">{{cite web | url=https://www.ntuh.gov.tw/neur/衛教資料/DocLib/一般症狀/成人之注意力不足及過動症.aspx | website=National Taiwan University Hospital | author1=廖曉菁| author2=楊智超 | title=成人之注意力不足及過動症 | access-date=2017-04-14 | deadurl=no | archiveurl=https://web.archive.org/web/20180129184901/https://www.ntuh.gov.tw/neur/%E8%A1%9B%E6%95%99%E8%B3%87%E6%96%99/DocLib/%E4%B8%80%E8%88%AC%E7%97%87%E7%8B%80/%E6%88%90%E4%BA%BA%E4%B9%8B%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E5%8F%8A%E9%81%8E%E5%8B%95%E7%97%87.aspx | archivedate=2018-01-29 }}</ref><ref name="Phamacokinetics in respect of clonidine">{{cite web | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=45679 | title=CLONIDINE HYDROCHLORIDE  - clonidine hydrochloride tablet | website=DailyMed | date=2017-04-13 | quote=Clonidine hydrochloride USP tablets act relatively rapidly. The patient's blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours. | deadurl=no | archiveurl=https://web.archive.org/web/20170414082043/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=45679 | archivedate=2017-04-14 }}</ref><ref>{{cite web | url=http://www.medsafe.govt.nz/profs/Datasheet/c/Cataprestabinj.pdf | language=en-nz | access-date=2017-04-13 | title=New Zealand Datasheet\Name of Medicine\CATAPRES®\Clonidine hydrochloride | date=2012-02-24 | deadurl=no | archiveurl=https://web.archive.org/web/20170408093644/http://medsafe.govt.nz/profs/Datasheet/c/Cataprestabinj.pdf | archivedate=2017-04-08 }}</ref><ref>{{cite web | url=http://www.rxlist.com/catapres-drug/clinical-pharmacology.htm | website=RxList | access-date=2017-04-13 | title=Catapres-drug/clinical-pharmacology | deadurl=no | archiveurl=https://web.archive.org/web/20170414162450/http://www.rxlist.com/catapres-drug/clinical-pharmacology.htm | archivedate=2017-04-14 }}</ref><ref>{{cite web | url=http://files.boehringer.com.au/files/PI/Catapres%20100%20Tabs%20PI.pdf | title=CATAPRES® 100 TABLETS | language=en-au | publisher=Boehringer Ingelheim Pty Limited | location=ABN 52 000 452 308 78 Waterloo Road NORTH RYDE NSW 2113 | date=2016-11-07 | access-date=2014-04-14 | quote=Pharmacokinetic Studies Absorption and distribution The pharmacokinetics of clonidine is dose-proportional in the range of 75-300 micrograms. Clonidine, the active ingredient of CATAPRES, is well absorbed from the gastrointestinal tract and undergoes a minor first pass effect. Peak plasma concentrations are reached within 1-3 hours after oral administration. The duration of action varies from 6-12 hours, the
duration of action being longer in the milder hypertensives. The plasma protein binding is 30-40%. Metabolism and excretion The terminal elimination half-life of clonidine has been found to range from 9-26 hours in patients with normal renal function. With impaired 
 enal function it has been reported to increase to 18-48 hours | deadurl=no | archiveurl=https://web.archive.org/web/20150228063706/http://files.boehringer.com.au/files/PI/Catapres%20100%20Tabs%20PI.pdf | archivedate=2015-02-28 }}</ref>|| 
*仿單標註：
**生效時間：<br/>約口服後三十分鐘<ref name="Phamacokinetics in respect of clonidine"/>。
**屬於{{tsl|en|sympathetic blocker|交感神經抑制劑}}，故[[氣喘|氣喘]]或有[[呼吸道|呼吸道]]疾病的患者使用此藥時，應同時監測呼吸道疾病的狀況。<ref name = clinp>{{cite journal|last1=Lowenthal|first1=DT|last2=Matzek|first2=KM|last3=MacGregor|first3=TR|title=Clinical pharmacokinetics of clonidine.|journal=Clinical Pharmacokinetics|date=1988-05|volume=14|issue=5|pages=287–310|doi=10.2165/00003088-198814050-00002|pmid=3293868}}</ref><ref name="UpToDate 2016 Asthma comorbidity">{{cite web | title=Treatment of hypertension in asthma and COPD | website=[[UpToDate|UpToDate]] | date=2016-02-01 | url=https://www.uptodate.com/contents/treatment-of-hypertension-in-asthma-and-copd#H2 | access-date=2017-11-02 | deadurl=no | archiveurl=https://web.archive.org/web/20171107023906/https://www.uptodate.com/contents/treatment-of-hypertension-in-asthma-and-copd#H2 | archivedate=2017-11-07 }}</ref><ref name="MedlinePlus concerning clonidine">{{cite web | title=Clonidine: MedlinePlus Drug Information | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a682243.html | access-date=2018-07-13 | deadurl=no | archiveurl=https://web.archive.org/web/20180423002207/https://medlineplus.gov/druginfo/meds/a682243.html | archivedate=2018-04-23 | df= }}</ref><ref name="UpToDate over palpitations"/><ref name="UpToDate regarding palpitations"/>
|-
| {{tsl|en|guanfacine|胍法新}} || alpha <sub>2</sub> 腎上腺素受體刺激劑/促進劑/激動劑/激活劑/活化劑、非中樞神經刺激劑（非興奮劑）|| 4-8 小時<ref name="Attention deficit and hyperkinetic disorders"/><ref name="MedlinePlus in respective to guanfacine">{{cite web | title=Guanfacine: MedlinePlus Drug Information | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a601059.html | access-date=2018-07-13 | deadurl=no | archiveurl=https://web.archive.org/web/20180527233149/https://medlineplus.gov/druginfo/meds/a601059.html | archivedate=2018-05-27 | df= }}</ref>||

*已經可在中國大陸取得。<ref name="MCE中国-您身边的抑制剂大师 | 活性小分子-抑制剂-激动剂-化合物库">{{cite web | title=Guanfacine hydrochloride (Guanfacine) - Adrenergic Receptor Agonist - MCE中国 | website=MCE中国-您身边的抑制剂大师 | 活性小分子-抑制剂-激动剂-化合物库 | url=http://www.medchemexpress.cn/Guanfacine-hydrochloride.html | language=zh | access-date=2017-12-15 | deadurl=no | archiveurl=https://web.archive.org/web/20171215221124/http://www.medchemexpress.cn/Guanfacine-hydrochloride.html | archivedate=2017-12-15 }}</ref>
|}

[[選擇性血清素再回收抑制劑|選擇性血清素再回收抑制劑]]、選擇性[[5-羥色胺和去甲腎上腺素再攝取抑制劑|血清素及正腎上腺素再回收抑制劑]]（SSNRI, Selective Serotonin and Norepinephrine Reuptake Inhibitor）等俗稱[[抗憂鬱劑|抗憂鬱劑]]的介入可能對於某些個案病情的改善亦有幫助。<ref name="Wilens-2010">{{cite journal 
|vauthors=Wilens TE, Spencer TJ 
| title = Understanding attention-deficit/hyperactivity disorder from childhood to adulthood 
| journal = Postgrad Med 
| volume = 122 
| issue = 5 
| pages = 97–109 
| date = 2010-09
|  pmid = 20861593 
| pmc = 3724232 
| doi = 10.3810/pgm.2010.09.2206 }}</ref>
<ref>
{{cite journal
|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910994/
|title=Duloxetine May Improve Some Symptoms of Attention-Deficit/Hyperactivity Disorder
|first=Helmut
|last=Niederhofer
|date=2010-01-01
|publisher=
|journal=Prim Care Companion J Clin Psychiatry
|volume=12
|issue=2
|via=PubMed Central
|doi=10.4088/PCC.09l00807pin
|pmid=20694126
|pmc=2910994}}</ref><ref name="UpToDate comorbid to generalized anxiety disorder and/or major depressive disorder">{{cite web | title=Pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder | website=UpToDate | url=https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder?search=adult%20adhd&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H437177578 | access-date=2018-03-17 | quote=For adults with ADHD and co-occurring generalized anxiety disorder, we suggest treatment with the combination of a stimulant and an SSRI over other medications. For adults with ADHD and co-occurring depression, we suggest first-line treatment with bupropionrather than other medications (Grade 2C). Treatment with an SSRI plus a stimulant is also a reasonable option. | deadurl=no | archiveurl=https://web.archive.org/web/20180317164936/https://www.uptodate.com/contents/pharmacotherapy-for-adult-attention-deficit-hyperactivity-disorder?search=adult%20adhd&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H437177578 | archivedate=2018-03-17 }}</ref>

[[安非他酮|安非他酮]]（[[國際非專利藥品名稱|國際非專利藥品名稱]]：{{lang|en|Bupropion}}{{NoteTag|name=amfebutamone|1=舊名：amfebutamone}}）是{{tsl|en|Nicotinic antagonist|菸鹼拮抗劑}}和較微弱的[[去甲腎上腺素-多巴胺再吸收抑制劑|去甲腎上腺素-多巴胺再吸收抑制劑]]：一种主要作为抗抑郁药和戒烟药使用的[[药物|药物]]、也可用作治療注意力不足過動症的第二線藥品與[[中樞神經刺激劑|中樞神經刺激劑]]合併使用，或作為中樞神經刺激劑的替代方案。<ref name=CNS09/>
<ref name="MortonMorton1999">{{cite book
 |name-list-format = vanc
 |author1          = Dr. Ian Morton
 |author2          = I.K. Morton
 |author3          = Judith M. Hall
 |title            = Concise Dictionary of Pharmacological Agents: Properties and Synonyms
 |url              = http://books.google.com/books?id=mqaOMOtk61IC&pg=PA57
 |date             = 1999-10-31
 |publisher        = Springer Science & Business Media
 |isbn             = 978-0-7514-0499-9
 |pages            = 57–
 |deadurl          = no
 |archiveurl       = https://web.archive.org/web/20160427122003/https://books.google.com/books?id=mqaOMOtk61IC&pg=PA57
 |archivedate      = 2016-04-27
}}</ref>
<ref>{{cite book
 |name-list-format = vanc
 |title            = Dictionary of Organic Compounds
 |url              = http://books.google.com/books?id=w5dpoQRjGNEC&pg=PA104
 |publisher        = CRC Press
 |isbn             = 978-0-412-54090-5
 |pages            = 104–
 |deadurl          = no
 |archiveurl       = https://web.archive.org/web/20160430152849/https://books.google.com/books?id=w5dpoQRjGNEC&pg=PA104
 |archivedate      = 2016-04-30
}}</ref>
<ref>{{cite book
 |name-list-format = vanc
 |title            = Index Nominum 2000: International Drug Directory
 |url              = http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA38
 |date             = 2000-01
 |publisher        = Taylor & Francis
 |isbn             = 978-3-88763-075-1
 |pages            = 38–
 |deadurl          = no
 |archiveurl       = https://web.archive.org/web/20160430130645/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA38
 |archivedate      = 2016-04-30
}}</ref>
<ref>{{Cite journal
|last=Childress
|first=A. C.
|last2=Sallee
|first2=F. R.
|date=2012
|title=Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder
|journal=Drugs of Today (Barcelona, Spain: 1998)
|volume=48
|issue=3
|pages=207–217
|doi=10.1358/dot.2012.48.3.1750904
|issn=1699-3993
|pmid=22462040}}</ref>
==== 第一線非中樞神經刺激劑 ====
{| class="wikitable"
|+ 思銳（Strattera）仿單上的建議劑量<ref name="Strattera label"/>

|-
! 體重 !! 每天服用的起始劑量!! 總計每天服用的目標劑量 !! 總計每天服用劑量的安全上限
|-
| 年齡小於18歲且體重小於70公斤 || 0.5 毫克/每公斤（mg/Kg） || 1.2 毫克/每公斤 || 1.4 毫克/每公斤
|-
| 年齡大於或等於18歲或年齡小於18歲且體重大於70公斤 || 40 毫克/天（mg/day） || 80 毫克/天 || 100 毫克/天<br/>（臨床試驗的劑量範圍為60 mg/day 到 120 mg/day<ref name="Clinical trial studies for adults with ADHD">{{cite web | title=STRATTERA- atomoxetine hydrochloride capsule STRATTERA- atomoxetine hydrochloride | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb | access-date=2018-12-16 | quote='''14.2 ADHD studies in Adults'''<br/>The effectiveness of STRATTERA in the treatment of ADHD was established in 2 randomized, double-blind, placebo-controlled clinical studies of adult patients, age 18 and older, who met DSM-IV criteria for ADHD.<br/>Signs and symptoms of ADHD were evaluated using the investigator-administered Conners Adult ADHD Rating Scale Screening Version (CAARS), a 30-item scale. The primary effectiveness measure was the 18-item Total ADHD Symptom score (the sum of the inattentive and hyperactivity/impulsivity subscales from the CAARS) evaluated by a comparison of mean change from baseline to endpoint using an intent-to-treat analysis.<br/>In 2 identical, 10-week, randomized, double-blind, placebo-controlled acute treatment studies (Study 5, N=280; Study 6, N=256), patients received either STRATTERA or placebo. STRATTERA was administered as a divided dose in the early morning and late afternoon/early evening and titrated according to clinical response in a range of 60 to 120 mg/day. The mean final dose of STRATTERA for both studies was approximately 95 mg/day. In both studies, ADHD symptoms were statistically significantly improved on STRATTERA, as measured on the ADHD Symptom score from the CAARS scale. Examination of population subsets based on gender and age (<42 and ≥42) did not reveal any differential responsiveness on the basis of these subgroupings. There was not sufficient exposure of ethnic groups other than Caucasian to allow exploration of differences in these subgroups. | archive-url=https://web.archive.org/web/20170902005439/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb | archive-date=2017-09-02 | dead-url=no }}</ref>）

|}

* 備註：
#建議劑量與種族無關。<ref name="Strattera label" />
#肝腎功能不全的患者的服用劑量應低於建議劑量<ref name="Strattera label" />（詳見：[[阿托莫西汀#劑量|阿托莫西汀§劑量]]）
#總計每天服用劑量的上限 = 無論分幾次服用，一天之內最多可攝取的劑量。
#每天的起始劑量應服用至少三天，使身體適應後，才可開始服用每天的目標劑量。<ref name="Strattera label"/> 
#若每天目標劑量效果不符預期，則可逐漸增加劑量至每天服用劑量的上限<ref name="Strattera label_2"/>
<div class="NavFrame collapsed" >
<div class="NavHead" style="background-color:#ffffff">更多注意力不足過動症藥物的圖片與解說II</div>
<div class="NavContent">
<gallery mode="packed-hover" heights="180"> File:Concerta_54mg_OROS.png|''[[哌甲酯|專思達]]''54毫克
File:Concerta OROS overcoat.gif|專思達長效推進機制
File:Concerta OROS diagram.png|專思達持續釋放(長效)推進機制(OROS)Concerta OROS Diagram
</gallery>
<gallery mode="packed-hover" heights="180">
File:Amph salts.jpg|''[[Adderall|Adderall]]''
File:Adderall 20mg capsules.JPG|Adderall長效膠囊(Capsule)
File:Front appearance of Concerta's container 專思（注）達的藥罐外觀.jpg|thumb|專思（注）達的藥罐外觀
File:Controlled med warning in Republic of China aka Taiwan 中華民國管制藥品標籤.jpg|中華民國管制藥品標籤（圖為專思達藥罐背面）
File:Ritalin LA exterior、outward appearance、藥罐外觀.jpg|[[利他能|利他能]]LA（Ritalin LA）藥罐外觀]]
</gallery>
註釋：XR為Extended Release的縮寫，持續釋放之意，表示「長效型」。
</div>
</div>

<div class="NavFrame collapsed" >

<div class="NavHead" style="background-color:#ffffff">更多注意力不足過動症藥物的圖片與解說I</div>
<div class="NavContent">


{|
| [[File:Ritalin-SR-20mg-1000x1000.jpg|center]]Ritalin（樣式A）]]
| [[File:Methylphenidate_Concerta.jpg|center]]Concerta；數字"18" 表示18毫克]]

| [[File:Methylphenidat_und_andere_Tabletten.jpg|center]]
| [[File:Ritalin.jpg|upright=1.4]](利他能)10毫克片劑|alt=A picture of a Ritalin packet]]
|}
</div>

</div>

==中醫==
{{Medical_citation_needed_section|time=2018-08-11}}
{{Globalize|章節| time=2018-08-11}}
[[中華民國中醫師公會全國聯合會|中華民國中醫師公會全國聯合會]]曾在2018年8月於[[臺灣|臺灣]]召開[[記者會|記者會]]指出，「長久以來，[[中醫|傳統中醫]]在改善（ADHD）這類慢性長期精神生理疾病症狀方面，具有顯著的療效」<ref name="中華民國中醫師公會全國聯合會 website version"/>。然而記者會中提供的[[新聞稿|新聞稿]]並未對此敘述提出[[文獻|文獻]]證明<!--客觀事實，故非原創研究。-->。<ref name="中華民國中醫師公會全國聯合會 website version">{{cite web |author=
 | title=中醫有效治療小兒過動症及妥瑞氏症記者會 | website=中華民國中醫師公會全國聯合會 | url=http://www.twtm.tw/new.php?cat=16&id=1257 | language=zh | access-date=2018-08-11 | quote=注意力不足過動症（Attention Deficit Hyperactivity Disorder，簡稱 ADHD）及妥瑞氏症（Tourette Syndrom，簡稱TS）是常見發病於兒童的慢性神經精神異常疾病(Neuropsychiatric disorder)，目前不論中西醫都在尋求根治的方法。長久以來，傳統中醫在改善這類慢性長期精神生理疾病症狀方面，具有顯著的療效及實證案例，透過中醫藥的幫助，減低病症對日常生活之影響，提升生活品質及學業表現，讓孩子有尊嚴、不受歧視、健康自在地活出自己 | archive-url=https://web.archive.org/web/20180811195419/http://www.twtm.tw/new.php?cat=16&id=1257 | archive-date=2018-08-11 | location=臺灣 | date=2018-08-09}}</ref>（參見：[[WP:可供查證|WP:可供查證]]）

中華民國中醫師公會全國聯合會另表示，2010 年發表於《{{tsl|en|Complementary Therapies in Medicine|醫學中的另類療法|醫學中的替代醫學療法}}》{{NoteTag|name=|1=中華民國中醫師公會全國聯合會將《Complementary Therapies in Medicine》翻譯為「醫學補充療法」}}（一個專門紀載[[替代醫學|替代醫學]]{{NoteTag|name=|1=（英文名稱：complementary and alternative medicine）}}的期刊）的一個隨機雙盲對照試驗顯示，「[[電針|電針]]加上行為療法對於注意力不足過動症小朋友有顯著的療效，且能減少{{tsl|en|relapse|復發|復發率}}。研究中針對頭部（[[百會|百會]]、[[四神聰|四神聰]]、[[神庭|神庭]]、[[本神|本神]]、[[太陽_(中醫)|太陽]]、[[印堂|印堂]]）、背部[[膀胱經|膀胱經]]（[[肝俞|肝俞]]、[[脾俞|脾俞]]、[[腎俞|腎俞]]）、足部[[腎經|腎經]]（[[太溪|太溪]]）、足部[[肝經|肝經]]（[[太衝|太衝]]）進行[[針灸|針刺治療]]，達到改善注意力不足與過動的症狀，同時改善情緒障礙與提升腦部發育。」<ref name="Chinese medicine">{{cite web| url=http://www.twtm.tw/userfiles/upload/153380022940080.pdf | website=中華民國中醫師公會全國聯合會 | title=中醫有效治療小兒過動症及妥瑞氏症記者會 | date=2018-08-09 | language=zh-tw | access-date=2018-08-11 | archive-url=https://web.archive.org/web/20180811195157/http://www.twtm.tw/userfiles/upload/153380022940080.pdf | archive-date=2018-08-11| location=臺灣 | quote=臨床實驗證明中醫藥治療注意力不足過動症及妥瑞氏症有一定優勢，如在緩解症狀、穩定病情上有較明顯的療效，同時能增進食慾，改善睡眠，消除或減少遺尿、夜遊、易驚、汗多、痰多等兼症，可以達到增強體質，固本增元，全面調節的作用。目前市面上已有許多藥物對於這類精神疾病有治療效果，如：利他能(Ritalin)等，但因容易產生失眠、腸胃不適及食慾不振、頭暈等副作用，因此尋求中醫診治成了不少家長的選擇。中藥、針灸雙管齊下 治療過動兒......}}</ref>{{Unreliable_fringe_source|sure=y}}{{reliable medical source needed}}

==對於治療方式的不同論點==
{{see also|注意力不足過動症#治療方式的爭議}}

中華民國（台灣）有[[社會學|社會學]]學者從[[新聞媒體|新聞媒體]]資料庫－[[聯合知識庫|聯合知識庫]]蒐集2001年起有關[[注意力不足過動症|注意力不足過動症]]的新聞報導，並從記者的報導中，利用[[內容分析|內容分析]]方法分析出「兒童的過動問題一開始就以生物醫學模式來解釋，在處遇建議上則呈現從行為治療轉向藥物治療的明確趨勢」的結論<ref>{{cite journal|author=曾凡慈、劉毓翔|doi=10.3966/221866892017020014003|title=建構童年異常：新聞媒體中的兒童過動症及其轉變 The Construction of ADHD and Its Transformation in the News|date=2017-02|volume=201702|issue=14| journal=社會分析| publisher=[[東吳大學_(臺灣)|東吳大學]]社會系；[[輔仁大學|輔仁大學]]社會系；[[世新大學|世新大學]]社會心理學系}}</ref><ref name="科技、醫療與社會 2014">{{cite web | title=兒童過動症的在地興起與專業技能網絡的變遷 | author=曾凡慈 | journal=《科技、醫療與社會》 Taiwanese Journal for Studies of Science, Technology and Medicine | issue=21 | date=2015年10月 | url=http://stm.ym.edu.tw/article/378 | language=zh | access-date=2017-06-23 | pages=15-76 | deadurl=no | archiveurl=https://web.archive.org/web/20170810211610/http://stm.ym.edu.tw/article/378 | archivedate=2017-08-10 }}</ref>。

美國有社會學家認為注意力不足過動症（ADHD）的治療是一個把「不常見且不被廣泛接受的行為」（deviant behavior）[[醫療化|醫療化]]的例子。抱持這種想法的社會學家認為ADHD的治療是把早期不屬於醫療範疇的學生在學表現的問題給醫療化（另有一說是指這是「特教醫療化」）。<ref name="Parrillo 2008 63">{{Cite book | title=Encyclopedia of Social Problems | author=Parrillo VN | year=2008 | publisher=SAGE | isbn=9781412941655 | page=63 |url=https://books.google.com/?id=mRGr_B4Y1CEC | accessdate=2 May 2009 }}</ref><ref name=Erk2009>{{cite book |vauthors=Mayes R, Bagwell C, Erkulwater JL | title=Medicating Children: ADHD and Pediatric Mental Health | publisher=Harvard University Press | date=2009 | pages=4–24 | isbn=978-0-674-03163-0 | edition=illustrated }}</ref>在中華民國，也有兩位學者附和這樣的論點。<ref>{{cite journal| url =http://www.sped.nutn.edu.tw/upload/journal/prog/21-1.pdf| author =張如杏、林幸台| journal =特殊教育與復健學報| title =特教醫療化現象之探討| date =2009| issue =21| pages =1∼17| deadurl =no| archiveurl =https://web.archive.org/web/20180307175033/http://www.sped.nutn.edu.tw/upload/journal/prog/21-1.pdf| archivedate =2018-03-07}}</ref>

<!--from 英文維基{{tsl|en|Controversy surrounding psychiatry#ADHD||Controversy surrounding psychiatry#ADHD}}or[[注意力不足過動症|Attention_deficit_hyperactivity_disorder#Controversies]]-->在美國，絕大多數的醫療人員相信ADHD是一個真實存在的「症」（genuine disorder）<ref name=Erk2009/>，至少在症狀較明顯的人身上是這樣沒錯。<ref name="Online">{{cite book| author=Silver LB |title=Attention-deficit/hyperactivity disorder | publisher=American Psychiatric Publishing | edition=3rd | year=2004 | isbn=978-1-58562-131-6 | pages=4–7 }}</ref><ref name="Schonwald">{{cite journal |vauthors=Schonwald A, Lechner E | title = Attention deficit/hyperactivity disorder: complexities and controversies | journal = Curr. Opin. Pediatr. | volume = 18 | issue = 2 | pages = 189–195 | date = April 2006 | pmid = 16601502 | doi = 10.1097/01.mop.0000193302.70882.70 }}</ref><!--<ref name=Erk2009/>-->美國醫療人員之間的爭議主要是圍繞在那些症狀輕微的病患的診斷及治療方式<ref name="Online"/><ref name="Schonwald" /><ref name=Erk2009/><ref>{{cite journal|last1=Merten|first1=EC|last2=Cwik|first2=JC|last3=Margraf|first3=J|last4=Schneider|first4=S|title=Overdiagnosis of mental disorders in children and adolescents (in developed countries).|journal=Child and adolescent psychiatry and mental health|date=2017|volume=11|pages=5|pmid=28105068|pmc=5240230}}</ref><ref>{{cite journal|last1=Taylor|first1=E|title=Attention deficit hyperactivity disorder: overdiagnosed or diagnoses missed?|journal=Archives of disease in childhood|date=April 2017|volume=102|issue=4|pages=376-379|doi=10.1136/archdischild-2016-310487|pmid=27821518}}</ref><ref name="Online">{{cite book| author=Silver LB |title=Attention-deficit/hyperactivity disorder | publisher=American Psychiatric Publishing | edition=3rd | year=2004 | isbn=978-1-58562-131-6 | pages=4–7 }}</ref><ref name="Schonwald">{{cite journal |vauthors=Schonwald A, Lechner E | title = Attention deficit/hyperactivity disorder: complexities and controversies | journal = Curr. Opin. Pediatr. | volume = 18 | issue = 2 | pages = 189–195 | date = April 2006 | pmid = 16601502 | doi = 10.1097/01.mop.0000193302.70882.70 }}</ref><ref name=Erk2009/>。（美國的ADHD流行率高於世界平均，詳見：[[注意力不足過動症#流行病學|注意力不足過動症 § 流行病學]]）

英國官方機構－{{tsl|en|National Institute for Health and Care Excellence|英國傑出國家健康照護機構}}（NICE）在2009年發表聲明，聲明中有提及目前存在的爭議，但表示：當前的治療策略與診斷方法都是基於大量學術文獻所形成的學術界共識而得。
<ref name=NICE2009-Diagnosis>{{cite book |title=Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults |author=National Collaborating Centre for Mental Health |series=NICE Clinical Guidelines |volume=72 |publisher=British Psychological Society |location=Leicester |isbn=978-1-85433-471-8 |date=2009 |url=https://www.ncbi.nlm.nih.gov/books/NBK53652/ |chapter=Diagnosis |pages=[https://www.ncbi.nlm.nih.gov/books/NBK53659/#ch5.s40 116–7], [https://www.ncbi.nlm.nih.gov/books/NBK53659/#ch5.s42 119] |chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK53659/ |via=NCBI Bookshelf |deadurl=no |archiveurl=https://web.archive.org/web/20160113133612/http://www.ncbi.nlm.nih.gov/books/NBK53652/ |archivedate=2016-01-13 }}</ref>

中華民國一位[[中央研究院|中央研究院]][[歷史語言研究所|歷史語言研究所]]的學者分析指出，台灣關於「[[西藥|西藥]]」的文化信念或[[成見|成見]]在注意力不足過動症治療方式的爭議之中，扮演著催化劑的角色。<ref name="柑仔店（kám-á-tiàm）">{{cite web | author=巫毓荃（[[中央研究院|中央研究院]][[歷史語言研究所|歷史語言研究所]]助研究員） | title=注意力不足過動症爭議的十個話題 | website=歷史學柑仔店（kám-á-tiàm） | url=http://kam-a-tiam.typepad.com/blog/2017/03/%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E9%81%8E%E5%8B%95%E7%97%87%E7%88%AD%E8%AD%B0%E7%9A%84%E5%8D%81%E5%80%8B%E8%A9%B1%E9%A1%8C.html | language=zh | access-date=2017-06-24 | date=March 24, 2017 | deadurl=no | archiveurl=https://web.archive.org/web/20170623235419/http://kam-a-tiam.typepad.com/blog/2017/03/%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E9%81%8E%E5%8B%95%E7%97%87%E7%88%AD%E8%AD%B0%E7%9A%84%E5%8D%81%E5%80%8B%E8%A9%B1%E9%A1%8C.html | archivedate=2017年6月23日 }}</ref>

==參考文獻==
<div style = "height:800px; overflow:auto; padding:3px; border:1px solid #aaa;">
{{Reflist|2}}
</div>

====參考資料群組====
群組A
{{reflist|group="references"|33em}}

群組B
{{reflist|group="sources"|33em}}

==註解==
{{refbegin|2}}
{{noteFoot}}
{{refend}}

== 注释 ==
{{div col|cols=2}}
{{notelist|iger=}}
{{div col end}}

==參見==
{{div col|cols=3}}
* [[成人ADHD#治療|成人注意力不足過動症§治療]]
* [[反省實踐|反省實踐]]
* {{tsl|en|Student–teacher_ratio|師生比}}
* {{tsl|en|Cognitive_restructuring|認知再建構}}
* {{tsl|en|Cognitive_processing_therapy|認知處理療法}}
* {{tsl|en|Trauma focused cognitive behavioral therapy|聚焦於創傷治療的認知行為療法}}
* {{tsl|en|Heuristics_in_judgment_and_decision-making|運用在判斷和決策中的啟發式教育}}
* {{tsl|en|Positive_Behavior_Interventions_and_Supports|正向行為介入與支持}}
* {{tsl|en|learning to read|學習閱讀}}
* [[預習|預習]]
* [[接收語言能力|接收語言能力]]
* [[接收詞彙|接收詞彙]]
* [[學前教育|學前教育]]
* [[語言表達能力|語言表達能力]]
* [[表達詞彙|表達詞彙]]
* [[詞彙檢索|詞彙檢索]]
* [[持之以恆|持之以恆]]
* {{tsl|en|Self-help|自助}}
* [[親子互動治療|親子互動治療]]
* {{tsl|en|Parent-infant_psychotherapy|親子心理治療}}
* {{tsl|en|Parent_education_program|父母教育課程}}
* [[早期療育|早期療育]]
* {{tsl|en|Drug_holiday|藥物假期}}
{{div col end}}

==外部連結==
{{wikisource|身心障礙者權利公約}}
* {{CDC|url=https://www.cdc.gov/ncbddd/adhd/behavior-therapy.html|article=Behavior therapy for young children with ADHD}}
* {{cite journal | title=中華民國注意力缺陷過動症學生學校特殊教育輔導手冊 | url=http://www.ycjh.chc.edu.tw/xoops/counsel/adhd.pdf | location=[[台灣|台灣]] | date=2001-06 | author=[[國立臺灣師範大學|國立臺灣師範大學特殊教育學系]] | author2=[[中華民國教育部|教育部特殊教育工作小組]]| archive-url=https://web.archive.org/web/20180719191119/http://www.ycjh.chc.edu.tw/xoops/counsel/adhd.pdf | archive-date=2018-07-20 }}
* {{cite journal| journal=特殊教育論文集 |url=http://www.ntcu.edu.tw/spc/aspc/6_ebook/pdf/9101/4.pdf | publisher=[[國立台中教育大學|國立台中教育大學]] | date= | title=注意力缺陷與過動症兒童的介入 | author=[[傅秀媚|傅秀媚]] | archive-date=2018-07-19 | archive-url=https://web.archive.org/web/20180719185508/http://www.ntcu.edu.tw/spc/aspc/6_ebook/pdf/9101/4.pdf}}
* {{cite journal| page=| title= 認知行為治療在注意力缺失/過動疾患兒童之應用 |author= 黃錦敦 | date= | url=https://archive.li/codDO#selection-34.1-83.7}}
* [https://www.facebook.com/permalink.php?story_fbid=1445461425492742&id=123853704320194 【ADHD教養原則TIPS】]	

{{ADHD}}
{{ADHD_pharmacotherapies}}

{{portal bar|醫學|神經科學|心理學|藥理學|社會學}}
[[Category:注意力不足過動症的治療|Category:注意力不足過動症的治療]]